



# Chicago

## Fall Group Meeting

OCTOBER 19-22, 2022



# Welcome to Chicago!

I can't believe it has been three years since I last was able to welcome you to Chicago, but I'm thrilled to be able to revive that long-standing tradition.

This SWOG group meeting will be another "hybrid" event, with virtual versions of all sessions accessible online, but for many of us it will be an old-fashioned chance to meet face to face, and to learn, teach, and be incredibly energized by the work and the people around us. We have one new feature, based on your survey responses after our spring meeting: each room will now include a webcam so virtual attendees can view the physical meeting space.

COVID remains as a serious threat to public health. Given the immune-compromised among our members and our patients, I strongly encourage you to mask up in all indoor public venues.



On a more positive note, we always have dynamic plenaries, but I think the ones you will attend at this meeting are particularly exciting.

Our translational medicine plenary (Plenary I) on Thursday will feature the work of a recent Coltman Fellow, an update on lung committee TM, and a presentation on using artificial intelligence to facilitate cancer trial enrollment (AI-aided accrual!).

Friday's general plenary (Plenary II) is all about MATCH making. MyeloMATCH, ComboMATCH, and ImmunoMATCH will soon launch, so come get educated! The program will start with an update on the Lung-MAP master protocol, which of course has led the way in NCI precision medicine trials.

Finally, our traditional Friday evening reception will feature a diversity, equity, and inclusion (DEI) meet-and-greet – a chance to meet, mingle, and learn more about DEI at SWOG.

Enjoy the meeting and Chicago, and please accept my gratitude for everything you contribute to SWOG!

A handwritten signature in dark ink that reads "Charles D. Blanke MD". The signature is written in a cursive, slightly slanted style.

**Charles D. Blanke, MD**  
SWOG Chair

# Group Meeting Index

Chair's Welcome Message	3
Hotel Maps and Information	6-10
Top Accruers	11
What is a Hybrid Meeting	12
Plenary Sessions	14
Special Sessions	13, 15, 19-23
CME Credit Information	16-17
Health & Safety	18
Upcoming Funding Opportunities	26
Schedule of Events	27-31
SWOG Administrative and Research Support Committees	31
Future Meeting Dates	31
<b>Committee Agendas and Accrual Reports</b>	
Barlogie-Salmon Myeloma Committee	32-35
Breast Committee	36-40
Cancer Control & Prevention Committee Leadership	41-42
Cancer Care Delivery Committee	43-46
Cancer Survivorship Committee	47-48
Early Therapeutics & Rare Cancer Committee	58-61
Gastrointestinal Committee	62-66
Genitourinary Committee	67-74
Immunotherapeutics Committee	75
Leukemia Committee	76-79
Lung Committee	80-86
Lymphoma Committee	87-90
Melanoma Committee	91-94
Palliative & End of Life Care Committee	49-50
Prevention & Epidemiology Committee	51-53
Symptom Control & Quality of Life Committee	54-57
SWOG Publications	95-102

**WE VALUE OUR  
MEETING PARTNERS**

**Thank  
You!**

CONTINUING MEDICAL  
EDUCATION SUPPORTERS

**Lilly**

**Novartis**

**AbbVie**

**AstraZeneca**

**Exact Sciences**

**Varian**

**Novocure**

# Hyatt Regency Chicago Floor Levels



## WELCOME TO HYATT REGENCY CHICAGO.

Meeting rooms, ballrooms, restaurants and guest amenities are listed in alphabetical order and color coded by floor. For help, dial Guest Services at Extension **4460**.

**ESCALATORS, ELEVATORS AND RESTROOMS** are indicated on each floor.

Elevators are conveniently located throughout the hotel for guests with disabilities or where no escalator is present.

## CROSSING BETWEEN

**TOWERS:** Cross between towers via the Skybridge or the Concourse. You may also cross from the lobby level via the crosswalk on Stetson Drive.

151 East Wacker Drive  
Chicago, Illinois 60601, USA

[hyattregencychicago.com](http://hyattregencychicago.com)

Phone: +1.312.565.1234


Fax: +1.312.239.4541

ACAPULCO ( <i>International and City Suites</i> ) West Tower, Ballroom Level	HONG KONG ( <i>International and City Suites</i> ) West Tower, Ballroom Level
ADDAMS ( <i>Founders Suites</i> ) West Tower, Third Floor	HORNER ( <i>Founders Suites</i> ) West Tower, Third Floor
AMERICAN CRAFT KITCHEN & BAR East Tower, Lobby Level	THE LIVING ROOM West Tower, Skyway Level
ATLANTA ( <i>International and City Suites</i> ) West Tower, Ballroom Level	MARKET CHICAGO East Tower, Lobby Level
BELL DESK East Tower, Skyway Level	MCCORMICK ( <i>Founders Suites</i> ) West Tower, Third Floor
BIG BAR East Tower, Skyway Level	MICHIGAN ( <i>Lakeshore Meeting Rooms</i> ) East Tower, Concourse Level
BURNHAM ( <i>Founders Suites</i> ) West Tower, Third Floor	MONROE ( <i>Lakeshore Meeting Rooms</i> ) East Tower, Concourse Level
BUSINESS CENTER, PACKAGE ROOM East Tower, Exhibit Level	NEW ORLEANS ( <i>International and City Suites</i> ) West Tower, Ballroom Level
COLUMBIAN ( <i>Landmark Suites</i> ) West Tower, Concourse Level	OGDEN ( <i>Founders Suites</i> ) West Tower, Third Floor
COLUMBUS HALL (ROOMS A-L) East Tower, Ballroom Level	PICASSO ( <i>Landmark Suites</i> ) West Tower, Concourse Level
COMISKEY ( <i>Landmark Suites</i> ) West Tower, Concourse Level	PLAZA BALLROOM East Tower, Lobby Level
CONCIERGE East Tower, Lobby Level	RANDOLPH ( <i>Lakeshore Meeting Rooms</i> ) East Tower, Concourse Level
CRYSTAL BALLROOM West Tower, Lobby Level	REGENCY BALLROOM West Tower, Ballroom Level
DUSABLE ( <i>Founders Suites</i> ) West Tower, Third Floor	RIVERSIDE CENTER East Tower, Exhibit Level
EAST TOWER MAIN ENTRANCE East Tower, Lobby Level	ROOSEVELT ( <i>Lakeshore Meeting Rooms</i> ) East Tower, Concourse Level
EAST TOWER VALET East Tower, Ballroom Level	SAN FRANCISCO ( <i>International and City Suites</i> ) West Tower, Ballroom Level
FIELD ( <i>Founders Suites</i> ) West Tower, Third Floor	SANDBURG ( <i>Founders Suites</i> ) West Tower, Third Floor
FITNESS CENTER West Tower, Skyway Level	SKYWAY MEETING ROOMS East Tower, Skyway Level
FRONT DESK East Tower, Skyway Level	SOLDIER FIELD ( <i>Landmark Suites</i> ) West Tower, Concourse Level
THE GALLERY COLLECTION West Tower, Skyway Level	STETSON CONFERENCE CENTER West Tower, Exhibit Level
GIFT SHOP East Tower, Concourse Level	STETSONS MODERN STEAK + SUSHI East Tower, Lobby Level
GOLD COAST ( <i>Landmark Suites</i> ) West Tower, Concourse Level	TORONTO ( <i>International and City Suites</i> ) West Tower, Ballroom Level
GRAND BALLROOM East Tower, Ballroom Level	WATER TOWER ( <i>Landmark Suites</i> ) West Tower, Concourse Level
GRAND SUITES East Tower, Ballroom Level	WEST TOWER VALET West Tower, Exhibit Level
HAYMARKET ( <i>Landmark Suites</i> ) West Tower, Concourse Level	WRIGHT ( <i>Founders Suites</i> ) West Tower, Third Floor
HERTZ East Tower, Lobby Level	WRIGLEY ( <i>Landmark Suites</i> ) West Tower, Concourse Level


# Chicago Travel & Hotel Information

151 East Wacker Drive | Chicago, Illinois 60601, USA  
hyattregencychicago.com | Phone: 312 565 1234 | Fax: 312 239 4541


## SKYWAY LEVEL Blue Level




## LOBBY LEVEL Green Level



## CONCOURSE LEVEL Bronze Level



## BALLROOM LEVEL Gold Level



## RIVERSIDE EXHIBIT LEVEL Purple Level



- ELEVATORS
- ESCALATORS AND STAIRS
- RESTROOMS
- MOTHER'S ROOM

# Chicago Travel & Hotel Information

151 East Wacker Drive | Chicago, Illinois 60601, USA  
hyattregencychicago.com | Phone: 312 565 1234 | Fax: 312 239 4541



## Arrival/Departure:

Check-in time is 3:00 p.m. Check-out time is 12:00 noon. Room amenities include a full bath, hair dryer, ironing board and iron. The concierge staff serves as a liaison between guests and the hotel and outside services.

## Hotel Safety Deposit Boxes:

For your convenience, safety deposit boxes are available at the front desk for your valuables. Please do not leave valuables in your room.

## Recreational Facilities:

The fitness center offers a variety of exercise equipment, free weights, treadmills, and more, exclusively for hotel guests. It is open 24 hours a day.

## Hotel Restaurants and Lounges:

**Stetsons Modern Steak & Sushi:** Non-traditional steakhouse experience in a comfortable urban setting, specializing in steaks and seafood. *Restaurant is open daily at 5:00 p.m.*

**American Craft Kitchen & Bar:** Regionally inspired by all corners of the country, they offer an approachable dining experience with handcrafted food and drink. This atrium restaurant is the perfect stop for a casual meal. *Open daily from 6:30 a.m. – 11:00 p.m.*

**Market Chicago:** Offers breakfast, lunch or dinner for a quick meal or coffee to go. *Open daily from 6:30 a.m. – 11:30 p.m.*

**The BIG Bar** features the longest free-standing bar in North America and specializes in a wide variety of cocktails, wines, champagnes and cognacs and snacks. *Open daily at 4:00 p.m.*

In-room dining is available from *6:00 a.m. - 12:00 a.m. daily.*



# Chicago Travel & Hotel Information

151 East Wacker Drive | Chicago, Illinois 60601, USA  
 hyattregencychicago.com | Phone: 312 565 1234 | Fax: 312 239 4541

## Business Center:

The Business Center is located on the Exhibit level in the East Tower of the hotel. It is open 24 hours a day, 7 days a week. The Business Center offers fax machines, computer services, color copies, mail drop, Internet access and photocopying.

## Ground Transportation:

- A taxi ride from O'Hare airport to the hotel is approximately **\$52.00 one-way**.
- A taxi ride from Midway airport to the hotel is approximately **\$35.00 one-way**.
- Valet parking at the hotel is **\$79.00 per day** for hotel guests.

## Temperature:

The average high for October is 64 degrees and the average low is 46 degrees.

## Area Attractions:

- Adler Planetarium and Astronomy Museum
- Architectural Boat Tours
- Art Institute of Chicago
- Brookfield Zoo
- Buckingham Fountain
- Chicago Architecture Foundation
- Chicago Botanic Garden
- Field Museum of National History
- John G. Shedd Aquarium
- John Hancock Center Observatory
- Lincoln Park Zoo and Conservatory
- Maggie Daley Park
- Millennium Park and Cloud Gate ("The Bean")
- Museum of Contemporary Art
- Museum of Science and Industry
- Navy Pier
- Rockefeller Memorial Chapel
- Willis Tower Skydeck



Wikimedia Commons

# Hyatt Regency Chicago Restaurant Guide

## DINING ON-SITE

### BIG BAR

*East Tower, Skyway Level*

### AMERICAN CRAFT KITCHEN & BAR

*East Tower, Lobby Level*

### MARKET CHICAGO

*East Tower, Lobby Level*

## LOCAL FAVORITES

### BILLY GOAT TAVERN

*American, \$*

430 N. Michigan Ave. • 312.222.1525

.1 miles from hotel

### GARRETT POPCORN SHOPS

*Gourmet Popcorn, \$*

4 E. Madison St. • 888.476.7267

.7 miles from hotel

### GIORDANO'S

*Pizza, \$\$*

130 E. Randolph St. • 312.616.1200

.2 miles from hotel

### LOU MALNATI'S

*Pizza, \$\$*

439 N. Wells St. • 312.828.9800

.9 miles from hotel

### PORTILLO'S HOT DOGS

*Quick Service, \$*

100 W. Ontario St. • 312.587.8910

.9 miles from hotel

### STAN'S DONUTS & COFFEE

*Gourmet Donuts, \$*

181 Michigan Ave. • 312.729.5480

.3 miles from hotel

## NEARBY DINING

### BEATRIX

*American, \$\$*

519 N. Clark St. • 312.284.1377

1 mile from hotel

### BROKEN ENGLISH TACO PUB

*Mexican, \$\$*

75 E. Lake St. • 312.929.3601

.4 miles from hotel

### THE DEARBORN

*American, \$\$*

145 N. Dearborn • 312.384.1242

.7 miles from hotel

### GIBSONS BAR & STEAKHOUSE

*Steakhouse, \$\$\$*

1028 N. Rush St. • 312.266.8999

1.2 miles from hotel

### ITALIAN VILLAGE

*Italian, \$\$*

71 W. Monroe St. • 312.332.7005

1 mile from hotel

### JOE'S SEAFOOD

*Seafood, Steakhouse, \$\$\$*

60 E. Grand Ave. • 312.379.5637

.7 miles from hotel

### MAGNOLIA BAKERY

*Coffee, Dessert, \$\$*

108 N. State Street. • 312.346.7777

.7 miles from hotel

### NANDO'S PERI-PERI

*Portuguese, Quick Service, \$\$*

117 E. Lake St. • 312.729.5340

.2 miles from hotel

### NUTELLA CAFE

*Cafe, Coffee Bar, \$\$*

189 N. Michigan Ave. • 800.861.4888

.2 miles from hotel

### POTBELLY SANDWICH SHOP

*Sandwiches, Quick Service, \$*

111 E. Wacker Dr. • 312.861.0013

.1 miles from hotel

### PURPLE PIG

*Mediterranean, \$\$*

500 N. MI Ave • 312.464.1744

.9 miles from hotel

### QUARTINO RISTORANTE

*Italian, \$\$*

626 N. State St. • 312.337.9400

.8 miles from hotel

### RAMEN-SAN

*Japanese, Sushi, \$\$*

59 W. Hubbard St. #2 • 312.377.9950

.9 miles from hotel

### ROTI

*Mediterranean, Quick Service, \$*

80 E. Lake St. • 312.858.8190

.3 miles from hotel

### RPM ITALIAN

*Italian, \$\$\$*

52 W. Illinois St. • 312.222.1888

.7 miles from hotel

### SHAKE SHACK

*American, Quick Service, \$\$*

12 S. Michigan Ave. • 312.646.6005

.5 miles from hotel

### SWEETWATER TAVERN & GRILLE

*American, Pub, \$\$*

225 N. Michigan Ave. • 312.698.7111

.3 miles from hotel

### WILDBERRY PANCAKES & CAFE

*Breakfast & Lunch, \$\$*

130 E. Randolph St. • 312.938.9777

.2 miles from hotel

### YOLK

*Brunch, Cafe, \$\$*

355 E. Ohio St. • 312.822.9655

.6 miles from hotel



# Our Top Accruers

Patient volunteers power our trials — and SWOG members connect us to them.

SWOG-Credited Registrations to SWOG Managed Trials  
July 1, 2021 – June 30, 2022

We appreciate their hard work and their confidence in our research.

## NCORP

Kaiser Permanente NCI Community  
Oncology Research Program

Heartland Cancer Research NCORP

Southeast Clinical Oncology  
Research Consortium NCORP

Gulf South Minority Underserved  
NCORP

Cancer Research of Wisconsin and  
Northern Michigan Consortium

## Main Member / LAPS

University of Texas MD Anderson  
Cancer Center LAPS

City of Hope Comprehensive  
Cancer Center

USC Norris Comprehensive Cancer  
Center LAPS

University of Rochester LAPS

Moffitt Cancer Center



A program of the National Cancer Institute  
of the National Institutes of Health



a National Cancer Institute program

# Just What Is a “Hybrid” Meeting?

## Welcome to SWOG’s Fall 2022 Hybrid Group Meeting!

We’ve long since mastered the face-to-face meeting, have become adept at the fully virtual event, and are now learning to rock the hybrid version as well, with this as our second (but probably not last) hybrid group meeting.



“Hybrid” means all fall meeting sessions will be held in person in Chicago but will also be accessible everywhere via Zoom.



Zoom links to all open meetings are posted on the virtual meeting page on the SWOG website. Zoom links to closed, invitation-only meetings will be emailed directly to those invited.



Each room will have a presentation laptop with a projector and screen. Virtual presentations by remote presenters will be visible on the projector screen to those in the room.



All presenters will have their slides displayed in the Zoom meeting interface. Virtual attendees will view them via Zoom, while in-person attendees will view them on the projector screen.



Audio will be two way as needed. For virtual presenters, the Zoom audio will be amplified for the room. For in-room speakers, audio from microphones will be fed into Zoom.



Web cams will be used to give virtual attendees a live view into meeting rooms.



For many sessions, virtual attendees can post questions for the presenters using the Zoom chat feature. In these sessions, a moderator will monitor the chat.



All sessions will be recorded, and recordings from open sessions will be available to attendees.

## Support SWOG with a Gift Today

### Hope Funds Research, Education, and Group Meetings!

The Hope Foundation uses .90 cents of every dollar to directly fund SWOG research. Hope has received the GuideStar Platinum Seal of Transparency and been in the top 3% of public charities for more than a decade.

[thehopefoundation.org/donate](https://thehopefoundation.org/donate)

**THE HOPE**  
FOUNDATION  
FOR CANCER RESEARCH

Thank you for your support  
of our shared mission  
to improve and  
lengthen lives.



# The Nicholas J. Vogelzang, MD, GU Symposium

honors the many valuable contributions Dr. Vogelzang has made in support of his colleagues and patients throughout his career with the SWOG Cancer Research Network.

FRIDAY, OCTOBER 21 | 9:30 – 11:30 AM CT

FALL 2022 SYMPOSIUM

## Organ Preservation in Bladder Cancer

- Introduction – **Daniel Petrylak, MD; Ian M. Thompson, Jr., MD; & Seth Lerner, MD**
- Patient advocate experience with bladder preservation
- Success and pitfalls of design in contemporary trials of bladder preservation – **Parminder Singh, MD**
- Urologist Perspective – Optimizing clinical staging and enrollment for bladder preservation trials – **Scott Delacroix, MD**
- Radiation Oncology – Variables for stratification – **Daniel Allan Hamstra, MD**
- Novel biomarker for new bladder preservation trials and optimizing biospecimen storage and processing for AI-driven biomarker discovery – **David J. McConkey, PhD**
- Panel Discussion of New Trial Ideas – If S1806 is positive or negative
- Conclusion and next steps – **Seth Lerner, MD**

### The Nicholas J. Vogelzang, MD, Scholarship

*Supporting a young investigator with mentorship and travel funding to attend SWOG group meetings*

&

### The Nicholas J. Vogelzang, MD, GU Symposium

*A special group meeting session dedicated to a range of topics in GU research*

Give Today

[thehopefoundation.org/donate](https://thehopefoundation.org/donate)

You can contribute to the future success of these initiatives and ensure that Dr. Vogelzang's legacy will continue for years to come.



SCAN ME



THE HOPE  
FOUNDATION  
FOR CANCER RESEARCH

## Plenary I

Thursday, October 20, 3:30 – 5:00 pm CT – Regency B-D, Ballroom Level

This fall's translational medicine plenary will feature the following speakers and topics:

Welcome and Introduction

**Lee M. Ellis, MD, FASCO**

SWOG Vice-Chair for Translational Medicine

MD Anderson Cancer Center



Coltman Fellow Update – Image Analysis-Based TILs Measurement Predicts Breast Cancer pCR in SWOG S0800 Neoadjuvant Chemotherapy Trial

**Kim Blenman, PhD, MS**


Yale Cancer Center



Updates from the Lung Cancer Translational Medicine Committee

**Phillip Mack, PhD**

UC Davis



Artificial Intelligence to Facilitate Cancer Clinical Trial Enrollment

**Aaron Cohen, MD, MSCE**

Flatiron Health



## Plenary II

MATCH Making: NCI's New Precision Medicine Initiative Master Protocols

Friday, October 21, 12:00 – 2:00 pm CT – Regency B-D, Ballroom Level

This fall's general plenary will feature updates by leaders of the new NCI precision medicine trials, all of which are expected to have component activations this year: MyeloMATCH, ComboMATCH, and ImmunoMATCH. These will be preceded by an update on the ongoing Lung-MAP trial, the NCI's first precision medicine master protocol. Presentations will be followed by a Q&A session.

Chair's Welcome and Update

**Charles D. Blanke, MD, FASCO, FAWM**

SWOG Group Chair

OHSU Knight Cancer Institute



Lung-MAP Update

**Roy S. Herbst, MD, PhD**

Lung-MAP Study Chair

Yale Cancer Center



The MyeloMATCH Trial

**Harry P. Erba, MD, PhD**

SWOG Leukemia Committee Chair and

MyeloMATCH Senior Science Council Co-Chair

Duke University




The ComboMATCH Trial

**James M. Ford, MD**

ComboMATCH Study Chair

Stanford University



The ImmunoMATCH Trial

**Siwen Hu-Lieskovan, MD, PhD**

SWOG Immunotherapeutics Committee Co-Chair and ImmunoMATCH SWOG PI

Huntsman Cancer Institute



Both Plenary I and Plenary II will also be live-streamed via Zoom, and questions for speakers will be fielded both in person and via Zoom's text chat feature.

October 19, 2022 | 4:30-6:30 PM CT

# TAKE ACTION Symposium:

## Hispanic/Latinx Populations: Ensuring Equity in Clinical Research

Presented by SWOG Recruitment & Retention Committee

### SPEAKERS



**Yonaira M. Rivera, PhD, MPH**

*Yonaira Rivera's scholarship focuses on reducing health inequities and improving the well-being of Latinx and underserved communities through health communication initiatives.*

*Her work uses qualitatively driven, mixed methods and community-based participatory research to study social media health misinformation, cancer control and prevention, and disaster relief. She conducts research in English and Spanish.*



**Barbara Segarra-Vázquez, DHSc**

*Barbara Segarra-Vázquez has been a faculty member at the University of Puerto Rico for more than 30 years, was the dean of the School of Health Professions for seven years, and is the*

*principal investigator of an R25 training program for young investigators. She is a two-time breast cancer survivor and is very active as a research advocate.*



**Gary W. Unzeitig, MD, FACS**

*Gary Unzeitig is the only breast surgeon serving more than 300,000 people in Laredo, nestled on the United States-Mexico border in southern Texas. Unzeitig has enrolled more than*

*1,200 patients on clinical trials over the past 20 years, and currently, he has more than 130 patients with breast cancer on clinical trials through the National Cancer Institute-funded National Clinical Trials Network.*

**Target Audience:** Investigators, research professionals, and patient advocates, NCORP and LAPS

### LEARNING OBJECTIVES:

- 1. Identify** evidence-based practical strategies for sites to ensure access & equity in SWOG clinical trials
- 2. Address** cultural values that support trust-building
- 3. Understand** current environment of the Hispanic/Latinx populations that impacts trial participation
- 4. Learn** strategies for enrolling Hispanic/Latinx populations in clinical trials

# TAKE ACTION

## *Recruitment & Retention*

### **Diversity, EQUITY, & Inclusion**

## *Disparities Research Trust*



# Procedures for CME Credit

## Group Meeting Target Audience and Educational Objectives

SWOG meets semi-annually to keep its members abreast of group science. The target audience for these meetings are physicians, nurse oncologists, and clinical research associates.

The educational objectives of these meetings are: to educate attendees about active and proposed studies so that they may implement the studies at their local institutions; to educate attendees about new treatments and prevention strategies that are available; to identify areas that can be improved in cancer research and study implementation and educate attendees on the best ways to implement the solutions at the local level.

These objectives apply to the following areas: Adolescent and Young Adult Committee; Cancer Control and Prevention, including Cancer Care Delivery Committee, Symptom Control & Quality of Life Committee, Prevention & Epidemiology Committee, Palliative & End of Life Care Committee, and Cancer Survivorship Committee; Genitourinary Committee; Early Therapeutics & Rare Cancers Committee; Myeloma Committee; Melanoma Committee; Surgery Committee; Radiation Oncology Committee; Plenary Sessions; Leukemia Committee; Breast Committee; Gastrointestinal Committee; Lung Committee;

Lymphoma Committee; Immunotherapeutics Committee; Digital Engagement Committee; Bone Marrow & Stem Cell Transplantation Committee; Recruitment and Retention Committee; and Advanced Practice Providers

## Continuing Medical Education Credit


The Hope Foundation is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. In addition, nurses, CRAs, and other researchers may be able to claim credits through their respective credentialing bodies.

The Hope Foundation designates this live activity for a maximum of 33.50 AMA PRA Category 1 Credits™. Learners should only claim credit commensurate with the extent of their participation in the activity.

## Speaker and Planner CME Disclosure Information

Each speaker and planner for The Hope Foundation — CME courses has been requested to complete a Faculty Disclosure Form prior to the activity in accordance with ACCME standards. THF strives to provide accurate and up-to-date information regarding affiliations or interests that might be perceived as a potential conflict of interest for those who control CME content. Best attempts will also be made to provide up to date information on introductory slides at each CME session.

**We've gone paperless! SWOG no longer requires members to submit paper forms to obtain CME credits. Getting your credits online is easy:**



Your certificate will automatically be emailed to you. Problems or questions?

Contact Courtney Wille in the SWOG operations office

at [cwille@swog.org](mailto:cwille@swog.org). To keep track of your credits during the meeting, use the form on the next page.



# Track Your CME Credits

## Instructions:

1. In the column labeled actual credit, please write in the amount of credit you are claiming for each meeting.
2. Then total the amount of credit you are claiming in the actual credit column. Return to [cwille@swog.org](mailto:cwille@swog.org). Your certificate will be emailed to you.

Day/Time	Session Title	Credits	
		Available	Actual
<b>WEDNESDAY, OCTOBER 19, 2022</b>			
9:00 am – 12:00 pm	Advanced Practice Provider Clinical Research Workshop	3.0	___
12:30 pm – 2:30 pm	Digital Engagement Committee	2.0	___
2:30 pm – 4:30 pm	Adolescent and Young Adult (AYA) Committee	2.0	___
4:30 pm – 6:30 pm	Take Action Symposium: Hispanic/Latinx Populations, Ensuring Equity in Clinical Research presented by the SWOG Recruitment and Retention Committee	2.0	___
4:30 pm – 6:30 pm	Immunotherapeutics Committee	2.0	___
<b>THURSDAY, OCTOBER 20, 2022</b>			
9:00 am – 11:00 am	Cancer Care Delivery Committee	2.0	___
10:00 am – 12:15 pm	Early Therapeutics and Rare Cancers Committee	2.25	___
11:15 am – 1:15 pm	Prevention and Epidemiology Committee	2.0	___
1:30 pm – 3:30 pm	Symptom Control and Quality of Life Committee	2.0	___
3:30 pm – 5:00 pm	Plenary I (Translational Medicine)	1.25	___
5:15 pm – 7:15 pm	Cancer Survivorship Committee	2.0	___
<b>FRIDAY, OCTOBER 21, 2022</b>			
7:30 am – 9:30 am	Palliative and End of Life Care Committee	2.0	___
9:00 am – 11:00 am	Lymphoma Committee	2.0	___
9:30 am – 11:30 am	Organ Preservation in Bladder Cancer Symposium	2.0	___
10:30 am – 12:00 pm	Bone Marrow & Stem Cell Transplantation Committee	1.5	___
12:00 pm – 2:00 pm	Plenary II (General)	2.0	___
2:00 pm – 4:00 pm	Radiation Oncology Committee	2.0	___
2:30 pm – 4:30 pm	Melanoma Committee	2.0	___
2:30 pm – 4:30 pm	Barlogie-Salmon Myeloma Committee	2.0	___
2:30 pm – 6:15 pm	GU Committee Part I: Prostate, TM, Cancer Control	3.75	___
4:00 pm – 6:00 pm	GI Committee	2.0	___
4:15 pm – 7:15 pm	Lung Committee	3.0	___
<b>SATURDAY, OCTOBER 22, 2022</b>			
9:15 am – 11:15 am	Surgery Committee	2.0	___
9:15 am – 12:15 pm	Breast Committee	3.0	___
9:15 am – 12:15 pm	GU Committee Part II: Bladder, Renal	3.0	___
9:30 am – 12:30 pm	Leukemia Committee	3.0	___
<b>Total Possible Credits</b>		<b>33.5</b>	<b>___</b>

# SWOG Fall 2022 Hybrid Group Meeting: Health & Safety

*In deciding to attend this meeting, you assume all responsibility for your own health and safety.*

*We strongly encourage you to wear a medical mask at all times while indoors.*


*Extra masks are available at the registration desk.*

## Full Vaccination and Booster Shot Required

Many SWOG members work with immunocompromised patients every day. The last thing they want is to bring a dangerous virus back with them after a trip to a meeting.

With this in mind, and given data showing reduced risk among those who have received a booster shot, SWOG requires that to attend the fall 2022 group meeting in person, you must be fully vaccinated (received all required doses of an FDA- or WHO-authorized two-dose or one-dose vaccine), and you must have received at least one vaccine booster shot prior to October 13.

*We strongly encourage you to get the newly updated COVID-19 booster, which better protects against the most recently circulating variant.*



The following are approved forms of vaccine verification.

*You must show one of these at the SWOG registration table when you pick up your name badge:*

- ✓ **A CDC vaccine card** or photo of vaccine card
- ✓ **Documented proof** of vaccination from medical record or vaccine provider
- ✓ **Proof of vaccination** from your state or county
- ✓ **Printed certificate or digital record** from [MyLRMobile.com](https://mylrmobile.com) (available in several states) or other apps
- ✓ **QR code or digital copy** of your COVID-19 vaccination record from a state-sponsored system


*If you cannot or choose not to comply with the mandate, or if you are unable to travel to the meeting, please join us online for live-streamed sessions.*

*If you find you need to take a COVID-19 test while onsite, tests will be available at the SWOG registration desk.*

*Please reach out to us at [healthandsafety@swog.org](mailto:healthandsafety@swog.org).*

# Diversity, Equity, and Inclusion Meet-and-Greet

Hosted by the Recruitment and Retention Committee



Look for our tables and balloons at the Friday evening reception to meet, mingle, and learn more about DEI at SWOG



# Advanced Practice Provider Clinical Research Workshop

*A special session of the  
SWOG Cancer Research Network fall group meeting*

Wednesday, October 19, 2022 | 9am-12pm CT  
Hyatt Regency, Chicago, IL and virtually



*Sponsored by the SWOG nursing research subcommittee  
and the palliative and end of life care committee;  
funded by The Hope Foundation for Cancer Research*

This hybrid event will focus on the essentials for advanced practice providers to provide safe care to patients on clinical trials and enhance their involvement with NCI-based research.

3 hours of CME devoted to the nuts and bolts of participating in NCI-sponsored trials at your practice site and beyond!



# ADVANCED PRACTICE PROVIDER CLINICAL RESEARCH WORKSHOP AGENDA

- Overview of NCI sponsored research and NCTN and NCORP Networks
- Becoming an NPIVR
- Different types of protocols
  - Treatment/Intervention
  - Cancer control
    - Symptom management
    - Survivorship
    - Palliative and EOL
    - Prevention
    - QOL
  - CCDR
- Facilitators of/Barriers to APP participation in NCI-sponsored research
- Panel: Opportunities for increased involvement in research bases
- Protocol review
  - Eligibility/Consenting
  - CTCAE grading
  - Dose modifications
  - RECIST criteria

## WORKSHOP FACULTY

### SWOG

**Christa Braun-Inglis, DNP, APRN, FNP-BC, AOCNP** (Member Nursing Research Sub-Committee)  
Nurse Practitioner/Assistant Researcher  
University of Hawaii Cancer Center/Hawaii M/U NCORP

**Jamie S Myers PhD, RN, AOCNS, FAAN**  
(Chair of Nursing Research Sub-Committee)  
Research Associate Professor  
University of Kansas

**Joyce Tull, MSN**  
Executive Director, Office of Clinical Research  
UC Davis Comprehensive Cancer Center

**Joyce Lee, PharmD, BCOP, BCPS**  
Senior Clinical Pharmacist, Investigational Drug Services and Oncology  
UC Davis Comprehensive Cancer Center

**Nichole Mahaffey, PhD, CCRP**  
Data Coordinator Supervisor  
UC Davis Comprehensive Cancer Center

### ECOG

**Bridget O'Brien, DNP, APRN, FNP-BC, AOCNP**  
(Chair Nursing Committee)  
Director of the Family Nurse Practitioner Program/Assistant Professor/ Family Nurse Practitioner  
Rush University

### COG

**Maureen Haugen, MS, APRN, CPRP, CPON**  
APP Manager/Pediatric Nurse Practitioner  
Ann & Robert H. Lurie Children's Hospital of Chicago

### WAKE FOREST

**Alisha T. DeTroye, PA-C, DFAAPA**  
Director of Advanced Practice  
Atrium Health Wake Forest Baptist

### NRG

**Melyssa Foust, MSN, RN, OCN**  
Cancer Control/CCDR Manager  
UC NCORP CCDR Coordinator  
Gibbs Cancer Center and Research Institute

### URCC


**Marie Flannery, PhD, RN, AOCN**  
Associate Professor, University of Rochester, School of Nursing

### NCI

**Kate Castro, RN, MS, AOCN**  
Nurse Consultant/Program Director  
Healthcare Delivery Research Program  
Office of the Associate Director, Division of Cancer Control and Population Science (DCCPS)

Saturday, Oct 22 | 9:50 am – 12:00 pm CT

# Come Learn More About MyeloMATCH at the SWOG Leukemia Committee Open Session



**MyeloMATCH** is the NCI’s initiative to accelerate precision medicine and develop new therapies in myeloid malignancies.

**Patients will be enrolled** at diagnosis of acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) and assigned to a trial in the MyeloMATCH portfolio based on clinical, cytogenetic, and molecular features.

**Attend the Leukemia Committee Open Session to learn more about**

the nuts and bolts of the MyeloMATCH screening protocol	how sites open MyeloMATCH studies	NCORP participation in MyeloMATCH	MyeloMATCH BEACON builds	the science underlying MyeloMATCH	MyeloMATCH cytogenetics and more!
---	-----------------------------------	-----------------------------------	--------------------------	-----------------------------------	-----------------------------------

**The MyeloMATCH Master Screening & Reassessment Protocol and the first wave of MyeloMATCH clinical trials are on track to open soon!**

*Also: don’t miss Harry Erba, MD, PhD, presenting on the MyeloMATCH trial at Plenary II, Friday, October 21, 12-2 pm CT.*

Wednesday, Oct 19, 2022 | 4:30 – 5:10 pm CT in the Immunotherapeutics Committee Meeting

## Come Learn About the Innovative ImmunoMATCH Study and Its Pilot Trial:

# S2101 BiCaZO Kick-Off

ALL PRINCIPAL INVESTIGATORS AND SITE STAFF ARE ENCOURAGED TO ATTEND.

**ImmunoMATCH** is one of the next generation of NCI precision medicine master protocols (MATCH = Molecular Analysis for Therapy Choice).

**S2101 BiCaZO is the iMATCH pilot:** a phase II study combining cabozantinib and nivolumab in participants with advanced solid tumors (IO-refractory melanoma or head & neck squamous cell carcinoma) stratified by tumor biomarkers.

The kick-off features presentations and a Q&A with


- Katerina Politi, PhD
- Siwen Hu-Lieskovan, MD, PhD
- Paul Swiecicki, MD
- Michael LeBlanc, PhD
- Katherine Minichiello, MS
- Dana Sparks, MAT
- Chris Kippola,
- James Moon, MS
- Gary Lyman, MD
- and the rest of the SWOG iMATCH team


ImmunoMATCH uses whole exome sequencing to calculate tumor mutational burden and gene expression profiling to generate a tumor inflammation score.

The BiCaZO pilot will test the feasibility of using these two assays to stratify patients up front, so they can be used in future ImmunoMATCH subprotocols.

**Come learn more about opening S2101 BiCaZO, the ImmunoMATCH pilot!**

*Also: don't miss Siwen Hu-Lieskovan, MD, PhD, presenting on the ImmunoMATCH trial at Plenary II, Friday, October 21, 12-2 pm CT.*





# SWOG has launched a new Learning Management System (LMS)!

THE EXPERTUSONE LMS WILL BE HOME TO ALL TRAINING THAT IS SPECIFIC TO SWOG MEMBERS.



**Training certificates** are viewable and printable for one year after completing a course.



**Courses are available** in brief 5- to 15-minute modules.



**Content is regularly added** and updated. See the “Announcements” window for new content.



**In a user-friendly interface**, you can view trainings, take surveys, and complete assessments all from one LMS content player – also available for mobile devices.



**Allows us to host** virtual classes integrated with WebEx or Zoom.

**NCTN-wide training — such as for protocol-specific requirements and PRO training — will remain in the CTSU CLASS system. But SWOG internal training for members and staff will be in ExpertusOne.**

**Some of the training content now within ExpertusOne:**

- Study Chair Workshop
- Young Investigator Workshop Online
- Investigational Agent Handling
- Clinical Trials Training Course
- Team Science

Access SWOG’s new LMS at [swog.exphosted.com](http://swog.exphosted.com), or link from the “Training for SWOG Members” item on the “Member Resources” menu. Use your CTEP IAM credentials to log in.

[swog.exphosted.com](http://swog.exphosted.com)


 **expertusone**  
www.expertusone.com



# Support SWOG Through Planned Giving

Your legacy gift can advance clinical trials for patients everywhere. By planning a gift for The Hope Foundation, you provide critical cancer prevention and treatment for future generations.

Including a charitable gift in your estate plans is easy. With the help of your tax advisor or estate planner, you can include language in your will or trust specifying a gift be made to The Hope Foundation as part of your estate plan. You can give a specific dollar amount or asset, a percentage of your estate, a gift from the balance or residue of your estate or make a beneficiary designation of certain assets.



## Maximize your impact and tax savings through a stock gift

Have you considered supporting The Hope Foundation through a stock gift?

When you give appreciated shares over a year old to The Hope Foundation, you receive credit for the full market value and do not pay capital gains. If you itemize your tax deductions, your savings can be substantial.

Your gift of stock will directly impact the patients and researchers across SWOG's 1,300+ member sites – and beyond.

To learn about planning a gift or giving through stock, visit

[thehopefoundation.org/donate](https://thehopefoundation.org/donate) or contact [funding@thehopefoundation.org](mailto:funding@thehopefoundation.org) or (734) 998-6887.

**THE HOPE**  
**FOUNDATION**  
FOR CANCER RESEARCH

THE **HOPE**  
FOUNDATION  
FOR CANCER RESEARCH

# Future Funding Opportunities

- SEED Fund Program: **December 1**
- Impact Award Program: **January 15 (LOI)**
- Coltman Fellowship Program: **March 1**
- Career Development Award: **March 1**

See all Hope Foundation programs at  
[THEHOPEFOUNDATION.ORG/FUNDING-OPPORTUNITIES](https://THEHOPEFOUNDATION.ORG/FUNDING-OPPORTUNITIES)

## SWOG CLINICAL TRIALS PARTNERSHIPS

AN LLC OF THE HOPE FOUNDATION FOR CANCER RESEARCH

Learn more about upcoming trials  
and partnership opportunities at the

### SWOG CTP Update Forum

Wednesday, October 19, 11:30 am - 12:30 pm CT

Can't be there in person?  
Attend virtually at [bit.ly/3RD7GHb](https://bit.ly/3RD7GHb)

SWOG CLINICAL TRIALS PARTNERSHIPS  
IS HOW SWOG CANCER RESEARCH  
NETWORK PARTNERS WITH INDUSTRY  
TO CONDUCT **CANCER CLINICAL TRIALS**

[swogctp.org](https://swogctp.org)



# Schedule of Events

## WEDNESDAY, OCTOBER 19, 2022

Group Meeting Registration & Information Desk  
8:00 am - 5:00 pm - Regency Foyer, Ballroom Level,  
West Tower

**\*Unless otherwise indicated, all meetings are in the West Tower of the hotel**

8:30 AM – 11:30 AM

**Acapulco, Ballroom Level**

Advocates Committee (Committee Members Only)

9:00 AM – 12:00 PM

**Regency B, Ballroom Level**

Advanced Practice Provider Clinical Research Workshop

9:30 AM – 11:00 AM

**Soldier Field, Concourse Level**

Quality Initiative Meeting (Committee Members Only)

11:00 AM – 12:00 PM

**Toronto, Ballroom Level**

ORP Executive and Education Cmte Members Prep/Working Group (Cmte Members Only)

11:30 AM – 12:30 PM

**Regency A, Ballroom Level**

Clinical Trials Partnerships Update Forum

12:00 PM – 12:30 PM

**Regency D Foyer, Ballroom Level**

SWOG NCORP Research Base Clinical Trials Workshop Check-In

12:30 PM – 2:00 PM

**Acapulco, Ballroom Level**

Core Office Staff Networking Session (Invitation Only)

12:30 PM – 2:30 PM

**Regency C, Ballroom Level**

Digital Engagement Committee

12:30 PM – 4:00 PM

**Regency D, Ballroom Level**

SWOG NCORP Research Base Clinical Trials Workshop

1:00 PM – 2:45 PM

**Soldier Field, Concourse Level**

Nursing Research Subcommittee (Committee Members Only)

2:00 PM – 3:30 PM

**Toronto, Ballroom Level**

SWOG Tissue Banking Meeting (Invitation Only)

2:30 PM – 4:30 PM

**Water Tower, Concourse Level**

Adolescent and Young Adult (AYA) Committee

3:30 PM – 5:00 PM

**Acapulco, Ballroom Level**

Hope Foundation Board Meeting (Board Members Only)

4:30 PM – 6:30 PM

**Regency C, Ballroom Level**

Take Action Symposium: Hispanic/Latinx Populations, Ensuring Equity in Clinical Research, presented by the SWOG Recruitment and Retention Committee

4:30 PM – 6:30 PM

**Regency B, Ballroom Level**

Immunotherapeutics Committee

5:30 PM – 7:30 PM

**Regency A, Ballroom Level**

Site Operations

5:30 PM – 8:00 PM

**Acapulco, Ballroom Level**

NCORP Research Base Executive Committee Meeting (Committee Members Only)

# Schedule of Events

## THURSDAY, OCTOBER 20, 2022

**Group Meeting Registration & Information Desk**  
8:00 am - 5:00 pm - Regency Foyer, Ballroom Level,  
West Tower

**Hope Foundation Information Desk**  
8:00 am - 5:00 pm - Regency Foyer, Ballroom Level,  
West Tower

**Exhibits & Complimentary Coffee Service**  
8:00 am - 5:00 pm - Toronto, Ballroom Level, West Tower

**\*Unless otherwise indicated, all meetings are in the West Tower of the hotel**

8:30 AM – 9:00 AM

**Regency B Foyer, Ballroom Level**     *Jeri & Noboru Oishi Symposium  
Check-In*

9:00 AM – 12:00 PM

**Regency B, Ballroom Level**     *Jeri & Noboru Oishi Symposium*

9:00 AM – 11:00 AM

**Acapulco, Ballroom Level**     *Lung-MAP Administrative Meeting  
(Invitation Only)*

9:00 AM – 11:00 AM

**Regency A, Ballroom Level**     *Cancer Care Delivery Committee*

10:00 AM – 12:15 PM

**Regency C, Ballroom Level**     *Early Therapeutics and Rare  
Cancers Committee*

11:00 AM – 1:00 PM

**Water Tower, Concourse Level**     *SWOG Latin America Initiative  
Symposium*

11:15 AM – 1:15 PM

**Regency A, Ballroom Level**     *Prevention and Epidemiology  
Committee*

12:00 PM – 1:00 PM

**New Orleans, Ballroom Level**     *Clinical Trials Partnerships  
Scientific Advisory Board  
(Invitation Only)*

12:00 PM – 2:00 PM

**Acapulco, Ballroom Level**

*Lung-MAP Site Coordinators  
Committee Meeting (Committee  
Members Only)*

12:30 PM – 1:10 PM

**Comiskey, Concourse Level  
Columbian, Concourse Level  
Wrigley, Concourse Level**

*ORP Open Forum  
Breakout Sessions 1-3  
(choose 1 session below)*

*Session 1: Regulatory 101  
Session 2: Understanding the PMB  
Session 3: Interactive Q&A*

1:15 PM – 2:00 PM

**Comiskey, Concourse Level  
Columbian, Concourse Level  
Wrigley, Concourse Level**

*ORP Open Forum Breakout  
Sessions 4-6 (choose 1 session  
below)*

*Session 4: SWOG Perspective &  
Common Challenges  
Session 5: Know Your IRBs  
Session 6: Interactive Q&A*

12:30 PM – 2:15 PM

**Picasso, Concourse Level**

*Sarcoma Working Group of the  
ETxRC Committee (Invitation Only)*

12:30 PM – 3:15 PM

**Gold Coast, Concourse Level**

*Myeloma Working Group (Working  
Group Members Only)*

1:30 PM – 2:30 PM

**Soldier Field Concourse Level**

*Lung Community Engagement  
Subcommittee (Committee  
Members Only)*

1:30 PM – 3:30 PM

**Regency A, Ballroom Level**

*Symptom Control and Quality of  
Life Committee*

2:30 PM – 3:30 PM

**Wrigley, Concourse Level**

*S2108CD Update Meeting*

2:30 PM – 3:30 PM

**Picasso, Concourse Level**

*ORP Liaison Subcommittee  
(Committee Members Only)*

2:30 PM – 3:30 PM

**Regency Foyer, Ballroom Level**

*Plenary Reception  
(Light Hors D'oeuvres)*

# Schedule of Events

3:30 PM – 5:00 PM

**Regency B-D, Ballroom Level**

Plenary I (Translational Medicine)

5:15 PM – 7:15 PM

**Wrigley, Concourse Level**

CNS Working Group

5:15 PM – 7:15 PM

**Regency A, Ballroom Level**

Cancer Survivorship Committee

5:15 PM – 7:15 PM

**Acapulco, Ballroom Level**

Lymphoma Working Group  
(Working Group Members Only)

5:15 PM – 7:15 PM

**Comiskey, Concourse Level**

Lung Working Group (Working  
Group Members Only)

5:15 PM – 7:15 PM

**New Orleans, Ballroom Level**

Conflict Management Committee  
(Committee Members Only)

## FRIDAY, OCTOBER 21, 2022

**Group Meeting Registration & Information Desk**  
7:00 am - 5:00 pm - Regency Foyer, Ballroom Level,  
West Tower

**Hope Foundation Information Desk**  
8:00 am - 5:00 pm - Regency Foyer, Ballroom Level,  
West Tower

**Exhibits & Complimentary Coffee Service**  
8:00 am - 5:00 pm - Toronto, Ballroom Level, West Tower

**\*Unless otherwise indicated, all meetings are in the  
West Tower of the hotel**

7:00 AM – 9:00 AM

**New Orleans, Ballroom Level**

Imaging Committee (Committee  
Members Only)

7:30 AM – 9:00 AM

**Soldier Field, Concourse Level**

Professional Review Committee  
(Committee Members Only)

7:30 AM – 9:30 AM

**Picasso, Concourse Level**

SWOG Data and Safety Monitoring  
Committee (Committee Members  
Only)

7:30 AM – 9:30 AM

**Regency A, Ballroom Level**

Palliative and End of Life Care  
Committee

8:00 AM - 10:00 AM

**Wrigley Concourse Level**

Lung Radiation/Surgery  
Subcommittee  
(Committee Members Only)

8:00 AM – 12:00 PM

**Plaza B, Lobby Level (East Tower)**

GI Working Group (Working Group  
Members Only)

9:00 AM – 10:00 AM

**Acapulco, Ballroom Level**

ORP Workgroup (Invitation Only)

9:00 AM – 11:00 AM

**Crystal A, Lobby Level**

Lymphoma Committee

9:00 AM – 11:00 AM

**Crystal C, Lobby Level**

Breast Working Group (Working  
Group Members Only)

# Schedule of Events

9:30 AM – 11:30 AM

**Plaza A, Lobby Level (East Tower)** *Melanoma Working Group  
(Working Group Members Only)*

2:30 PM – 4:30 PM

**Crystal C, Lobby Level** *Melanoma Committee*

9:30 AM – 11:30 AM

**Crystal B, Lobby Level** *Organ Preservation in Bladder  
Cancer Symposium*

2:30 PM – 4:30 PM

**Plaza B, Lobby Level (East Tower)** *Barlogie-Salmon Myeloma  
Committee*

10:00 AM – 11:30 AM

**Picasso, Concourse Level** *Quality Assurance Committee  
(Committee Members Only)*

2:30 PM – 6:15 PM

**Regency A, Ballroom Level** *GU Committee Part I: Prostate; TM;  
Cancer Control*

10:00 AM – 12:00 PM

**Water Tower, Concourse Level** *Pharmaceutical Sciences  
Committee and Drug Information  
Subcommittee*

3:00 PM – 6:00 PM

**Comiskey, Concourse Level** *Breast Translational Medicine  
Working Group (Working Group  
Members Only)*

10:30 AM – 12:00 PM

**Comiskey, Concourse Level** *Bone Marrow & Stem Cell  
Transplantation Committee*

4:00 PM – 5:00 PM

**Acapulco, Ballroom Level** *ORP Executive Committee  
(Committee Members Only)*

11:00 AM – 12:00 PM

**Regency Foyer, Ballroom Level** *Plenary Reception (Light Hors  
D'oeuvres)*

4:00 PM – 6:00 PM

**Regency B, Ballroom Level** *GI Committee*

11:30 AM – 12:00 PM

**Acapulco, Ballroom Level** *Publications Committee  
(Committee Members Only)*

4:15 PM – 7:15 PM

**Regency C, Ballroom Level** *Lung Committee*

12:00 PM – 2:00 PM

**Regency B-D, Ballroom Level** *Plenary II (General)*

6:00 PM – 7:00 PM

**Crystal Ballroom, Lobby Level** *Group Reception & Diversity,  
Equity and Inclusion Meet  
and Greet*

2:00 PM – 4:00 PM

**Crystal A, Lobby Level** *Radiation Oncology Committee*

2:15 PM – 3:15 PM

**Water Tower, Concourse Level** *NCORP/MU-NCORP Site PI Meeting*

2:15 PM – 3:45 PM

**Crystal B, Lobby Level** *Lung-MAP Update Meeting*

2:15 PM – 4:15 PM

**Plaza A, Lobby Level (East Tower)** *Leukemia Working Group  
(Working Group Members Only)*

# Schedule of Events

## SATURDAY, OCTOBER 22, 2022

**Group Meeting Registration & Information Desk**  
7:00 am - 11:00 am - Regency Foyer, Ballroom Level, West Tower

**Hope Foundation Information Desk**  
8:00 am - 11:00 am - Regency Foyer, Ballroom Level, West Tower

*\*Unless otherwise indicated, all meetings are in the West Tower of the hotel*

7:00 AM – 7:45 AM

**Regency C, Ballroom Level**      Board of Governors (Board Members Only)

8:00 AM – 9:00 AM

**Regency C, Ballroom Level**      Committee Chairs (Committee Chairs Only)

8:00 AM – 9:00 AM

**Regency A, Ballroom Level**      GU Trials Kickoff Meeting (in person only, no hybrid option)

9:15 AM – 11:15 AM

**Water Tower, Concourse Level**      VA Committee

9:15 AM – 11:15 AM

**Comiskey, Concourse Level**      Surgery Committee

9:15 AM – 12:15 PM

**Regency B, Ballroom Level**      Breast Committee

9:15 AM – 12:15 PM

**Regency A, Ballroom Level**      GU Committee Part II: Bladder; Renal

9:30 AM – 12:30 PM

**Regency C, Ballroom Level**      Leukemia Committee

# Committees

## Administrative Committees

### Board of Governors

Charles D. Blanke, MD

### Publications

Hagen F. Kennecke, MD

### Conflict Management

Paul Okunieff, MD

### Professional Review

Paul Hesketh, MD

## Research Support Committees

### Adolescent and Young Adult

Rebecca Johnson, MD

### Patient Advocates

Rick Bangs, MBA

### Bone Marrow and Stem Cell Transplantation

Patrick J. Stiff, MD

### Pharmaceutical Sciences

Siu-Fun Wong, PharmD

### Digital Engagement

Don S. Dizon, MD

### Radiation Oncology

Interim Chair  
James Yu, MD

### Imaging

Lawrence H. Schwartz, MD

### Recruitment and Retention

Allison Caban-Holt, PhD

### Oncology Research Professionals

Connie Szczepanek,  
RN, BSN, CCRP

### Surgery

Syed A. Ahmad, MD

### Veterans Affairs

Stephen D. Bartlett, RPh

## Future Meeting Dates

2023		2024	
Spring	Fall	Spring	Fall
May 10-13 San Francisco, CA	October 11-14 Chicago, IL	April 3-6 Seattle, WA	October 16-19 Chicago, IL

# Barlogie-Salmon Myeloma Committee

## Leadership

Chair: ..... Robert Z. Orlowski, MD, PhD  
 Vice-Chair: ..... Sikander Ailawadhi, MD  
 Vice-Chair: ..... Jing Christine Ye, MD, MSc  
 Executive Officer: ..... Susan M. O'Brien, MD  
 Statisticians: ..... Antje Hoering, PhD  
 ..... Rachael Sexton, MS  
 ..... Adam Rosenthal

## Scientific Leadership

Translational Medicine: ..... Brian A. Walker, BSc, PhD  
 Radiation: ..... Chelsea Camille Pinnix, MD, PhD  
 Surgery: ..... TBD  
 Imaging: ..... Eric M. Rohren, MD, PhD  
 Pathology: ..... Pei Lin, MD  
 Early Therapeutics: ..... Frits van Rhee, MD, PhD

## Designates

DEI Champion: ..... Manuel Espinoza-Gutarra, MD  
 Digital Engagement: ..... TBD  
 NCORP Representative: ..... Charles S. Kuzma, MD  
 Veterans Affairs: ..... Thomas R. Chauncey, MD, PhD  
 Data Coordinators: ..... Daria Chugina  
 ..... Hannah Hale  
 Oncology Research Professionals:  
 CRA: ..... TBD  
 Nurses: ..... Deborah A. Shaw, RN  
 ..... Teresa Witcher, BSN, RN  
 Patient Advocate: ..... Jack Aiello, MS  
 Pharmaceutical Science: ..... Craig Elg, PharmD  
 ..... Ila M. Saunders, PharmD  
 Protocol Project Manager: ..... Sharon Palmer  
 Clinical Trials Program Manager: ..... TBD

## Time/Location

Friday, October 21, 2022 2:30 pm - 4:30 pm  
 Room: Plaza B (Lobby Level, East Tower)

## Active Studies

**S1803**, "Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)." Drs. A. Krishnan and P. Hari. Activated: 6/27/19.

**S2005**, "A Phase II Randomized Study of Ibrutinib and Rituximab with or Without Venetoclax in Previously Untreated Waldenström's Macroglobulinemia (WM)." Drs. S. Ailawadhi and D. Bhutani. Activated: 6/24/21. Temporarily Closed: 7/16/21. Re-opened to accrual: 10/15/21. Temporary Closed: 4/08/22.

**EAA171**, "Optimizing Prolonged Treatment in Myeloma Using MRD Assessment (OPTIMUM)." Dr. S. Kumar. Activated: 6/1/21.

**EAA173**, "Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma." Activated: 4/30/19.

**EAA181**, "Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial." Activated: 10/27/20.

## Closed Studies

**S1211**, "A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide with or Without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM)." Drs. S. Usmani, S. Ailawadhi, and B. Lipe. Activated: 11/9/12. Closed: 6/2/16.

**S1702**, "A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients with Previously Treated AL Amyloidosis." Drs. T. Parker and V. Sanchorawala. Activated: 3/08/18; Closed: 9/30/19.

**S1304**, "A Phase II Randomized Study Comparing Two Doses of Carfilzomib with Dexamethasone for Relapse/Refractory Multiple Myeloma." Dr. S. Ailawadhi. Activated: 10/18/13. Closed: 11/6/15.



# Barlogie-Salmon Myeloma Committee

**S0777**, "Frontline Phase III Rev/Dex +/- Vel, no upfront transplant." Dr. B. Durie. Activated: 4/1/18. Closed: 2/2/12.

**S0120**, "A prospective Observational Biologic Study of Asymptomatic Patients with Monoclonal Gammopathy and Plasmaproliferative Disorders." Dr. M. Dhodapkar. Activated: 6/1/02. Closed: 4/1/11.

**CTN 0702**, "Single Autologous Transplant with or without RVD Consolidation versus Tandem Transplant and Maintenance Therapy." Dr. G. Somlo. Activated: 2/15/11. Closed: 11/15/13.

**A061402**, "Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone after Radiation Therapy in Treating Patients with Solitary Plasmacytoma of Bone." Dr. A. Kuman Mahindra. Activated: 12/23/15. Closed: 8/15/19.

**E1A11**, "Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDUR-ANCE)." Drs. S. Kumar, A. Cohen, and J. Zonder. Activated: 11/22/13. Closed: 1/29/19.

**E3A06 (was S0909)**, "High-risk AMM – Revlimid." Dr. M. Dhodopkar. Activated: 1/17/11. Closed: 7/14/17.

**A061402**, "Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone after Radiation Therapy in Treating Patients with Solitary Plasmacytoma of Bone." Dr. A. Kumar Mahindra. Activated: 12/23/15. Closed: 8/15/19.

**E1A11**, "Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDUR-ANCE)." Drs. S. Kumar, A. Cohen and J. Zonder. Activated: 11/22/13. Closed: 1/29/19.

## Proposed Studies

**S2209**, "A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or Ineligible for Stem Cell Transplant Comparing Upfront Bortezomib-Lenalidomide-Dexamethasone-Lite (VRd-Lite) with Daratumumab-Lenalidomide-Dexamethasone (DRd)." Drs. S. Ailawadhi, C. Ye, and A. Gowin.

**S2213**, "Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone (D-VCD) Induction Followed by Autologous Stem Cell Transplant or D-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis." Dr. P. Hagen

**S1911**, "Phase III Study of Optimal Induction Therapy for Newly Diagnosed High-Risk Multiple Myeloma (HRMM) RVD Dara +/- xx." Dr. B. Lipe.

## Proposed Studies-Pre-Triage/On Hold

1. Bhutani: Randomized Phase II of CAEL-101 vs Placebo in Renal AL Amyloidosis. Amyloid two-arm study.
2. Gowin: PCL Phase II study of VTD-PACE like regimen/Belanatumab Mafodotin/Autologous menStem Cell Transplant (ASCT).
3. Atrash: PVD +/- Sel in RRMM with del(17p) and prior therapy.
4. Former S1710 (Now VTE substudy proposal for S2209): Randomized Phase II Trial of Apixaban (or Riveroxiban) for Prevention of Thromboembolism in High Risk Patients being Treated with IMiDs for Multiple Myeloma (MM)- David Calverly
5. Chakraborty: An Open-Label Randomized Phase 2 Trial to Incorporate Venetoclax in Early Relapsed t(11;14) Multiple Myeloma

## Barlogie-Salmon Myeloma Committee

Accrual from trial opening through 6/30/2022 by Institution and Study

	S1803	S2005	EAA173	EAA181
<i>Ascension Providence Hospitals - Southfield</i>	1	-	-	-
<i>Banner University Medical Center - Tucson</i>	6	-	-	-
<i>Boston Medical Center</i>	5	-	-	-
<i>CWRU Case Comprehensive Cancer Center LAPS</i>	15	-	3	-
<i>Cancer Research for the Ozarks NCORP</i>	1	-	-	-
<i>Cancer Research of Wisconsin and Northern Michigan Consortium</i>	3	-	-	-
<i>Cedars-Sinai Medical Center</i>	5	-	-	-
<i>City of Hope Comprehensive Cancer Center</i>	78	-	-	-
<i>Columbus NCI Community Oncology Research Program</i>	7	-	-	-
<i>CommonSpirit Health Research Institute</i>	3	-	-	-
<i>Dayton NCI Community Oncology Research Program</i>	5	-	-	-
<i>Duke University - Duke Cancer Institute LAPS</i>	3	-	-	-
<i>Fred Hutchinson Cancer Research Center LAPS</i>	-	-	4	-
<i>Georgia NCI Community Oncology Research Program</i>	11	-	-	-
<i>Gulf South Minority Underserved NCORP</i>	4	-	-	-
<i>Heartland Cancer Research NCORP</i>	14	-	-	-
<i>Kaiser Permanente NCI Community Oncology Research Program</i>	37	-	-	-
<i>Lahey Hospital and Medical Center</i>	3	-	-	-
<i>Loyola University Medical Center</i>	19	-	3	-
<i>Medical University of South Carolina Minority Underserved NCORP</i>	29	-	1	-
<i>Moffitt Cancer Center</i>	36	-	-	-
<i>Montana Cancer Consortium NCORP</i>	4	-	-	-
<i>Nevada Cancer Research Foundation NCORP</i>	-	-	1	-

## Barlogie-Salmon Myeloma Committee

Accrual from trial opening through 6/30/2022 by Institution and Study

	S1803	S2005	EAA173	EAA181
<i>New Mexico Minority Underserved NCORP</i>	8	-	-	-
<i>Ohio State University Comprehensive Cancer Center LAPS</i>	4	-	-	-
<i>Oregon Health and Science University</i>	17	-	2	3
<i>Pacific Cancer Research Consortium NCORP</i>	10	-	-	-
<i>Southeast Clinical Oncology Research Consortium NCORP</i>	3	-	-	-
<i>UC Davis Comprehensive Cancer Center LAPS</i>	17	-	-	-
<i>UC Irvine Health/Chao Family Comprehensive Cancer Center</i>	7	-	-	-
<i>University of Arkansas for Medical Sciences</i>	-	-	-	1
<i>University of Cincinnati Cancer Center-UC Medical Center</i>	-	-	-	1
<i>University of Kansas Cancer Center - MCA Rural MU NCORP</i>	23	-	-	-
<i>University of Michigan Comprehensive Cancer Center LAPS</i>	9	-	-	-
<i>University of Oklahoma Health Sciences Center LAPS</i>	2	-	-	-
<i>University of Rochester LAPS</i>	12	-	-	-
<i>University of Texas Health Science Center at San Antonio</i>	12	-	-	-
<i>University of Texas MD Anderson Cancer Center LAPS</i>	19	-	-	-
<i>University of Utah - Huntsman Cancer Institute LAPS</i>	12	-	3	1
<i>Upstate Carolina Consortium Community Oncology Research Program</i>	3	-	-	-
<i>Wayne State University - Karmanos Cancer Institute LAPS</i>	10	-	-	-
<i>Wisconsin NCI Community Oncology Research Program</i>	16	-	-	-
<i>Yale University - Yale Cancer Center LAPS</i>	-	-	2	1
<b>ALLIANCE</b>	139	-	-	-
<b>ECOG-ACRIN</b>	117	1	-	-
<b>NRG</b>	72	-	-	-
<b>Total</b>	<b>801</b>	<b>1</b>	<b>19</b>	<b>7</b>

# Breast Committee

## Leadership

Chair: ..... Lajos Pusztai, MD, PhD  
 Vice-Chair: .....Priyanka Sharma, MD  
 Executive Officer: ..... Anne Chiang, MD, PhD  
 Statisticians: ..... William E. Barlow, PhD  
 ..... Danika Lew, MA  
 ..... Jieling Miao, MS

## Scientific Leadership

Translational Medicine: ..... Alastair M. Thompson, MD  
 ..... Andrew K. Godwin, PhD  
 Radiation Oncology: ..... Reshma Jagsi, MD  
 Surgery: ..... Joshua M.V. Mammen, MD, PhD  
 Imaging: ..... Joanne E. Mortimer, MD  
 ..... Wei Tse Yang, MBBS  
 Pathology: ..... David L. Rimm, MD, PhD  
 Early Therapeutics: ..... Stephanie L. Graff, MD

## Designates

Cancer Control Liaisons: ..... Melinda L. Irwin, PhD, MPH (Survivorship)  
 ..... Dawn L. Hershman, MD (Cancer Care Delivery)  
 ..... Banu Arun, MD (Prevention)  
 ..... Helen K. Chew, MD (Symptom Control & QOL)  
 DEI Champion: ..... Gayathri Nagaraj, MD  
 Digital Engagement: ..... Sarah S. Mougalian, MD  
 NCORP Representative: ..... Philip E. Lammers, MD  
 Data Coordinators: ..... Iris Syquia  
 ..... Larry Kaye  
 ..... Ojasvi Mittal  
 ..... Gabi Herbert  
 Oncology Research Professionals:  
 CRAs: ..... Karyn N. Hart, CCRP  
 ..... Avidanka Baftirovska, BS, CCRP  
 Nurse: ..... TBD  
 Patient Advocates: ..... Roberta A. Albany  
 ..... Ginny Mason, RN, BSN  
 Pharmaceutical Science: ..... Jorge G. Avila, PharmD  
 ..... Dawud Nael Dawud Ellayan, Pharm D  
 Protocol Project Manager: ..... Alicia Aranda  
 Clinical Trials Program Manager: ..... TBD

## Time/Location

Saturday, October 22, 2022 9:15 am - 12:15 pm  
 Room: Regency B (Ballroom Level, West Tower)

## Agenda

**9:30 – 9:35 am Welcome and Introductions** - Lajos Pusztai, M.D., D.Phil. (Chair) and Priyanka Sharma, M.D. (Vice-chair)

**9:35 - 10:35 am Mini symposium “Improving Diversity in Clinical Trials - Bridging Gaps and Creating Opportunities”**

Facilitator - Andrew K. Godwin, PhD: Professor and Division Director, Genomic Diagnostics; Deputy Director, University of Kansas Comprehensive Cancer Center, & Founding Director, Kansas Institute for Precision Medicine, University of Kansas Medical Center).

**9:35 - 9:50 am “Improving Diversity in Clinical Trials: Why, What and How?”** - Gayathri Nagaraj, MD Associate Professor of Medicine and Breast Medical Oncologist at Loma Linda University Cancer Center.

**9:50 - 10:00 am Interactive questions – “Diversity, Equity, and Inclusion in Clinical Trials: What are You Doing at Your Institute?”**

**10:00 - 10:15 am - “Engaging Communities and Providers to Enhance Clinical Trials Access”** - Hope Krebill, MSW, BSN, RN: Executive Director, Masonic Cancer Alliance, the University of Kansas Cancer Center) & Ronald Chen, MD, MPH, FASCO, FASTRO: Professor and Chair, Radiation Oncology, the University of Kansas Medical Center.

**10:15 - 10:30 am “Building Trust and Relationships: A Patient Prospective”**  
 Roberta Albany: Patient Advocate SWOG Breast Committee

**10:30 - 10:35 am “Plan of Action”** - Gayathri Nagaraj, MD

**10:35 – 10:45 am Publication update** – William Barlow, Ph.D.

**10:45 – 10:55 am Advocate update** – Ginny Mason & Roberta Albany

**10:55 – 11:05 am Translational Medicine Sub-Committee update**  
 Alastair Thompson, M.D. & Andrew K. Godwin, Ph.D.

**11:05 – 11:45 am Review of open CTSU trials**

**11:45 – 12:05 pm Recently approved and developing Concepts**

**12:05 - 12:25 pm Reports from Committee Liaisons**

Radiotherapy - Reshma Jagsi, M.D.

Surgery – Joshua Mammen, M.D.

Cancer Survivorship - Melinda L. Irwin, Ph.D., M.P.H.

Cancer Care Delivery - Dawn Hershman, M.D.

Prevention – Banu Arun, M.D.

Symptom Control & QOL - Helen K. Chew, M.D.

NCORP – Philip Lammers, M.D.

DEI - Gayathri Nagaraj, M.D.

**12:25 - 12:30 pm Closing Comments and Adjourn**

# Breast Committee

## Proposed Studies

**S2212**, "Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), a Randomized Phase III Study." Drs. Sharma and Mitri.

**S2206**, "Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) plus Chemotherapy versus Chemotherapy Alone for MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer." Drs. Cobain and Pusztai.

## Active Studies

**S2007**, "A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients with HER2-Negative Breast Cancer and Brain Metastases." Drs. Brenner and Kaklamani. Activated: 12/15/20.

**S1706**, "A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer." Drs. Jagsi and Chalasani. Activated: 09/12/18.

**CTSU/A011202**, "A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy." Dr. Boughhey. SWOG Champion: Dr. Mammen. Activated: 02/07/14. Temporarily closed: 01/14/2022.

**CTSU/A011801**, "The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSESSment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib." Dr. O'Sullivan. SWOG Champion: Dr. Murthy. Activated: 01/06/21.

**CTSU/CCTG MA.39**, "Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive and T3N0 Breast Cancer." Dr. Whelan. SWOG Champion: Dr. Jagsi. Activated: 05/30/18.

**CTSU/EA1181**, "(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response Part 1 Component of: The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSESSment to Optimize Therapy in HER2-Positive Breast Cancer)" Dr. Tung. SWOG Champions: Breast Committee: Dr. Tang, Imaging Committee: Dr. Lu. Activated: 02/11/20.

**CTSU/EA1183**, "FDG PET to Assess Therapeutic Response in Patients with Bone-Dominant Metastatic Breast Cancer, FEATURE." Dr. Specht. SWOG

Champions: Breast Committee: Dr. Linden, Imaging Committee: Dr. Wright. Activated: 04/02/20.

**CTSU/NRG-BR002**, "A Phase II/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer." Drs. Chmura and White. SWOG Champion: Dr. Jagsi. Activated: 12/24/14. Temporarily closed: 09/13/19.

**CTSU/NRG-BR003**, "A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer." Dr. Valero. SWOG Champion: Dr. Makhoul. Activated: 06/26/15.

**CTSU/NRG-BR004**, "A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer." Dr. Geyer. SWOG Champion: Dr. Cobain. Activated: 03/12/19.

**CTSU/NRG-BR005**, "A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients with Clinical/Radiologic Complete Response after Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment without Surgery." Dr. Basik. SWOG Champion: Dr. Thompson. Activated: 04/13/17. Temporarily closed: 07/02/19.

**CTSU/NRG-BR007**, "A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)." Dr. White. SWOG Champion: Dr. Shumway. Activated: 06/07/21.

## Closed Studies

**S1418**, "A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with  $\geq 1$  CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) after Neoadjuvant Chemotherapy." Drs. Pusztai and Mammen. Activated: 11/15/16. Permanently closed: 06/30/21.

**S1207**, "Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer. e<sup>3</sup> Breast Cancer Study-Evaluating Everolimus with Endocrine Therapy." Drs. Chavez-MacGregor and Pusztai. Activated: 09/04/13. Permanently closed: 05/01/19.

# Tweeting the Meeting

Twitter is a major venue you can use to get out word about what you learn at the group meeting.

@SWOG has more than 12K followers and can amplify your message!

Follow SWOG at  
[twitter.com/SWOG](https://twitter.com/SWOG)

With your group meeting tweets ...

tag your @SWOG friends

use the hashtag  
**#SWOGonc**



## Breast Committee

### Active Cancer Survivorship Study

S1501, "Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III." Drs. Floyd and Leja. Activated: 09/15/17.

### Active Symptom Control and Quality of Life Studies

S1614, "A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy for Solid Tumors." Drs. Hwang and Lok. Activated: 02/21/19.

S1714, "A Prospective Observational Cohort Study to Develop a Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients." Drs. Trivedi and Hershman. Activated 03/01/19.

### Active Cancer Care Delivery Studies

S1703, "Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive HER-2 Negative Breast Cancer." Drs. Accordino and Hershman. Activated: 07/16/18.

CTSU/EA1151, "Tomosynthesis Mammographic Imaging Screening Trial (TMIST)." Dr. Pisano. SWOG Champion: Dr. Arun. Activated: 07/06/17.

### Active Cancer Prevention Study

S1904, "Cluster Randomized Controlled Trial of Patient and Provider Decision Support to Increase Chemoprevention Informed Choice among Women with Atypical Hyperplasia or Lobular Carcinoma In Situ – Making Informed Choices on Incorporating Chemoprevention into Care (MiCHOICE)." Drs. Crew, and Kukafka. Activated: 09/01/20.

### Active Early Therapeutics and Rare Cancers Studies

S1609, "DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors." Drs. Patel and Chae. Activated 01/13/17.

CTSU/EAY131, "Molecular Analysis for Therapy Choice (MATCH)". Dr. Flaherty. Activated 08/12/15.

## Breast Committee

Accrual from trial opening through 6/30/2022 by Institution and Study

	S1418	S1706	S2007	A011202	A011401	A011801	EA1131	EA1181	EA1183	MA39	NRGBR003	NRGBR004	NRGBR007
Ascension Prov Hosp - Southfield	6	2	-	4	10	-	1	2	-	1	3	1	-
Ascension Via Christi Hosp Wichita	9	-	-	-	-	-	-	-	-	-	-	-	-
Banner MD Anderson CC	3	-	-	-	-	-	-	-	-	-	-	-	-
Banner U Med Ctr - Tucson	4	1	-	1	6	-	-	6	-	-	-	-	-
Baptist Mem HC/Mid South MU NCORP	9	3	-	1	4	-	-	1	-	-	-	1	-
Bay Area Tumor Inst NCORP	3	-	-	-	-	-	-	-	-	-	-	-	-
Baylor U Med Ctr	-	-	-	1	-	-	-	-	-	-	-	-	-
Boston Med Ctr	-	-	-	-	3	-	-	10	-	-	-	-	-
CWRU Case CCC LAPS	12	-	1	-	2	-	-	-	-	1	9	1	-
Ca Res Consortium of West Mich NCORP	24	-	-	-	1	-	-	-	-	-	-	-	-
Ca Res for the Ozarks NCORP	9	1	-	-	1	1	-	-	-	-	3	-	-
Ca Res of Wisconsin & N Mich Consort	7	-	-	-	-	-	-	-	-	-	-	-	-
Carle CC NCORP	3	-	1	-	-	-	-	-	-	-	-	-	-
City of Hope CCC	9	-	-	-	-	-	-	-	-	-	-	-	-
Columbia U MU NCORP	8	2	-	-	-	-	-	3	-	-	-	-	-
Columbus NCORP	13	-	-	-	-	-	-	-	-	-	-	-	-
CommonSpirit Hlth Res Inst	19	1	-	-	2	-	-	-	-	-	-	-	-
Cotton O'Neil CC / Stormont Vail Hlth	-	-	-	1	1	-	-	-	-	-	1	-	-
Dayton NCORP	3	-	-	-	1	-	1	7	-	-	-	-	-
Desert Regional Med Ctr	1	-	-	7	4	-	-	-	-	-	-	-	-
Essentia Health NCORP	3	-	-	-	-	-	-	-	-	-	-	-	-
Fred Hutchinson Ca Res Ctr LAPS	10	3	-	-	12	-	-	-	-	-	-	-	-
Georgia NCORP	23	2	-	-	2	-	4	-	-	-	1	-	-
Gulf South MU NCORP	5	1	-	-	-	-	-	2	-	-	4	-	-
Hawaii MU NCORP	5	-	-	-	-	-	-	-	-	-	-	-	-
Heartland Ca Res NCORP	19	3	-	-	-	1	-	-	-	-	-	-	-
Henry Ford Hospital	1	-	-	-	-	-	1	-	-	-	-	-	-
Houston Methodist Hospital	-	-	-	-	-	1	-	-	-	-	-	-	-
Kaiser Permanente NCORP	51	-	-	1	55	-	-	-	-	-	25	1	-
Lahey Hospital & Med Ctr	3	-	-	-	9	-	1	4	-	-	-	1	-
Loma Linda U Med Ctr	1	-	-	3	-	-	-	-	-	-	-	-	-
Loyola U Med Ctr	3	-	-	-	6	-	2	1	-	-	-	-	-
Medical U South Carolina MU NCORP	11	-	-	-	-	-	-	-	3	-	-	-	-
Meharry Medical College	-	-	-	-	3	-	-	-	-	-	1	-	-
Michigan Ca Res Consortium NCORP	21	1	-	-	-	-	-	-	-	-	-	-	-
Moffitt CC	-	-	-	1	3	-	-	-	-	-	-	-	-
Montana Cancer Consortium NCORP	2	3	-	-	-	-	-	-	-	-	-	-	-
Mount Sinai Hospital	3	-	-	-	-	-	-	1	-	-	-	-	-
NCORP Carolinas (Prisma Hlth NCORP)	4	-	-	-	-	-	-	-	-	-	-	-	-
Nevada Ca Res Foundation NCORP	11	-	-	-	-	-	-	-	-	-	-	-	-

## Breast Committee

Accrual from trial opening through 6/30/2022 by Institution and Study

	S1418	S1706	S2007	A011202	A011401	A011801	EAT131	EAT181	EAT183	MA39	NRGBR003	NRGBR004	NRGBR007
New Mexico MU NCORP	19	4	1	-	-	-	-	-	-	-	-	-	-
Northwell Health NCORP	-	-	1	-	-	-	-	-	-	-	-	-	1
Northwestern U LAPS	2	1	-	-	-	-	-	2	1	-	1	-	-
Ohio State U CCC LAPS	-	1	-	-	-	-	-	-	-	-	-	-	-
Oregon Health & Science U	19	-	-	-	-	-	-	-	3	-	3	-	-
Orlando Health Ca Inst	1	-	-	-	1	-	-	-	-	-	-	-	-
Pacific Ca Res Consortium NCORP	19	-	-	-	3	-	-	-	-	-	1	-	-
SCL Health Saint Joseph Hospital	-	-	-	-	1	-	-	-	-	-	-	-	-
Salem Hospital	-	-	-	4	-	-	-	-	-	-	-	-	-
Scott & White Mem Hospital	-	-	-	-	4	-	-	-	-	-	-	-	-
Southeast Clin Onc Res Consort NCORP	46	-	-	-	-	-	-	-	-	-	-	-	-
Sutter Ca Res Consortium	3	-	-	-	8	2	1	3	-	-	4	2	-
The Don and Sybil Harrington CC	7	3	-	11	8	2	-	-	-	-	-	-	-
James Graham Brown CC, U of Louisville	-	-	-	2	-	-	-	-	-	-	-	-	-
The West Clinic - Wolf River	-	-	-	9	-	-	-	-	-	-	-	-	-
UC Davis CCC LAPS	8	5	-	2	4	-	-	4	-	-	-	1	-
UC Irvine Hlth/Chao Family CCC	6	-	1	3	2	-	-	-	-	-	1	-	-
UC San Diego Moores CC	-	-	-	-	2	-	-	-	-	-	1	-	-
USC Norris CCC LAPS	3	-	-	4	-	-	-	-	-	2	-	-	-
U Arkansas for Medical Sciences	17	2	-	-	3	-	-	-	-	-	-	-	-
U Colorado CC LAPS	11	1	-	42	27	1	-	11	-	1	-	-	-
U Kansas CC - MCA Rural MU NCORP	22	2	-	4	23	-	-	-	-	1	-	-	-
U Michigan CCC LAPS	13	2	-	-	14	-	-	1	-	4	3	-	-
U Mississippi Med Ctr	-	-	-	-	-	-	-	1	-	-	-	-	-
U Oklahoma HSC LAPS	2	-	-	-	-	-	-	-	-	-	-	-	-
U Rochester LAPS	2	1	-	-	-	-	7	1	-	-	9	-	-
U Texas HSC at San Antonio	5	-	1	6	2	-	-	-	-	-	4	-	-
U Texas MD Anderson CC LAPS	21	1	-	-	-	-	-	-	-	-	-	-	-
U Utah - Huntsman Ca Inst LAPS	6	2	-	-	7	1	-	3	-	-	-	-	-
Upstate Carolina Consortium NCORP	8	-	-	-	1	-	-	-	-	-	-	-	-
Virginia Mason Med Ctr	1	-	-	-	-	-	-	-	-	-	-	-	-
Wayne State U - Karmanos Ca Inst LAPS	3	-	-	11	12	-	6	12	3	-	6	-	-
Western States Ca Res NCORP	3	-	-	-	-	-	-	-	-	-	-	-	-
William Beaumont Hosp-Royal Oak	1	-	-	6	5	-	-	-	-	-	-	-	-
Wisconsin NCORP	2	1	-	-	-	-	-	-	-	-	-	-	-
Yale U - Yale CC LAPS	8	-	-	5	81	1	6	7	-	-	9	1	-
ALLIANCE	144	10	4	-	-	-	-	-	-	-	-	-	-
CCTG	39	6	-	-	-	-	-	-	-	-	-	-	-
ECOG-ACRIN	129	5	1	-	-	-	-	-	-	-	-	-	-
NRG	307	34	-	-	-	-	-	-	-	-	-	-	-
<b>Total</b>	<b>1,195</b>	<b>104</b>	<b>11</b>	<b>129</b>	<b>333</b>	<b>10</b>	<b>30</b>	<b>82</b>	<b>10</b>	<b>10</b>	<b>89</b>	<b>9</b>	<b>1</b>



# Cancer Control & Prevention Committee

## Leadership

Vice-Chair NCORP: ..... Dawn L. Hershman, MD, MS  
 Cancer Care Delivery Cmte Co-Chairs: ..... Dawn L. Hershman, MD, MS  
 ..... Scott D. Ramsey, MD, PhD  
 Cancer Survivorship Cmte Co-Chairs: ..... Halle C.F. Moore, MD  
 ..... Melinda L. Irwin, PhD, MPH  
 Palliative & End of Life Cmte Co-Chairs: ..... Robert S. Krouse, MD, FACS  
 ..... Mark A. O'Rourke, MD  
 ..... Marie Bakitas, DNSc, CRNP  
 Prevention and Epidemiology Cmte Co-Chairs: ..... Banu Arun, MD  
 ..... Marian L. Neuhouser, PhD, RD  
 Symptom Control & QOL Cmte Co-Chairs: ..... Michael J. Fisch, MD, MPH  
 ..... Norah Lynn Henry, MD, PhD  
 Executive Officers: ..... Katherine D. Crew, MD (Palliative, Prevention,  
 ..... Survivorship)  
 ..... Gary H. Lyman, MD (CCD, Symptom Control & QOL)  
 Senior Advisor: ..... Frank L. Meyskens, Jr., MD  
 Statisticians: ..... Garnet Anderson, PhD  
 ..... William E. Barlow, PhD  
 ..... Katherine Guthrie, PhD  
 ..... Cathy Tangen, DrPH  
 ..... Joseph M. Unger, PhD  
 ..... Riha Vaidya, PhD  
 ..... Kathryn B. Arnold, MS  
 ..... Amy K. Darke, MS  
 ..... Phyllis J. Goodman, MS  
 ..... Danika Lew, MA  
 ..... Hongli Li, MS  
 ..... Anna Moseley, MS  
 ..... Eddie Mayerson, MS  
 Administrative Lead  
 Statistics & Data Management Center (SDMC): ..... Monica Yee, CCRP

## Scientific Leadership

NCORP Representative: ..... Mark A. O'Rourke, MD  
 Radiation Oncology Committee: ..... Kiri A. Cook, MD  
 Surgery Committee: ..... Robert S. Krouse, MD, FACS  
 Translational Medicine: ..... James (Jimmy) Rae, PhD  
 Liaisons:  
 Barlogie-Salmon Myeloma Committee: ..... Charles S. Kuzma, MD  
 Breast Committee: ..... Melinda L. Irwin, PhD, MPH (Survivorship)  
 ..... Helen K. Chew, MD (Symptom Control & QOL)

..... Dawn Hershman, MD, MS (CCD)  
 ..... Banu Arun, MD (Prevention)  
 ..... Philip Lammers, MD  
 Early Therapeutics & Rare Cancers: ..... Lara E. Davis, MD (Survivorship)  
 ..... Jason M. Prosek, MD  
 Gastrointestinal Committee: ..... Jason A. Zell, DO (Prevention)  
 ..... Afsaneh Barzi, MD (CCD)  
 Genitourinary Committee: ..... Peter J. Van Veldhuizen, Jr., MD  
 International Liaison: ..... Kathy S. Albain, MD  
 Leukemia Committee: ..... Stephanie B. Tsai, MD  
 Lung Committee: ..... Gary E. Goodman, MD  
 Lymphoma Committee: ..... Hayder Saeed, MD  
 Melanoma Committee: ..... Sancy Leachman, MD, PhD  
 ..... Thach-Giao Truong, MD (Survivorship)  
 Recruitment and Retention Committee: ..... Allison M. Caban-Holt, PhD  
 Digital Engagement: ..... Jennifer R. Klemp, PhD (Survivorship)  
 ..... Krishna Soujanya Gunturu, MD (Survivorship)  
 ..... Mina S. Sedrak, MD (CCD)  
 ..... Katherine D. Crew, MD (Prevention)  
 ..... Michael J. Fisch, MD (Symptom Control & QOL)  
 Veterans Affairs: ..... Yeun-Hee Anna Park, MD

## Designates

### Oncology Research Professionals

CRAs: ..... Amanda R. Dinsdale, MHA, CCRC  
 ..... Amy Jo Koffarnus, BS, CCRP  
 ..... Samantha Wright, MS, CCRP  
 ..... Shirley S. Sui, BS  
 Nurses: ..... Connie Szczepanek, RN, BSN  
 ..... Melyssa W. Foust, MSN, RN  
 Pharmaceutical Sciences Committee: ..... Kimberly McConnell, PharmD  
 ..... Siu-Fun Wong, PharmD  
 ..... Sun "Coco" Yang, PharmD, PhD  
 SDMC Data Coordinators and Staff: ..... Kimberly Carvalho  
 ..... Sam Dzingle  
 ..... Mat Eng  
 ..... Manny Kharbanda  
 ..... Diane Liggett, CCRP  
 ..... Roxanne Topacio, CCRP  
 ..... Monica Yee, CCRP  
 Recruitment and Retention Specialist: ..... TBD  
 Patient Advocates: ..... Barbara Segarra-Vazquez, DHSc (CCD)

# Cancer Control & Prevention Committee

.....Amy Geschwender, PhD (Symptom Control & QOL)  
 ..... Hartley "Lee" M. Jones, MBA (Survivorship)  
 ..... Cheryl L. Jernigan, CPA (Prevention & Epidemiology)  
 .....Valerie Fraser (Palliative & End of Life Care)  
 Protocol Project Manager (Cancer Care Delivery;  
 Prevention and Epidemiology): ..... Patricia O’Kane  
 Protocol Project Manager (Survivorship):..... Taj Pereira

Protocol Project Manager (Symptom Control and  
 Quality of Life):..... Mariah Norman, MS  
 Protocol Project Manager (Palliative Care): ..... Christy Klepetko  
 Clinical Trials Program Manager (Palliative Care): .....TBD  
 Clinical Trials Program Manager (CCD; Prevention;  
 Survivorship): .....TBD  
 Clinical Trials Project Manager (Symptom Control):.....Crystal Miwa

LUNG-MAP UPDATE MEETING | FRIDAY, OCTOBER 21 | 2:15 – 3:45 PM CT

## A Master Protocol to Evaluate Biomarker-Driven and Immune Therapies in Previously Treated Non-Small Cell Lung Cancer

### CURRENT LUNG-MAP SUB-STUDIES:

- **S1800D:** N-803 + pembrolizumab vs standard of care in patients with Stage IV or recurrent NSCLC previously treated with anti-PD-1/PD-L1 therapy
- **S1900E:** Sotorasib (AMG 510) in patients with previously treated Stage IV or recurrent KRAS G12C-mutated NSCLC
- **S1900F:** Carboplatin + pemetrexed with or without seliperatinib in patients with RET fusion-positive stage IV NSCLC that progressed on prior RET-directed therapy

*Come learn more about where the NCI's first precision medicine master protocol is and where it is going.*

*And don't miss the Lung-MAP presentation at Plenary II, Friday, 12:00 – 2:00 pm CT!*



All welcome! Can't attend in person? Attend virtually at <https://bit.ly/3eX4Fmq>

# Cancer Care Delivery (CCD) Committee

## Leadership

Co-Chairs: ..... Dawn L. Hershman, MD, MS  
 ..... Scott D. Ramsey, MD, PhD

## Time/Location

Thursday, October 20, 2022 9:00 am - 11:00 am  
 Room: Regency A (Ballroom Level, West Tower)

## Agenda

### Presentations

- Development and Testing of a Culturally Responsive Decision Aid Intervention to Promote Diversity in Clinical Trial Participation, Vida Henderson, Ph.D., Pharm.D., Fred Hutchinson Cancer Center
- Results from S1415CD, "A Pragmatic Trial To Evaluate a Guideline-Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as Prophylaxis for Patients Receiving Chemotherapy with Intermediate Risk for Febrile Neutropenia - Trial Assessing CSF Prescribing, Effectiveness and Risk (TrACER)," Dr. Scott Ramsey, M.D., Ph.D., Fred Hutchinson Cancer Center
- Pragmatic Trials and Cluster Randomization Considerations, William Barlow, Ph.D., Fred Hutchinson Cancer Center

### Active Studies

- S2108CD, "Randomized Comparison of an Educationally Enhanced Genomic Tumor Board (eGTB) Intervention to Usual Practice of Incorporating Genomic Test Results into Clinical Care." Dr. Jens Rueter, M.D., Maine Cancer Genomics Initiative; Dr. Meghna Trivedi, M.D., Columbia University
- S1912CD, "A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)." Dr. Veena Shankaran, M.D., University of Washington. Activated 7/26/21.
- S1703, "Randomized Non-inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic

Hormone Receptor Positive HER-2 Breast Cancer," Dr. Melissa Accordini, M.D., Activated 7/16/18.

### Developing Studies

S2201CD, Managing Oral Anti-Cancer Agents in Community Oncology Practices: Implementation and Impact, Karen B. Farris, Ph.D., Emily Mackler, Pharm.D., University of Michigan

Development of a Multilevel Intervention to Promote Guideline-Concordant Colorectal Cancer Surveillance – Dr. Christine Veenstra, M.D., University of Michigan

Patient-centered Video Education Intervention to Improve Rural Cancer Care Delivery – Randall Holcombe, M.D., MBA, Izumi Okado, Ph.D., University of Hawaii

### Studies with CCD/CCP Components

- S1904, "Cluster Randomized Controlled Trial of Patient and Provider Decision Support to Increase Chemoprevention Informed Choice Among Women with Atypical Hyperplasia or Lobular Carcinoma In Situ – Making Informed Choices on Incorporating Chemoprevention into Care (MiCHOICE)," Dr. K. Crew. Activated 9/1/20. (Committee: Prevention/Epidemiology)
- S2010, Active Symptom Monitoring and Endocrine Therapy Persistence in Young Women with Breast Cancer – Lynn Henry, M.D., University of Michigan; Dawn Hershman, M.S. M.S., Columbia University

### Closed Studies

- S1415CD, "A Pragmatic Trial To Evaluate a Guideline-Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as Prophylaxis for Patients Receiving Chemotherapy with Intermediate Risk for Febrile Neutropenia - Trial Assessing CSF Prescribing, Effectiveness and Risk (TrACER)." Drs. S. Ramsey, D. Hershman, G. Lyman, et al. Activated: 10/7/16. Closed: 4/15/20.
- S1417CD, "Implementation of a Prospective Financial Impact Assessment Tool in Patients with Metastatic Colorectal Cancer." Dr. V. Shankaran. Activated: 4/15/16. Closed: 2/1/19.

# Cancer Care Delivery (CCD) Committee

## Substudies (Economic Analyses / Cost Effectiveness from NCTN trials)

**S1806**, Healthcare Cost Comparison of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle-invasive Bladder Cancer, Dr. R. Vaidya, Dr. J. Unger

**S1204**, A Sero-Epidemiologic Survey and Cost-effectiveness Study of Screening for Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Among Newly Diagnosed Cancer Patients, Dr. R. Vaidya

## Database/Grant Funded Projects

### Published

Sex Differences in Adverse Event Reporting in SWOG Chemotherapy, Biologic/Immunotherapy and Targeted Agent Cancer Clinical Trials. Dr. J. Unger

Trends in Obesity Among Patients Registered to SWOG Cancer Clinical Treatment Trials. Dr. R. Vaidya

# Get the Scoop!

Want the Front Line blog every Friday?

Or the Translational Medicine Link of the Week?

How about the Hope Foundation Monthly E-Newsletter?



**THE HOPE FOUNDATION FOR CANCER RESEARCH**

**Virtual Symposium Will Feature Community Sites**

Part of a New Initiative to Improve Representation in Cancer Clinical Trials

[Register for Symposium](#)

The Hope Foundation is helping SWOG launch an effort in collaboration with Genentech, a member of the Roche Group, and other future funders to improve representation of minority and underserved populations in cancer clinical trials.

Designed as a multi-phase, multi-year initiative, [the project kicks off on May 21 with a two-hour virtual symposium](#) highlighting the work of staff at community sites across the country who currently treat diverse and traditionally underserved patients with cancer.

Staff from eight community-based sites, part of the National Cancer Institute's Community Oncology Research Program (NCORP), will present short talks on trial accrual strategies, sharing ideas about what does and does not work – and why.

*"The NCORP community and Minority Underserved sites have been addressing and refining strategies to recruit patients to clinical trials for decades," says Dr. Dawn Hershman, SWOG Vice Chair of the NCORP's research portfolio. "We want to harness all they have learned and work across the National Clinical Trials Network (NCTN) to learn from each other and develop best practices for strategies to enhance diverse accrual to all of our trials."*

Symposium talks will also showcase examples of real-time changes clinicians and researchers can make to boost poorly performing clinical trials when enrollment is lagging despite the potential value of the novel cancer treatments they offer. Discussion segments will be moderated by two panels, made up of select site leaders from within the NCORP and patient advocates.

*"Increasing accessibility of cancer clinical trials, and engaging underserved communities effectively, is a core focus for Hope and SWOG," says Hope President and CEO, Jo Horn. "It requires a deep bench – we need to center voices from these communities."*

**Email [communications@swog.org](mailto:communications@swog.org) to get on a list – one or all three**

# Cancer Care Delivery (CCD) Committee

Accrual from trial opening through 6/30/2022 by Institution and Study

	S1703	S1912CD	A191901	A231601C	A231602C	A231701C	A231901C	EAQ171CD	NHLBIMDS	NRGCC007
Ascension Prov Hospitals - Southfield	-	-	4	-	-	-	-	-	1	-
Banner U Med Ctr - Tucson	1	-	-	-	-	-	-	-	-	-
Baptist Mem Hlth Care/Mid South MU NCORP	-	-	-	-	-	-	1	2	1	-
CWRU Case CCC LAPS	17	-	-	-	-	-	-	-	5	-
Ca Res Consortium of West Michigan NCORP	-	3	-	-	-	-	-	-	-	-
Ca Res for the Ozarks NCORP	-	1	-	-	-	-	-	-	-	-
Ca Res of Wisconsin & N Mich Consort	10	1	1	-	-	-	-	-	-	-
Carle CC NCORP	8	1	-	-	-	-	-	-	-	-
Columbia U MU NCORP	16	3	-	-	-	-	-	-	13	-
Columbus NCORP	4	-	-	-	-	-	-	-	-	-
CommonSpirit Health Research Inst	8	-	-	-	-	-	-	-	-	-
Cotton O'Neil CC / Stormont Vail Hlth	1	-	-	-	-	-	-	-	-	-
Dayton NCORP	3	1	-	-	-	-	-	-	-	-
Fred Hutchinson Ca Res Ctr LAPS	-	-	-	-	-	-	-	-	16	-
Georgia NCORP	2	-	-	-	-	-	-	-	-	-
Gulf South MU NCORP	6	-	-	1	-	-	-	-	-	-
Hawaii MU NCORP	6	-	-	-	-	-	-	-	5	-
Heartland Ca Res NCORP	13	4	-	-	-	-	-	-	-	1
Kaiser Permanente NCORP	4	2	-	-	-	-	-	-	5	-
Kansas City Veterans Affairs Med Ctr	-	-	-	-	-	-	-	-	4	-
Kansas Inst of Med Cancer & Blood Ctr	-	-	-	-	-	-	-	-	2	-
Lahey Hospital & Med Ctr	4	-	-	-	-	-	-	-	-	-
Loyola U Med Ctr	2	-	4	-	-	-	-	-	-	-
Massachusetts Veterans ERIC	-	-	-	-	-	-	-	-	28	-
Medical U of South Carolina MU NCORP	-	-	-	-	-	1	-	-	3	-
Michigan Ca Res Consortium NCORP	9	1	-	-	-	-	-	-	-	-

## Cancer Care Delivery (CCD) Committee

Accrual from trial opening through 6/30/2022 by Institution and Study

	S1703	S1912CD	A191901	A231601C	A231602C	A231701C	A231901C	EAQ171CD	NHLBIMDS	NRGCC007
Moffitt CC	-	-	-	-	-	-	-	-	8	-
Montana Cancer Consortium NCORP	7	-	-	-	-	-	-	-	-	-
MultiCare Tacoma General Hospital	-	-	21	-	-	-	-	1	-	-
NCORP Carolinas (Prisma Hlth NCORP)	6	-	-	-	-	-	-	-	2	-
Nevada Ca Res Foundation NCORP	1	-	-	-	-	-	-	-	-	-
New Mexico MU NCORP	12	-	-	-	-	-	-	-	-	-
Northwell Health NCORP	-	-	-	-	-	-	-	-	1	-
Oregon Health & Science U	-	-	-	-	-	-	-	-	9	-
Pacific Ca Res Consortium NCORP	10	2	-	-	-	-	-	-	-	-
Southeast Clin Onc Res Consort NCORP	4	1	-	-	-	-	-	-	-	-
UC Davis CCC LAPS	-	-	3	-	-	-	-	-	-	-
UC Irvine Health/Chao Family CCC	-	-	-	-	-	-	-	-	20	-
UC San Diego Moores CC	-	-	-	-	-	-	-	-	25	-
U Arkansas for Medical Sciences	3	-	-	-	-	-	-	-	-	-
U Colorado CC LAPS	-	-	-	-	-	-	-	-	8	-
U Kansas CC - MCA Rural MU NCORP	5	1	-	-	4	-	-	-	-	22
U Rochester LAPS	4	-	-	-	-	-	-	-	-	-
U Utah - Huntsman Cancer Inst LAPS	-	-	2	-	-	-	-	-	-	-
Upstate Carol Consort Comm Onc Res Prog	-	2	-	-	-	-	-	-	-	-
Western States Ca Res NCORP	-	1	1	-	-	-	-	-	-	-
William Beaumont Hosp-Royal Oak	-	-	-	-	-	-	-	-	2	-
Wisconsin NCORP	1	1	-	-	-	-	-	-	-	-
Yale U - Yale CC LAPS	27	-	-	-	-	-	-	-	7	-
ALLIANCE	4	4	-	-	-	-	-	-	-	-
ECOG-ACRIN	16	1	-	-	-	-	-	-	-	-
NRG	14	-	-	-	-	-	-	-	-	-
<b>Total</b>	<b>228</b>	<b>30</b>	<b>36</b>	<b>1</b>	<b>4</b>	<b>1</b>	<b>1</b>	<b>3</b>	<b>165</b>	<b>23</b>

# Cancer Survivorship Committee

## Leadership

Co-Chairs: ..... Melinda Irwin, PhD, MPH  
 ..... Halle Moore, MD

## Time/Location

Thursday, October 20, 2022 5:15 pm - 7:15 pm  
 Room: Regency A (Ballroom Level, West Tower)

## Agenda

**Welcome:** Melinda Irwin and Halle Moore

### Survivorship Presentation: "Health Equity in Cancer"

**Melissa A Simon MD MPH**

Vice Chair of Research, Department of Obstetrics and Gynecology

George H. Gardner Professor of Clinical Gynecology

Professor of Obstetrics and Gynecology, Preventive Medicine and

Medical Social Sciences

Founder/Director, Center for Health Equity Transformation

Founder/Director, Chicago Cancer Health Equity Collaborative

Northwestern University, Feinberg School of Medicine and Robert H.

Lurie Comprehensive Cancer Center

## Discussion

**Patient Advocate Update:** Lee Jones

## New Ideas

## Active Study

**S1501**, "Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III." Drs. J. Floyd and M. Leja. Activated 9/15/2017.

## Concepts in Development

**S2204**, "Randomized Phase III Trial of a Perioperative Physical Activity Intervention in Older Adults with Lung Cancer and their Family Caregivers." Drs. D. Raz and V. Sun.

**S2013 I-CHECKIT**: Immune CHECKpoint Inhibitory Toxicity analysis: Krishna Gunturu. Concept approved (Also in QOL and Symptom Control Committee)

Impact of immune checkpoint inhibitors on gonadal reserve: a longitudinal analysis of biospecimens from S1404: Katy Tsai

SWOG 0816 a secondary analysis of predictors of muscle wasting, Vickie Baracos

Randomized, phase II trial of vortioxetine for the reduction of ADT-induced cognitive impairment. Chethan Ramamurthy, MD and Ian M. Thompson II, MD

**ALTE2131**: "Gonadotropin-Releasing Hormone Analogs (GnRHa) and Protection of Ovarian Reserve in Adolescents and Young Adults with Cancer." COG led, SWOG champion is Halle Moore

Use of Continuous Glucose Monitoring to Improve Glycemic Safety and Reduce Infectious Complications in AYA ALL patients: GOG led (Allison Grimes), SWOG champion is Stephanie Tsai

## Liaison Updates

## Cardiac Advisory Panel Update

## Other Business

## Closed Study

**S1316**, "Prospective Comparative Effectiveness Trial for Malignant Bowel Obstruction." Drs. R. Krouse, J. Denevee, and V. Sun. Activated: 3/9/15; Permanently Closed: 5/15/20.

## Cancer Survivorship Committee

Accrual from trial opening through 6/30/2022 by Institution and Study

	S1501	E1Q11	EA9131
<i>Ascension Providence Hospitals - Southfield</i>	4	-	-
<i>Baptist Memorial Health Care/Mid South Minority Underserved NCORP</i>	6	-	1
<i>Bay Area Tumor Institute NCORP</i>	2	-	-
<i>CWRU Case Comprehensive Cancer Center LAPS</i>	14	-	-
<i>Cancer Research for the Ozarks NCORP</i>	9	-	-
<i>City of Hope Comprehensive Cancer Center</i>	43	-	-
<i>Columbia University Minority Underserved NCORP</i>	2	-	-
<i>CommonSpirit Health Research Institute</i>	1	-	-
<i>Fred Hutchinson Cancer Research Center LAPS</i>	4	-	-
<i>Georgia Cares Minority Underserved NCORP</i>	-	-	1
<i>Georgia NCI Community Oncology Research Program</i>	12	-	-
<i>Gulf South Minority Underserved NCORP</i>	4	-	-
<i>Hawaii Minority Underserved NCORP</i>	-	21	-
<i>Heartland Cancer Research NCORP</i>	18	-	-
<i>Henry Ford Hospital</i>	1	-	-
<i>Kaiser Permanente NCI Community Oncology Research Program</i>	1	-	60
<i>King Faisal Specialist Hospital and Research Centre</i>	3	-	-
<i>Lahey Hospital and Medical Center</i>	6	-	-
<i>Loyola University Medical Center</i>	8	-	-
<i>Medical University of South Carolina Minority Underserved NCORP</i>	1	-	-
<i>Michigan Cancer Research Consortium NCORP</i>	3	-	-
<i>Moffitt Cancer Center</i>	17	-	-
<i>Montana Cancer Consortium NCORP</i>	1	-	-
<i>NCORP of the Carolinas (Prisma Health NCORP)</i>	2	-	-
<i>National Cancer Center-Korea</i>	1	-	-
<i>New Mexico Minority Underserved NCORP</i>	6	1	-
<i>Oregon Health and Science University</i>	1	-	-
<i>UC Davis Comprehensive Cancer Center LAPS</i>	2	-	-
<i>USC Norris Comprehensive Cancer Center LAPS</i>	4	-	-
<i>University of Kansas Cancer Center - MCA Rural MU NCORP</i>	7	-	-
<i>University of Michigan Comprehensive Cancer Center LAPS</i>	10	-	-
<i>Upstate Carolina Consortium Community Oncology Research Program</i>	-	1	-
<i>Wayne State University - Karmanos Cancer Institute LAPS</i>	6	-	-
<i>ALLIANCE</i>	20	-	-
<i>ECOG-ACRIN</i>	34	-	-
<i>NRG</i>	20	-	-
<b>Total</b>	<b>273</b>	<b>23</b>	<b>62</b>



# Palliative & End of Life Care Committee

## Leadership

Co-Chairs: ..... Robert S. Krouse, MD  
 ..... Mark A. O'Rourke, MD  
 ..... Marie Bakitas, DNSc

## Time/Location

Friday, October 21, 2022 7:30 am- 9:30 am

Room: Regency A (Ballroom Level, West Tower)

## Agenda

**7:30 - 7:35 am**      **Welcome and Introductions** – Co-Chairs

**7:35 - 7:40 am**      **Committee Liaison Updates** - Patient Advocates/ORP

**7:40 - 8:10 am**      **Plenary: "Palliative Care Patient-Reported Experience Measures: Heard & Understood"** - Katherine Ast, MSW, LCSW, PhD student, Director, Quality and Research, American Academy of Hospice and Palliative Medicine (AAHPM)

**8:10 - 8:40 am**      **Developing Studies Updates**

"Randomized multicenter placebo-controlled trial evaluating lanreotide for the reduction of postoperative pancreatic fistulae." Jonathan G. Sham, MD, Charles A. Coltman, Jr. Fellow

S2016, "Randomized Phase III Trial of a Primary Palliative Care Intervention in Pancreatic Cancer." Drs. Chung and Sun.

"Depression Screening and Treatment in Patients Requesting Medical Aid in Dying (MAID)" Drs. Salman and Blanke

**8:40 - 8:45 am**      **Active Study Update**

S1820, "A Randomized Trial of the Altering Intake, Managing Symptoms Intervention for Bowel Dysfunction in Rectal Cancer Survivors Compared to a Healthy Living Education Control: A Feasibility and Preliminary Efficacy Study (AIMS-RC)." Dr. Sun. Activated: 12/9/19. Permanently Closed to Accrual for Step 1: 4/12/22

**8:45 - 8:50 am**      **Pre-SWOG Active Study Updates**

Hope/CAPC Provider Communication Study, Drs. Ishwaria M. Subbiah and Rajiv Agarwal

"Study of Breast Cancer Survivor Symptoms Correlation with Fatigue Measured by Prolonged Wrist Actigraphy," Lauren A. Fowler PhD and Jamie S. Myers PhD, RN

Sleep Hygiene Education, ReadWatch™ actigraphy, and telehealth cognitive behavioral training for insomnia Effect, on Symptom Relief for Men with Prostate Cancer Receiving Androgen Deprivation Therapy (ADT) (SHERE-Relief 2), funded by the Oncology Nursing Foundation as an RE03 two-year grant. Jamie S. Myers, PhD, RN and Lauren A. Fowler, PhD

**8:50 - 8:55 am**      **Closed Study Update**

S1316, "Prospective Comparative Effectiveness Trial for Malignant Bowel Obstruction." Dr. Krouse. Activated: 3/9/15; Closed: 5/15/20.

**8:55 - 9:10 am**      **New Concepts**

"Phase III Trial of Telehealth Intervention for Self-Management of Eating after Gastroesophageal Cancer Surgery" – Jae Kim, MD and Virginia Sun, PhD, RN

"Feasibility Study of a Hope Workshop Intervention Designed to Improve Cancer Survivor Hopefulness and Endocrine Therapy Adherence," David Feldman, PhD and Ben Corn, MD

Feasibility and Acceptability of an Online Intervention to Enhance Hopefulness Among Oncology Professionals David Feldman, PhD and Ben Corn, MD

**9:10 - 9:25 am**      **Open Discussion and Q&A**

**9:25 - 9:30 am**      **Closing Comments and Adjourn:** Co-Chairs

## Palliative and End of Life Care Committee

<b>Accrual from trial opening through 6/30/2022 by Institution and Study</b>	<b>51820</b>
<i>Banner University Medical Center - Tucson</i>	1
<i>City of Hope Comprehensive Cancer Center</i>	3
<i>Columbus NCI Community Oncology Research Program</i>	1
<i>Fred Hutchinson Cancer Research Center LAPS</i>	6
<i>Hawaii Minority Underserved NCORP</i>	2
<i>Heartland Cancer Research NCORP</i>	7
<i>Michigan Cancer Research Consortium NCORP</i>	2
<i>NCORP of the Carolinas (Prisma Health NCORP)</i>	5
<i>New Mexico Minority Underserved NCORP</i>	2
<i>Northwestern University LAPS</i>	2
<i>UC Irvine Health/Chao Family Comprehensive Cancer Center</i>	10
<i>University of Cincinnati Cancer Center-UC Medical Center</i>	1
<i>University of Texas MD Anderson Cancer Center LAPS</i>	11
<i>Upstate Carolina Consortium Community Oncology Research Program</i>	3
<i>Virginia Mason Medical Center</i>	5
<b>ALLIANCE</b>	4
<b>ECOG-ACRIN</b>	1
<b>NRG</b>	29
<b>Total</b>	<b>95</b>

# Prevention & Epidemiology Committee

## Leadership

Co-Chairs: ..... Banu Arun, MD  
 ..... Marian L. Neuhouser, PhD, RD

## Time/Location

Thursday, October 20, 2022 11:15 am - 1:15 pm  
 Room: Regency A (Ballroom Level, West Tower)

## Agenda

### Introduction

Welcome & Opening Comments Marian Neuhouser & Banu Arun

**Cancer Prevention Presentation: "The Promise of Multicancer Early Detection"** Eric A. Klein, MD, Professor and Chair Emeritus, Glickman Urological and Kidney Institute, Cleveland Clinic Lerner College of Medicine

**Patient Advocate update** Cheryl Jernigan

### Active Studies

**S0820**, "A Double-Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III – Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)." Drs. J. Zell, P. Brown, M.P. Lance, et al. Activated: 3/1/13.

**S1823**, "A Prospective Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients with Newly Diagnosed Germ Cell Tumors". Drs. C. Nichols and L. Nappi. Activated: 6/1/20.

**S1904**, "Cluster Randomized Controlled Trial of Patient and Provider Decision Support to Increase Chemoprevention Informed Choice Among Women with Atypical Hyperplasia or Lobular Carcinoma In Situ – Making Informed Choices on Incorporating Chemoprevention into Care (MiCHOICE)." Drs. K. Crew, R. Kukafka, et al. Activated 9/1/20.

## Other Group Studies with SWOG Study Champions

**CTSU A151804**, "Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events." Dr. G. Lyman. Activated: 1/31/20.

**CTSU A212102**, "A Blinded Reference Set for Multicancer Early Detection Blood Tests." Dr. J. McGuinness. Activated: 8/1/22.

**CTSU EA1151**, "Tomosynthesis Mammographic Imaging Screening Trial (TMIST)." Dr. B. Arun. SWOG Activated: 7/6/17.

**CTSU/NHLBI-MDS**, "The National Myelodysplastic Syndromes Natural History Study." Drs. D. Hill and C. Arana Yi. Activated: 4/5/16.

## Studies approved by triage and pending DCP approval

**S2304**, Phase II Randomized Trial of Intraoperative Radiotherapy (IORT) versus NO IORT for Postmenopausal Women with Low-Risk Ductal Carcinoma In Situ (DCIS) after Breast Conserving Surgery." Dr. E. Connolly.

## Substudies - Pending CTEP Approval

**Amendment to S1418**, "Exploratory Study to Evaluate Mammographic Density Changes in Patients Receiving Pembrolizumab in S1418." Dr. B. Arun.

**Amendment to S1007**, "Effects of Chemoprevention and Adjuvant Endocrine Therapy on a Convolutional Neural Network-Based Breast Cancer Risk Model Using Mammographic Datasets from S0812 and S1007." Drs. K. Crew, K. Kalinsky, R. Ha.

## Concepts in Development

"Treatment Tolerability with an Alternate Dose of Exemestane or Low-dose Tamoxifen Compared to Standard Dose Exemestane Among Postmenopausal Women with Atypical Hyperplasia, Lobular Carcinoma in situ and Hormone Receptor-Positive Ductal Carcinoma in situ", Dr. J. McGuinness.

## New Business/Open Discussion for new ideas

## Prevention &amp; Epidemiology Committee

Accrual from trial opening through 6/30/2022 by Institution and Study

	S0820	S1823	S1904	A211102	A211601	EA1151	EA2185	NRGCC008
Ascension Providence Hospitals - Southfield	1	-	-	-	2	-	-	-
Ascension Via Christi Hospitals Wichita	12	-	-	-	-	-	-	-
Banner MD Anderson Cancer Center	10	-	-	-	-	1	-	-
Banner University Medical Center - Tucson	-	4	-	-	-	56	-	-
Baptist Memorial Health Care/Mid South Minority Underserved NCORP	4	-	2	-	-	2	-	-
Bay Area Tumor Institute NCORP	1	4	-	-	-	-	-	-
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	-	-	-	-	-	-	-	2
Brooke Army Medical Center	1	-	-	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-	-	135	-	-
Cancer Research Consortium of West Michigan NCORP	2	-	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	1	5	-	-	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	1	1	-	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	4	12	-	-	2	-	-
City of Hope Comprehensive Cancer Center	1	-	7	2	-	-	-	-
Columbia University Minority Underserved NCORP	1	-	18	1	-	-	-	-
Columbus NCI Community Oncology Research Program	6	8	-	-	-	-	-	-
CommonSpirit Health Research Institute	4	-	-	-	-	-	-	-
Dayton NCI Community Oncology Research Program	1	-	-	-	-	-	-	-
Essentia Health NCI Community Oncology Research Program	4	1	-	-	-	97	-	-
Georgia Cares Minority Underserved NCORP	2	-	-	-	-	-	-	-
Georgia NCI Community Oncology Research Program	2	-	-	-	-	-	-	-
Gulf South Minority Underserved NCORP	-	7	-	-	-	-	-	-
Hawaii Minority Underserved NCORP	10	2	10	-	-	-	-	-
Heartland Cancer Research NCORP	2	13	4	-	-	-	-	-
Henry Ford Hospital	-	-	-	-	-	133	-	-
Kaiser Permanente NCI Community Oncology Research Program	40	91	6	-	-	-	-	-
Lahey Hospital and Medical Center	-	-	3	-	-	-	-	-
Loma Linda University Medical Center	2	5	-	-	-	-	-	-
Loyola University Medical Center	2	-	1	-	-	-	-	-
Massachusetts Veterans Epidemiology Research and Information Center	3	-	-	-	-	-	5	-
Medical University of South Carolina Minority Underserved NCORP	-	-	-	-	-	4	-	-
Meharry Medical College	1	-	-	-	-	-	-	-
Memorial Hermann Texas Medical Center	-	-	-	-	-	8	-	-
Michigan Cancer Research Consortium NCORP	11	-	-	-	-	-	-	-
MultiCare Tacoma General Hospital	2	-	-	-	-	-	-	-

## Prevention &amp; Epidemiology Committee

Accrual from trial opening through 6/30/2022 by Institution and Study

	S0820	S1823	S1904	A21102	A211601	EA1151	EA2185	NRGCC008
NCORP of the Carolinas (Prisma Health NCORP)	-	10	-	-	-	416	-	-
Nevada Cancer Research Foundation NCORP	1	1	-	-	-	-	-	-
New Mexico Minority Underserved NCORP	2	4	-	-	-	-	-	-
Northwell Health NCORP	-	7	-	-	-	-	-	-
Ohio State University Comprehensive Cancer Center LAPS	-	2	-	-	-	-	-	-
Oregon Health and Science University	-	13	-	-	-	-	1	-
Pacific Cancer Research Consortium NCORP	2	-	-	-	-	-	-	-
Salem Hospital	-	3	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	3	2	-	-	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	30	3	-	-	-	-	-	-
UC San Diego Moores Cancer Center	-	18	-	-	-	-	-	-
UCLA / Jonsson Comprehensive Cancer Center	-	30	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	5	29	-	-	-	-	-	-
University of Arkansas for Medical Sciences	-	-	-	-	-	350	2	-
University of Cincinnati Cancer Center-UC Medical Center	-	3	-	-	-	-	-	-
University of Colorado Cancer Center LAPS	8	11	-	-	-	2	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	4	-	-	-	-	-	-	-
University of Kentucky/Markey Cancer Center	-	-	-	-	-	9	-	-
University of Mississippi Medical Center	1	3	-	-	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	-	2	-	-	-	-	-	-
University of Rochester LAPS	-	11	-	-	-	231	-	-
University of Texas Health Science Center at San Antonio	9	-	-	-	-	-	-	-
University of Texas MD Anderson Cancer Center LAPS	5	-	-	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	18	-	-	-	-	-
Upstate Carolina Consortium Community Oncology Research Program	-	-	-	-	-	619	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	6	-	-	-	-	-	-
Virginia Mason Medical Center	9	10	-	-	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	2	-	-	-	-	-	-	-
Western States Cancer Research NCORP	1	-	-	-	-	67	-	-
Wisconsin NCI Community Oncology Research Program	1	-	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	25	-	-	-	-	-	-	-
ALLIANCE	36	61	44	-	-	-	-	-
CCTG	-	90	-	-	-	-	-	-
ECOG-ACRIN	30	39	21	-	-	-	-	-
NRG	38	25	37	-	-	-	-	-
<b>Total</b>	<b>339</b>	<b>528</b>	<b>183</b>	<b>3</b>	<b>2</b>	<b>2,132</b>	<b>8</b>	<b>2</b>

# Symptom Control & Quality of Life Committee

## Leadership

Co-Chairs: ..... Michael J. Fisch, MD, MPH  
 ..... Norah Lynn Henry, MD, PhD

## Time/Location

Thursday, October 20, 2022 1:30 pm - 3:30 pm  
 Room: Regency A (Ballroom Level, West Tower)

## Agenda

The Translational Spectrum in Symptom Control: From Measurement Science to Biological Correlates

### Patient-Reported Outcomes – What is a Meaningful Change?

Plenary speaker: Salene Jones, PhD

### Opportunities and Challenges as a Translational Symptom Scientist at SWOG

Plenary speaker: Daniel Hertz, PhD

## Active Studies

**S1600**, “A Randomized Phase III Double-Blind Clinical Trial Evaluating the Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes (SIMMune).” Drs. Hamilton-Reeves, Holzbeierlein, Kukreja, et al. Activated: 2/21/19; Temporarily closed: 8/9/22.

**S1614**, “A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy for Solid Tumors.” Drs. Hwang, Lok, Gehring, et al. Activated: 2/21/19.

**S2013**, “Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study.” Drs. Gunturu, Hershman, Kuderer, et al. Activated: 8/16/21.

## Other Concepts in Development (Soon to activate)

**S2010**, “A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone to Improve Persistence with Endocrine Therapy in Young Women with Stage I-III Breast Cancer (ASPEN).” Drs. Henry, Hershman, and Skaar.

**S2205**, “ICE COMPRESS: Randomized Trial of Limb Cryocompression Versus Continuous Compression Versus Low Cyclic Compression for the Prevention of Taxane-Induced Peripheral Neuropathy.” Drs. Accordino, Pennington, Hershman, et al.

## Closed Studies

**S1714**, “A Prospective Observational Cohort Study To Develop A Predictive Model Of Taxane-Induced Peripheral Neuropathy In Cancer Patients”- Drs. Trivedi, Hershman, Brannagan, et al. Activated 3/1/19.

**S0702**, “A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients with Bone Metastases Starting Zoledronic Acid Treatment.” Dr. Van Poznak and Dr. Gralow M.D. Activated 12/15/2008. Closed to Accrual 06/01/19.

**S1200**, “Randomized Blinded Sham- and Waitlist-Controlled Trial of Acupuncture for Joint Symptoms Related to Aromatase Inhibitors in Women with Early Stage Breast Cancer.” Drs. Hershman and Crew. Activated: 3/27/12. Closed: 2/15/17.

## Committee Business

1. What is happening with our open studies?
2. What other studies are we planning?
3. What other updates should we know about?

Patient Advocate update

Statistical Center update

## Other SWOG Studies with Symptom Control and QOL Component

### Breast

**S1706**, “A Phase II Randomized, Double-Blinded, Placebo-Controlled Trial of Olaparib Administered Concurrently with Radiotherapy for Inflammatory Breast Cancer.” Dr. Jagsi. Activated: 9/12/18.

### Cancer Care Delivery

**S1703**, “Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (Stmddm) Versus Usual Care in Patients with Metastatic Hormone Receptor Positive Her-2 Negative Breast Cancer.” Drs. Accordino, Hershman, and Ramsey. Activated: 7/16/18.

**S1912CD**, “A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT).” Drs. Shankaran, Carlos, Hershman, et al. Activated: 7/26/21.

# Symptom Control & Quality of Life Committee

**S2108CD**, "A Cluster Randomized Trial Comparing an Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy." Drs. Reuter, Trivedi, Symington, et al. Activated: 8/22/22.

## GU

**S1802**, "Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer." Dr. Chapin. Activated: 9/17/18.

**S1806**, "Phase III Randomized Trial of Concurrent Chemoradiotherapy with or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer." Dr. Singh. Activated: 4/19/18.

## Leukemia

**S1925**, "Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study." Drs. Stephens, Hill, Pagel, et al. Activated: 12/14/20.

## Lung

**S1914**, "A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC#783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC." Drs. Daly, Simone, Kelly, et al. Activated: 3/25/20.

**S1827**, "MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)." Drs. Rusthoven, Brown, Wefel, et al. Activated: 1/10/20.

## Lymphoma

**S1826**, "A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age  $\geq$  12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma." Drs. Herrera, Friedberg. Activated: 7/19/19.

**S1918**, "A Phase II/III Randomized Study of R-miniCHOP with or without Oral Azacitidine (CC-486) in Participants Age 75 Years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIb Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements." Drs. Brem, Smith, Henry, et al. Activated: 3/19/21.

## Myeloma

**S1803**, "Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)." Drs. Krishnan, Chhabra, and Callander. Activated: 6/27/19.

## Prevention and Epidemiology

**S0820**, "A Double-Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III – Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)." Drs. Zell, Brown, Lance, et al. Activated: 3/1/13.

**S1904**, "Cluster Randomized Controlled Trial of Patient and Provider Decision Support To Increase Chemoprevention Informed Choice Among Women with Atypical Hyperplasia or Lobular Carcinoma in Situ - Making Informed Choices on Incorporating Chemoprevention into Care (MiCHOICE)." Drs. Crew, Kukafka, Hershman, et al. Activated: 9/1/20.

## NCTN Studies

**CTSUNRG-GI004**, "Colorectal Cancer Metastatic dMMR Immunotherapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or Without Atezolizumab or Atezolizumab Monotherapy in the First Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer." Dr. Overman. Activated: 11/7/17; Temporarily closed: 6/4/20; Reactivated: 1/29/21.

## Symptom Control & Quality of Life Committee

Accrual from trial opening through 6/30/2022 by Institution and Study

	S1600	S1614	S1714	S2013	A221505	A221602	A221702	A221805	A222004	EAQ202	EAZ171
Ascension Prov Hospitals - Southfield	-	-	-	7	-	-	-	-	-	-	-
Ascension Via Christi Hospitals Wichita	-	-	1	-	-	-	-	-	-	-	-
CWRU Case CCC LAPS	-	-	-	-	3	-	1	-	-	-	-
Ca Res Consortium of West Mich NCORP	-	-	146	-	-	-	-	-	-	-	-
Ca Res for the Ozarks NCORP	-	-	10	1	-	-	-	-	-	-	-
Ca Res of Wisconsin and N Mich Consort	-	-	-	26	-	-	-	-	-	-	-
Carle CC NCORP	-	-	6	3	-	-	-	-	-	-	-
City of Hope CCC	4	-	-	-	-	-	-	-	-	-	-
Columbia University MU NCORP	-	-	27	8	-	3	-	-	-	-	-
Columbus NCORP	-	-	-	7	-	-	-	-	-	-	-
CommonSpirit Hlth Res Inst	-	-	71	6	-	-	-	-	-	-	-
Dayton NCORP	-	-	-	-	-	1	-	1	-	-	-
Desert Regional Med Ctr	-	-	3	-	-	3	-	-	-	-	-
Fred Hutchinson Ca Res Ctr LAPS	10	-	-	-	-	-	-	-	-	-	-
Georgia NCORP	-	-	18	12	-	-	-	-	-	-	-
Grupo Onc Cooperativo de Invest	-	-	10	-	-	-	-	-	-	-	-
Gulf South MU NCORP	1	-	26	7	1	-	-	-	-	-	1
Hawaii MU NCORP	-	-	70	-	-	-	-	-	-	-	-
Heartland Ca Res NCORP	-	-	38	54	-	-	-	-	-	-	-
Henry Ford Hospital	7	-	-	-	-	-	-	-	-	-	-
Instituto Nacional De Cancerologia	-	-	10	-	-	-	-	-	-	-	-
Instituto Nacional De Cancerologia de Mexico	-	-	60	-	-	-	-	-	-	-	-
Kaiser Permanente NCORP	-	2	65	1	-	-	-	-	-	-	-
Lahey Hospital and Med Ctr	-	-	22	19	-	-	-	-	-	-	-
Loyola University Med Ctr	-	-	2	-	-	-	-	-	-	-	-
Massachusetts Vet Epi Res & Info Ctr	-	-	-	4	-	-	-	-	-	-	-



## Symptom Control & Quality of Life Committee

Accrual from trial opening through 6/30/2022 by Institution and Study

	S1600	S1614	S1714	S2013	A221505	A221602	A221702	A221805	A222004	EAQ202	EAZ171
Medical U South Carolina MU NCORP	-	-	-	-	-	-	-	-	-	-	2
Montana Cancer Consortium NCORP	-	-	-	2	-	-	-	-	-	-	-
NCORP Carolinas (Prisma Hlth NCORP)	-	-	30	-	-	-	-	-	-	29	-
Nevada Ca Res Foundation NCORP	-	-	-	-	-	-	-	-	-	3	-
Northwell Health NCORP	-	-	-	-	2	3	-	-	-	-	-
Oregon Health & Science U	-	-	-	10	-	-	-	-	-	-	-
Pacific Ca Res Consortium NCORP	-	-	2	-	-	-	-	-	-	-	-
Southeast Clin Onc Res Consort NCORP	-	-	278	36	-	-	-	-	-	-	-
The West Clinic - Wolf River	-	-	-	-	6	-	-	-	-	-	-
Tulane U Hlth Sciences Ctr	-	-	1	-	-	-	-	-	-	-	-
UC Irvine Hlth/Chao Family CCC	-	-	-	-	1	4	-	-	-	-	-
USC Norris CCC LAPS	59	-	-	-	-	-	-	-	-	-	-
U Arkansas for Medical Sciences	-	-	68	5	-	-	-	-	-	-	-
U Colorado CC LAPS	6	-	2	-	16	-	1	2	-	-	-
U Kansas CC - MCA Rural MU NCORP	37	-	24	-	-	-	-	2	-	-	-
U Kentucky/Markey CC	-	-	-	-	-	10	-	-	-	-	-
U Rochester LAPS	10	-	-	-	-	-	14	-	-	-	-
U Texas Hlth Science Ctr San Antonio	-	-	14	5	-	-	-	-	-	-	-
U Texas MD Anderson CC LAPS	-	1	-	-	-	-	-	-	-	-	-
U Utah - Huntsman Ca Inst LAPS	-	-	-	-	-	8	-	-	2	-	-
Upstate Carolina Consortium NCORP	-	-	118	-	1	-	-	-	-	-	-
Wayne State U - Karmanos Ca Inst LAPS	-	-	-	-	-	-	1	-	-	-	-
Wisconsin NCORP	-	-	-	5	-	-	-	-	-	-	-
ALLIANCE	5	-	44	39	-	-	-	-	-	-	-
ECOG-ACRIN	-	-	80	23	-	-	-	-	-	-	-
NRG	1	1	90	28	-	-	-	-	-	-	-
<b>Total</b>	<b>140</b>	<b>4</b>	<b>1,336</b>	<b>308</b>	<b>30</b>	<b>32</b>	<b>17</b>	<b>5</b>	<b>2</b>	<b>32</b>	<b>3</b>

# Early Therapeutics & Rare Cancers Committee

## Leadership

Chair: ..... Razelle Kurzrock, MD  
 Vice-Chair: ..... Young Kwang Chae, MD, MPH  
 Executive Officer: ..... Christopher W. Ryan, MD  
 Statisticians: ..... Megan Othus, PhD  
 ..... Melissa Plets, MS  
 ..... Edward Mayerson, MS

## Designates

Data Coordinators: ..... Christine Magner  
 Digital Engagement: ..... Kanwal Raghav, MD, MBBS  
 Oncology Research Professionals:  
 CRAs: ..... TBD  
 Nurse: ..... TBD  
 Pharmaceutical Science: ..... Craig Elg, PharmD  
 ..... Sun "Coco" Yang, PharmD, PhD  
 Patient Advocate: ..... Marcia K. Horn, JD  
 Protocol Project Manager: ..... Catrina Mireles  
 Clinical Trials Program Manager: ..... TBD

## Early Therapeutics Liaisons

Breast Committee Liaison: ..... Stephanie L. Graff, MD  
 Cancer Control Liaison: ..... Jason M. Prosek, MD  
 ..... Lara E. Davis, MD  
 Genitourinary Committee Liaison: ..... Neeraj Agarwal, MD  
 Imaging: ..... TBD  
 Lung Committee Liaison: ..... Shirish M. Gadgeel, MD  
 Lymphoma Committee Liaison: ..... Nasheed Mohammad Hossain, MD  
 Melanoma Committee Liaison: ..... Jeffrey A. Sosman, MD  
 Myeloma Committee Liaison: ..... Frits van Rhee, MD, PhD

## Time/Location

Thursday, October 20, 2022 10:00 am - 12:15 pm  
 Room: Regency C (Ballroom Level, West Tower)

## Agenda

**10:00 - 10:05 am** Welcome and Introduction - Razelle Kurzrock, MD  
**10:05 - 10:30 am** Updates from Sarcoma Working Group - Lara Davis, MD  
**10:30 - 10:45 am** New Approved Study: S2012, "Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC #783608) in Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)" - David Zhen, MD  
**10:45 - 11:10 am** CIMAC and Translational Immunology in DART - Young Chae, MD

**11:10 - 11:30 am** Translational findings from non-pancreatic neuroendocrine DART cohorts from CIMAC - Cara Haymaker, PhD

**11:30 - 11:50 am** DART: Clinical Trial Update - Sandip Patel, MD

**11:50 - 12:10 pm** Update from CNS Working Group - Manmeet Ahluwalia, MD

**12:10 - 12:15 pm** Wrap-Up - Razelle Kurzrock, MD

## Active Studies

**S1609**, "DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors." Drs. Patel, Chae, and Kurzrock. Activated: 1/13/17.

**S2012**, "Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)." Drs. Zhen, Chiorean, Burgess, Swisher. Activated: 12/2/21.

**CTSU/EAY131**, "Molecular Analysis for Therapy Choice (MATCH)." Activated: 8/12/2015.

**CTSU/NRG-BN007**, "A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab versus Temozolomide in Patients with Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma." Dr. Lassman. SWOG Champion: Dr. Ahluwalia. Activated: 8/6/20. Temporarily closed: 4/27/22.

**CTSU/EA2183**, "A Phase III Study of Consolidative Radiotherapy in Patients with Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma." Dr. Uboho. SWOG Champion: Dr. Saeed. Activated: 2/6/20.

**CTSU/EA3163**, "Phase II Randomized Trial of Neoadjuvant Chemotherapy Followed by Surgery and Post-Operative Radiation versus Surgery and Post-Operative Radiation for Organ Preservation of T3 and T4a (and Selected T4b) Nasal and Paranasal Sinus Squamous Cell Carcinoma (NPNSCC)." Dr. Saba. SWOG Champion: Dr. Swiecicki. Activated: 3/28/18.

**CTSU/A071601**, "Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas." Dr. Brasti-anos. SWOG Champion: Dr. Ahluwalia. Activated: 8/4/17. Temporarily Closed (Cohort A): 9/8/20.

**CTSU/NRG-GY006**, "A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer." Dr. Leath. SWOG Champion: Dr. Robinson. Activated: 1/15/16.

# Early Therapeutics & Rare Cancers Committee

**CTSU/A071401**, "Phase II Trial of SMO/AKT/NF2/CDK Inhibitors in Progressive Meningiomas with SMO/AKT/NF2/CDK Pathway Mutations." Dr. Brastianos. SWOG Champion: Dr. Piccioni. Activated: 8/28/2015.

**AGCT1531**, "A Phase III Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors" SWOG Champion: Dr. D'Souza Activated: 5/8/17.

**AOST2031**, "A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma" SWOG Champion: Dr. Hofstetter. Activated: 2/15/22

**A071702**, "A Phase II Study of Checkpoint Blockade Immunotherapy in Patients with Somatic Hy-per-mutated Recurrent Glioblastoma." SWOG Champion: Dr. M. Ahluwalia. Activated: 10/30/20

## Proposed Studies

**NRG-BN1803**, "NRG-COG Phase II Trial of Radiation Plus Concurrent and Adjuvant ONC201 for New-ly Diagnosed, H3 K27M-Mutant Gliomas." SWOG Champion: Dr. Ahluwalia.

**NRG-OV1821**, "A Randomized Phase II Trial of Olaparib Versus Olaparib + Tremelimumab in Plati-num-Sensitive Recurrent Ovarian Cancer." Dr. Robinson.

**NRG-BN1855**, "A Randomized Phase II/III Open Label Study of Ipilimumab and Nivolumab Vs Te-mozolomide in Patients with Newly Unmethylated MGMT (Tumor O-6-Methylguanine DNA Methyl-transfer-ase) Glioblastoma." Dr. M. Ahluwalia.

**NRG-HN1854**, "An Open-label, Phase III Study of Platinum-Gemcitabine with or Without Nivolumab in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma." Dr. P. Swiecicki.

**NRG-UC1805**, "Randomized Phase III Trial of Radiation +/- Pembrolizumab for High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer." Dr. W. Robinson.

## Closed Studies

**CTSU/NRG-GY020**, "A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometri-oid Endometrial Cancer." Dr. Backes. SWOG Champion: Dr. Robinson. Activated: 2/7/20. Closed: 8/29/22.

**NCICOV19**, "NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study." Dr. Karim. Activated: 5/21/20. Closed: 2/1/2022.

**CTSU/NRG-GY009**, "A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer." Dr. O'Ceirbhail. SWOG Champion: Dr. Robin-son. Activated: 5/12/17. Closed 10/14/2021

**CTSU/NRG-HN007**, "An Open-Label, Phase III Study of Platinum-Gemcitabine with or without Nivolumab in the First-Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma." Dr. Brigitte B. Y. Activated: 9/8/20; Closed: 10/28/21

## Early Therapeutics & Rare Cancers Committee

Accrual from trial opening through 6/30/2022 by Institution and Study

	S1609	S2012	A071401	AGCT1531	EAY131
Ascension Providence Hospitals - Southfield	1	-	-	-	3
Baptist Memorial Health Care/Mid South Minority Underserved NCORP	2	-	-	-	-
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	-	-	-	-	3
CWRU Case Comprehensive Cancer Center LAPS	7	-	-	-	10
Cancer Research for the Ozarks NCORP	1	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	3	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	3	-	-	-	-
Cedars-Sinai Medical Center	8	-	-	-	6
City of Hope Comprehensive Cancer Center	2	-	-	-	6
Columbus NCI Community Oncology Research Program	3	-	-	-	-
CommonSpirit Health Research Institute	17	-	1	-	9
Dayton NCI Community Oncology Research Program	2	-	-	-	1
Essentia Health NCI Community Oncology Research Program	4	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	10	-	-	-	2
Georgia NCI Community Oncology Research Program	6	-	-	-	-
Gulf South Minority Underserved NCORP	2	-	-	-	-
Hawaii Minority Underserved NCORP	4	-	-	-	1
Heartland Cancer Research NCORP	15	-	-	-	1
Henry Ford Hospital	17	-	-	-	11
Houston Methodist Hospital	-	-	-	-	1
Intermountain Medical Center	1	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	27	-	-	-	6
Loma Linda University Medical Center	6	-	-	-	1
Loyola University Medical Center	4	-	-	-	-
Massachusetts Veterans Epidemiology Research and Information Center	5	-	-	-	-
Medical University of South Carolina Minority Underserved NCORP	4	-	-	-	2
Michigan Cancer Research Consortium NCORP	12	-	-	-	-
Moffitt Cancer Center	22	-	-	-	-
Montana Cancer Consortium NCORP	16	-	-	-	-
MultiCare Tacoma General Hospital	2	-	-	-	-
Nevada Cancer Research Foundation NCORP	18	-	-	-	-

## Early Therapeutics & Rare Cancers Committee

Accrual from trial opening through 6/30/2022 by Institution and Study

	S1609	S2012	A071401	AGCT1531	EAY131
New Mexico Minority Underserved NCORP	18	-	-	-	-
Northwestern University LAPS	16	-	-	-	-
Oregon Health and Science University	11	-	-	-	-
Pacific Cancer Research Consortium NCORP	12	-	-	-	-
Saint Luke's Hospital of Kansas City	-	-	-	-	1
Southeast Clinical Oncology Research Consortium NCORP	-	-	-	-	8
Sutter Cancer Research Consortium	2	-	-	-	4
The Don and Sybil Harrington Cancer Center	-	-	-	1	-
Tulane University Health Sciences Center	-	-	-	-	1
UC Davis Comprehensive Cancer Center LAPS	11	-	-	-	9
UC Irvine Health/Chao Family Comprehensive Cancer Center	8	-	1	-	19
UC San Diego Moores Cancer Center	27	-	2	-	-
USC Norris Comprehensive Cancer Center LAPS	4	-	-	-	-
University of Arkansas for Medical Sciences	5	-	-	-	3
University of Colorado Cancer Center LAPS	6	-	1	-	9
University of Kansas Cancer Center - MCA Rural MU NCORP	35	-	-	-	6
University of Kentucky/Markey Cancer Center	-	-	-	-	13
University of Michigan Comprehensive Cancer Center LAPS	32	-	-	-	24
University of Mississippi Medical Center	5	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	2	-	-	-	-
University of Rochester LAPS	5	-	-	-	-
University of Texas Health Science Center at San Antonio	5	-	-	-	7
University of Texas MD Anderson Cancer Center LAPS	19	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	3	-	-	-	-
Upstate Carolina Consortium Community Oncology Research Program	4	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	-	-	3
Wisconsin NCI Community Oncology Research Program	12	-	-	-	-
Yale University - Yale Cancer Center LAPS	7	-	2	-	13
ALLIANCE	105	1	-	-	-
ECOG-ACRIN	78	-	-	-	-
NRG	137	-	-	-	-
<b>Total</b>	<b>793</b>	<b>1</b>	<b>7</b>	<b>1</b>	<b>183</b>

# Gastrointestinal Committee

## Leadership

Chair: ..... Philip A. Philip, MD, PhD, FRCP  
 Vice-Chair: ..... Elena G. Chiorean, MD  
 Executive Officer: ..... Christopher W. Ryan, MD  
 Statisticians: ..... Katherine A. Guthrie, PhD  
 ..... Sarah Colby, MS

## Scientific Leadership

Phase I Studies: ..... Sandip P. Patel, MD  
 Gastroesophageal: ..... Syma Iqbal, MD  
 ..... Zev A. Wainberg, MD  
 Pancreatic: ..... Elena Gabriela Chiorean, MD  
 ..... Andrew M. Lowy, MD (Surgical representative)  
 Hepatobiliary: ..... Anthony B. El-Khoueiry, MD  
 ..... Rachna T. Shroff, MD  
 ..... Syed Ahmad, MD (Surgical representative)  
 Colon: ..... Philip J. Gold, MD  
 ..... Wells A. Messersmith, MD  
 Neuroendocrine Tumors: ..... Nageshwara Arvind Dasari, MD  
 ..... Jonathan R. Strosberg, MD  
 Ano-Rectal: ..... Lisa A. Kachnic, MD  
 ..... Hagen F. Kennecke, MD  
 Translational Medicine: ..... Heinz-Josef Lenz, MD  
 ..... Christopher H. Lieu, MD  
 ..... Daniel Catenacci, MD  
 Imaging: ..... Anthony F. Shields, MD, PhD  
 Pathology: ..... Mary Kay Washington, MD, PhD  
 Radiation Oncology: ..... Lisa A. Kachnic, MD  
 Surgery: ..... Stephen W. Behrman, MD

## Designates

Cancer Control Liaisons: ..... Jason A. Zell, DO (Prevention)  
 ..... Afsaneh Barzi, MD (CCD)  
 Community Liaisons: ..... Gary L. Buchsacher, MD, PhD (Med Oncology)  
 ..... Mohamed E. Salem, MD (Med Oncology)  
 ..... Jeremiah Lee Deneve, DO (Surgical)  
 ..... Flavio Rocha, MD (Surgical)  
 ..... David Horowitz, MD (Radiation Oncology)  
 ..... Chan Shen, PhD, MS (Health Outcomes)  
 ..... Mark A. O'Rourke, MD (Palliative Care)  
 DEI Champion: ..... Colmar Figueroa-Moseley, PhD, MPH  
 Digital Engagement: ..... Heloisa Soares, MD, PhD  
 Data Coordinators: ..... Christine Wagner  
 ..... Brian Zeller  
 ..... Ojasvi Mittal

## Oncology Research Professionals:

CRA: ..... Michelle A. Springer, BA  
 Nurse: ..... TBD  
 Patient Advocate (Pancreatic): ..... Carole Seigel, MBA  
 Patient Advocate (Colon): ..... Florence Kurttila, MS  
 Pharmaceutical Science: ..... Jane E. Rogers, PharmD  
 Protocol Project Manager: ..... Christy Klepetko  
 Clinical Trials Program Manager: ..... TBD

## Time/Location

Friday, October 21, 2022 4:00 pm - 6:00 pm  
 Room: Regency B (Ballroom Level, West Tower)

## Agenda

1. Welcome
2. Announcements & Introductions Philip Philip / Gabriella Chiorean
3. GI Committee DEI initiatives Rachel Safyan  
Colmar Figueroa- Moseley
4. SWOG led trials (15 min)
  - a. S2104 Heloisa Soares/Syed Ahmed
  - b. S2107 Van Morris/ Steve Kopetz
  - c. S2001 Vincent Chung
  - d. S1992 Michael Overman
  - e. S0802 Jason Zell
5. CTEP ctDNA working group update Philip Philip
6. Select NCTN Studies and new approvals
  - a. EA2183 mGE cancers oligomet Paul Oberstein
  - b. EA2186 GIANT pancreatic David Zhen
  - c. A021602 NET cabo vs placebo Arvind Dasari
  - d. NRG GI-004 MSI-High 1L mCRC Michael Overman
  - e. EA2201 MSI-High rectal May Cho
7. Gastroesophageal Cancers (12 min) Syma Iqbal, Zev Wainberg
  - a. Highlights of major recent clinical trials
  - b. Ongoing NCTN studies
  - c. Future plans
8. Hepatobiliary (12 min) Anthony El-Khoueiry  
Rachna Shroff
  - a. Highlights of major recent clinical trials

# Gastrointestinal Committee

- b. Ongoing NCTN studies
  - c. Future plans
9. Pancreatic (12 min) Andrew Lowy, Davendra Sohal
- a. Highlights of major recent clinical trials
  - b. Ongoing NCTN studies
  - c. Future plans
10. Colon (12 min) Marwan Fakih, Philip Gold, Sepideh Gholami
- a. Highlights of major recent clinical trials
  - b. Ongoing NCTN studies
  - c. Future plans
11. Anal and Rectal (12 min) Lisa Kachnic, Hagen Kennecke
- a. Highlights of major recent clinical trials
  - b. Ongoing NCTN studies
  - c. Future plans
12. Neuroendocrine (12 min) Jon Strosberg, Arvind Dasari
- a. Highlights of major recent clinical trials
  - b. Ongoing NCTN studies
  - c. Future plans
13. Adjourn

## Gastroesophageal

### Proposed Studies

S2303, "Phase II/III Trial of Nivolumab + Cabozantinib or Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS  $\geq$  5 Advanced Gastric and Esophageal Adenocarcinoma." Dr. Saeed.

### Active Studies

CTSU/EA2174, "A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients with Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma." Dr. Kelly. Activated: 1/17/19.

CTSU/EA2183, "A Phase III Study of Consolidative Radiotherapy in Patients with Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma (EGA)." Dr. Horowitz. Activated: 2/6/2020. Temporarily closed: 06/15/21.

## Pancreatic

### Active Studies

S2001, "Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab

Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 Mutations." Dr. Chung. Activated: 12/4/20.

CTSU/A021804, "A Prospective, Multi-Institutional Phase II Trial Evaluating Temozolomide vs. Temozolomide and Olaparib for Advanced Pheochromocytoma and Paraganglioma." Dr. C. Lopez. Activated: 11/2/20.

CTSU/A021806, "A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer." Dr. Noel. Activated: 7/1/20.

CTSU/EA2186, "A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment Naïve Metastatic Pancreatic Cancer (GIANT)." Dr. Zhen. Activated: 6/18/20.

CTSU/EA2192, "APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Adjuvant Chemotherapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation." Drs. Chiorean and Philip. Activated: 4/29/21.

### Proposed Studies

S2211, "Randomized Phase II/III Study of Gemcitabine and nab-paclitaxel with and without CEND-1 for 1st Line Treatment of Metastatic Pancreatic Cancer." Dr. Botta.

## Neuroendocrine

### Active Studies

S2104, "Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide versus Observation in High-Risk Pancreatic Neuroendocrine Tumors." Dr. Soares. Activated: 10/14/21.

CTSU/A021602, "Randomized Double-Blinded Phase III Study of CABozantinib versus Placebo IN Advanced Neuroendocrine Tumors after Progression on Prior Therapy (CABINET)." Dr. Strosberg. Activated: 7/18/18.

## Hepatobiliary

### Proposed Studies

S2301, "Phase II Single Arm Study of Tremelimumab and Durvalumab (T300+D) in Advanced Hepatocellular Carcinomas with Child-Pugh-B Cirrhosis (STRIDE in CP-B)." Dr. Arora.

# Gastrointestinal Committee

## Active Studies

[CTSUNRG-GI003](#), "A Phase III Randomized Trial of Protons Versus Photons for Hepatocellular Carcinoma." Dr. El-Khoueiry. Activated: 6/21/17.

[CTSUEA2197](#), "Optimal Perioperative Therapy for Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial." Dr. Rocha. Activated: 12/22/20.

[CTSUEA2187](#), "A Phase 2 Study of Pevonedistat in Combination with Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma." Dr. Stein. Activated: 1/31/20. Temporarily closed: 03/31/21.

## Closed Studies

[S1815](#), "A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers." Dr. Shroff. Activated: 12/3/18. Permanently Closed: 2/15/21.

## Colorectal

### Active Studies

[S2107](#), "Randomized Phase II Trial of Encorafenib and Cetuximab with or without Nivolumab for Patients with Microsatellite Stable, BRAFV600E Metastatic Colorectal Cancer." Dr. Morris. Activated: 6/06/22.

[CTSUNRG-GI005](#), "Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)." Dr. Scott. Activated: 12/16/19.

[CTSUA021703](#), "Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS)." Dr. Cohen. Activated: 9/30/19.

[CTSUA021502](#), "Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair." Dr. Lieu. Activated: 9/12/17.

[CTSUNRG-GI004](#), "Colorectal Cancer Metastatic dMMR/MSI-H Immunotherapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination versus Single Agent Atezolizumab in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer." Dr. Overman. Activated: 11/7/17.

[S0820](#), "A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac

to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III – Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)." Dr. Zell. Activated: 3/1/13.

## Closed Studies

[S1613](#), "A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (MCRC) with HER-2 Amplification." Dr. Raghav. Activated: 10/19/17. Step 1 closed to accrual: 1/1/2022.

## Anal

### Active Studies

[CTSUEA2176](#), "Randomized Phase III Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-Naïve Metastatic Anal Cancer Patients." Dr. Morris. Activated: 10/15/20.

[CTSUEA2182](#), "A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)." Dr. Murphy. Activated: 11/12/19.

[CTSUEA2201](#), "A Phase II Study of Neoadjuvant Nivolumab Plus Ipilimumab and Short-Course Radiation in MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma." Dr. Cho. Activated 5/13/21.

## Other

### Active Studies

[S1922](#), "Randomized Phase II Selection Study of Ramucirumab and Paclitaxel Versus FOLFIRI in Refractory Small Bowel Adenocarcinoma." Dr. Overman. Activated: 12/16/19.

[S1609](#), "DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors." Dr. Patel. Activated 1/13/17.

[EAY131](#), "Molecular Analysis for Therapy Choice." Dr. Villalobos. Activated: 8/12/15.



# Gastrointestinal Committee

Accrual from trial opening through 6/30/2022 by Institution and Study

	EA2165	EA2174	EA2176	EA2182	EA2186	EA2187	EA2197	NRGG1004	NRGG1005
Ascension Prov Hospitals - Southfield	1	-	-	-	2	-	-	-	1
Ascension Via Christi Hospitals Wichita	-	-	-	-	-	-	-	-	-
Banner U Med Ctr - Tucson	-	-	-	-	-	-	-	-	-
Baptist Mem Hlth Care/Mid South MU NCORP	-	-	-	-	-	-	-	-	2
Baylor Coll Med/Dan L Duncan CCC	-	-	-	-	-	-	-	-	-
Boston Med Ctr	1	-	-	-	-	-	-	-	-
CWRU Case CCC LAPS	-	1	-	1	-	3	-	-	-
Ca Res Consortium West Mich NCORP	-	-	-	-	-	-	-	-	-
Ca Res for the Ozarks NCORP	-	-	-	-	-	-	-	-	-
Ca Res of Wisconsin & N Mich Consort	-	-	-	-	-	-	-	-	-
City of Hope CCC	-	-	-	-	1	-	-	-	-
Columbus NCORP	-	-	-	-	-	-	-	-	-
CommonSpirit Health Research Inst	-	-	-	-	-	-	-	-	-
Dayton NCORP	-	-	-	-	1	-	-	-	-
Fred Hutchinson Ca Res Ctr LAPS	3	-	-	-	-	-	-	-	-
Gulf South MU NCORP	1	-	-	-	-	-	-	-	-
Hawaii MU NCORP	-	-	-	-	2	-	-	-	-
Heartland Ca Res NCORP	-	-	-	-	-	-	-	-	-
Henry Ford Hospital	-	-	-	-	-	-	-	-	1
Houston Methodist Hospital	-	-	-	-	-	-	-	1	-
Kaiser Permanente NCORP	6	-	3	-	-	-	-	-	6
Lahey Hospital & Med Ctr	-	-	-	-	-	-	-	-	-
Loyola U Med Ctr	-	-	-	-	-	-	-	-	-
Michigan Ca Res Consortium NCORP	-	-	-	-	-	-	-	-	-
Moffitt CC	-	-	-	-	-	-	-	-	-
Montana Cancer Consortium NCORP	-	-	-	-	-	-	-	-	-
NCORP Carolinas (Prisma Hlth NCORP)	1	-	-	-	-	-	-	-	-
New Mexico MU NCORP	-	-	-	-	-	-	-	-	-
Northwell Health NCORP	-	-	-	-	1	-	-	-	-
Northwestern U LAPS	-	-	-	-	1	-	-	-	-

## Gastrointestinal Committee

Accrual from trial opening through 6/30/2022 by Institution and Study

	EA2165	EA2174	EA2176	EA2182	EA2186	EA2187	EA2197	NRGG004	NRGG005
Oregon Health & Science U	4	-	1	1	-	-	1	-	1
Pacific Ca Res Consortium NCORP	-	-	-	-	-	-	-	-	-
SCL Health Saint Joseph Hospital	1	-	-	-	-	-	-	-	-
Southeast Clin Onc Res Consort NCORP	-	-	-	-	-	-	-	-	-
Sutter Ca Res Consortium	2	-	-	-	-	1	-	-	-
The Don and Sybil Harrington CC	-	-	-	-	-	-	-	-	-
The West Clinic - Wolf River	-	-	-	-	-	-	-	-	-
UC Davis CCC LAPS	5	-	-	-	-	-	1	-	1
UC Irvine Health/Chao Family CCC	-	-	1	-	1	-	-	-	1
USC Norris CCC LAPS	-	1	-	-	-	-	-	-	-
U Alabama Birm/Deep South RC LAPS	1	-	-	-	-	-	-	-	-
U Arkansas for Medical Sciences	7	-	-	-	-	-	-	-	-
U Cincinnati CC-UC Med Ctr	1	-	1	-	-	-	-	-	-
U Colorado CC LAPS	-	-	-	-	1	-	-	-	-
U Kansas CC - MCA Rural MU NCORP	-	-	-	-	-	1	-	-	2
U Michigan CCC LAPS	-	-	-	-	-	-	-	-	-
U Rochester LAPS	-	-	-	-	4	2	-	1	-
U Texas HSC at San Antonio	-	-	-	-	2	-	-	-	-
U Texas MD Anderson CC LAPS	-	-	6	-	-	-	-	13	1
U Utah - Huntsman Ca Inst LAPS	-	-	-	-	-	-	-	-	-
Upstate Carolina Consortium NCORP	-	-	-	-	-	-	-	-	-
Vanderbilt U - Ingram CC LAPS	-	-	-	-	-	-	-	-	-
Virginia Mason Med Ctr	-	-	-	-	-	-	-	-	-
Wayne State U - Karmanos Ca Inst LAPS	3	-	-	-	-	-	-	-	-
William Beaumont Hosp-Royal Oak	-	-	-	-	-	-	-	-	-
Wisconsin NCORP	-	-	-	-	-	-	-	-	-
Yale U - Yale CC LAPS	-	-	-	-	-	-	-	-	4
ALLIANCE	-	-	-	-	-	-	-	-	-
ECOG-ACRIN	-	-	-	-	-	-	-	-	-
NRG	-	-	-	-	-	-	-	-	-
<b>Total</b>	<b>37</b>	<b>2</b>	<b>12</b>	<b>2</b>	<b>16</b>	<b>7</b>	<b>2</b>	<b>15</b>	<b>20</b>

# Genitourinary Committee

## Leadership

Chair: ..... Ian M. Thompson, Jr., MD  
 Vice-Chair: ..... Daniel P. Petrylak, MD  
 Executive Officer: ..... Christopher W. Ryan, MD  
 Statisticians: ..... Cathy M. Tangen, DrPH  
 ..... Melissa Plets, MS  
 ..... Eddie Mayerson, MS

## Scientific Leadership

Translational Medicine: ..... David J. McConkey, PhD (GU Chair)  
 ..... Joshua J. Meeks, MD, PhD (Bladder)  
 ..... Amir Goldkorn, MD (Prostate)  
 ..... Sumanta "Monty" K. Pal, MD (Renal)  
 Radiation Oncology: ..... James B. Yu, MD  
 ..... Daniel A. Hamstra, MD  
 Imaging: ..... Evan Y. Yu, MD  
 ..... Hiram Shaish, MD  
 ..... John D. Hazle, PhD  
 Pathology: ..... M. Scott Lucia, MD  
 Surgery: ..... Kelly L. Stratton, MD  
 Liaison to the SPORES: ..... Colin P.N. Dinney, MD  
 Early Therapeutics: ..... Neeraj Agarwal, MD  
 Bladder Organ Site Chairs: ..... Seth P. Lerner, MD (Localized)  
 ..... Thomas W. Flaig, MD (Localized)  
 ..... Daniel P. Petrylak, MD (Advanced)  
 Prostate Organ Site Chairs: ..... Daniel W. Lin, MD (Localized)  
 ..... David I. Quinn, MD, PhD (Advanced)  
 Renal Organ Site Chairs: ..... Brian Shuch, MD (Localized)  
 ..... Ulka N. Vaishampayan, MD (Advanced)

## Designates

Cancer Control: ..... Peter J. Van Veldhuizen, Jr., MD  
 DEI Champion: ..... Jessica McDermott, MD  
 Digital Engagement: ..... Neema Navai, MD  
 Veterans Affairs ..... Michael M. Goodman, MD  
 Data Coordinators: ..... Jeri Jardine  
 ..... Tonya Johnson  
 ..... Michele Counts  
 ..... Laura Wells  
 Oncology Research Professionals:  
 CRAs: ..... Abagail L. Cornette, MS  
 ..... Cheryl Farlow, RN, OCN  
 Nurses: ..... Deborah A. Shaw, RN  
 ..... Cheryl Kefauver, RN  
 Patient Advocates: ..... Rick Bangs, MBA (Bladder)  
 ..... Tony Crispino (Prostate)  
 ..... Margaret "Peggy" Zuckerman, MEd (Renal)

Pharmaceutical Science: ..... Joyce Lee, PharmD  
 ..... Allison Schepers, PharmD  
 Protocol Project Manager: ..... Taj Pereira  
 Clinical Trials Program Manager: ..... TBD

## Time/Location

GU Committee Part I: Friday, October 21, 2022 2:30 pm - 6:15 pm  
 Room: Regency A (Ballroom Level, West Tower)

## Time/Location

GU Committee Part II: Saturday, October 22, 2022 9:15 am - 12:15 pm  
 Room: Regency A (Ballroom Level, West Tower)

## Agenda

### GU Committee Part I

2:30 – 2:45 pm: Chair's Welcome and Opening Remarks. Ian Thompson  
 2:45 – 4:00 pm: Prostate Organ Site (Dr. Tanya Dorff and Dr. Daniel Lin)  
 4:00 – 5:15 pm: Translational Medicine (Dr. David McConkey)  
 5:15 – 6:15 pm: Cancer Control (Dr. Peter Van Veldhuizen)

### Prostate

Organ Site Chairs: Dr. Tonya Dorff (Advanced) and Dr. Daniel W. Lin (Local)

### Priority Study

**S1802**, "Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer." Drs. B. Chapin, A. Aparicio, and R. Valicenti. Activated: 9/17/18.

### Concepts in Development

**S2210**, "Targeted neoadjuvant treatment for patients with localized prostate cancer and germline DNA repair deficiency." Dr. H. Cheng. CTEP Concept approval: 8/2/22.

### Active Studies

**CTSU/A031102**, "A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors." Dr. D. Quinn. Activated: 7/1/15.

# Genitourinary Committee

**CTSU/EA8171**, "Multiparametric MRI (mpMRI) for Preoperative Staging and Treatment Planning for Newly-Diagnosed Prostate Cancer." Dr. M. Liss. Activated: 7/9/18.

**CTSU/EA8184**, "A Phase II Randomized Double Blinded Study of Green Tea Catechins (GTC) vs. Placebo in Men on Active Surveillance for Prostate Cancer: Modulation of Biological and Clinical Intermediate Biomarkers." Dr. R. Kopp. Activated: 5/10/21.

**CTSU/NRG-GU002**, "Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy with or Without Adjuvant Docetaxel." Dr. D. Raben. Activated: 12/30/16.

**CTSU/NRG-GU008**, "Randomized Phase III Trial Incorporating Abiraterone Acetate with Prednisone and Apalutamide and Advanced Imaging into Salvage Treatment for Patients with Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE\*) \*Intensifying Treatment for Node Positive Prostate Cancer by Varying the Hormonal Therapy." Dr. D. Lin. Activated: 3/5/20; Temporarily Closed: 6/24/21; Re-activated: 12/1/21.

**CTSU/NRG-GU009**, "Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (PREDICT-RT\*)." Dr. S. Zhang. Activated: 10/15/20; Temporarily Closed: 6/24/21; Re-activated: 12/15/21.

## Closed Studies

**S1216**, "A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer." Drs. N. Agarwal, A. Goldkorn, S. Gupta, et al. Activated: 3/6/13; Permanently Closed: 7/15/17.

**CTSU/NRG-GU005**, "Phase III IGRT and SBRT Vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer." Dr. A. Solanki. Activated: 11/16/17; Closed to accrual: 6/8/22.

**CTSU/NRG-GU006**, "A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy with or Without Enhanced Anti-Androgen Therapy with Apalutamide in Recurrent Prostate Cancer." Dr. J. Zeng. Activated: 4/27/18; Permanently Closed: 5/19/20.

**CTSU/RTOG-0924**, "Androgen Deprivation Therapy and High Dose Radiotherapy with or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial. Dr. T. Marshall. Activated: 7/7/11; Permanently Closed: 6/24/19.

**CTSU/NRG-GU007**, "Randomized Phase II Trial of Niraparib with Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (with Initial Phase I) (NADIR\*) \*Randomized Phase II Trial of Niraparib With Standard Combination Androgen Deprivation Therapy (ADT) and Radiotherapy In High Risk Prostate Cancer (With Initial Phase I)." Dr. D. VanderWeele. Activated: 6/3/19; Temporarily Closed: 5/5/21; Reactivated of dose level 2 (phase I) for 1 additional patient: 9/14/21; Temporarily closed to accrual for phase I dose level 2: 11/4/21; Re-activated to accrual for phase I/dose level 3: 12/6/21; Temporarily Closed: 7/11/2022.

**CTSU/EA8153**, "Cabazitaxel with Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial." Dr. P. Corn. Activated: 2/8/18; Permanently Closed: 4/2/21; Tobacco use assessment sub-study permanently closed: 10/8/21.

**CTSU/AGCT1531**, "A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors." Dr. A. D'Souza. Activated: 5/8/17; PRO study Temporarily Closed: 2/12/21.

## Translational Medicine

Chair: Dr. David McConkey

Bladder Chair: Dr. Joshua Meeks

Prostate Chair: Dr. Amir Goldkorn

Renal Chair: Dr. Sumanta "Monty" Pal

## Cancer Control

Liaison: Dr. Peter J. Van Veldhuizen

## Closed Studies

**S1600**, "A Randomized Phase III Double-Blind Clinical Trial Evaluating the Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes." Drs. J. Hamilton-Reeves and J. Holzbeierlein. Activated: 2/21/19. Temporarily Closed to Accrual: 8/9/2022.

# Genitourinary Committee

## Agenda

### GU Committee Part II

9:15 – 10:30 am: Bladder Organ Site (Dr. Seth Lerner and Dr. Thomas Flaig)

10:30 – 12:15 pm: Renal Organ Site (Dr. Ulka Vaishampayan and Dr. Brian Shuch)

## Bladder

Organ Site Chairs: Dr. Thomas Flaig (Advanced) and Dr. Seth Lerner (Local)

### Priority Study

**S2011**, “Randomized Phase II Trial of Gemcitabine, Avelumab, and Carboplatin vs. No Neoadjuvant Therapy Preceding Surgery for Cisplatin Ineligible Muscle-Invasive Urothelial Carcinoma.” Drs. Sonpavde M. Liss, and S. Lerner, et al. Activated: 10/6/21.

### Active Studies

**S1937**, “A Phase III Trial of Eribulin (NSC #707389) with or Without Gemcitabine Versus Standard of Care (Physician’s Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy.” Drs. S. Sadeghi and P. Lara. Activated: 2/16/21.

**S1806**, “Phase III Randomized Trial of Concurrent Chemoradiotherapy with or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer.” Drs. P. Singh, S. Lerner, J. Efstathiou, et al. Activated: 4/19/19.

**CTSU/A031701**, “A Phase II Study of Dose-Dense Gemcitabine Plus Cisplatin (ddGC) in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations.” Drs. A. Gupta and S. Gupta. Activated: 8/1/18.

**CTSU/A031803**, “Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer.” Drs. D. Tyson and C. Ramamurthy. Activated: 1/6/20.

**CTSU/EA8185**, “Phase II Study of Bladder-Sparing Chemoradiation with MEDI4736 (Durvalumab) in Clinical Stage III, Node Positive Bladder Cancer (INSPIRE).” Drs. T. Mitin and J. Meeks. Activated: 8/25/20.

**CTSU/EA8192**, “A Phase II/III Trial of MEDI4736 (Durvalumab) and Chemotherapy for Patients with High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy” Drs. S. Psutka and A. Tripathi. Activated: 5/6/21.

## Closed Studies

**S1011**, “A Phase III Surgical Trial to Evaluate the Benefit of a Standard Versus an Extended Pelvic Lymphadenectomy Performed at Time of Radical Cystectomy for Muscle Invasive Urothelial Cancer.” Drs. S. Lerner, A. Alva, and T. Koppie, et al. Activated: 8/1/11; Permanently Closed: 4/15/17.

**S1602**, “A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG Naïve High-Grade Non-Muscle Invasive Bladder Cancer.” Drs. R. Svatek, A. Alva, and S. Lerner. Activated: 2/7/17; Permanently Closed: 12/15/2020.

**S1605**, “Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer.” Drs. P. Black, P. Singh, and S. Lerner. Activated: 2/7/17; Permanently Closed: 7/5/19.

## Renal

Organ Site Chairs: Dr. Ulka Vaishampayan (Advanced) and Dr. Brian Shuch (Local)

### Priority Study

**S1931**, “Phase III Trial of Immunotherapy-Based Combination Therapy with or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE Trial).” Drs. H. Kim and U. Vaishampayan. Activated: 11/16/20.

### Concepts in Development

**S2200**, “A Phase II Randomized Trial of Cabozantinib (NSC #761968) with or without Atezolizumab (NSC #783608) in Patients with Advanced Papillary Renal Cell Carcinoma (PAPMET2)” Drs. B. Maughan and S. Pal. CTEP Approval on hold: 8/15/22.

### Active Studies

**CTSU/AREN1721**, “A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups.” Dr. M. Parikh. Activated: 10/9/18; Temporarily Closed: 3/24/21; Re-activated: 2/7/22.

**CTSU/A031704**, “PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer [PDI-GREE].” Dr. T. Zhang. Activated: 5/9/19; Step 1 temporarily closed: 3/8/21; Step 1 re-activated: 3/26/21.

# Genitourinary Committee

**CTSU/A031801**, "A Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients with Advanced Renal Cell Carcinoma with Bone Metastasis (Radical)." Dr. M. Parikh. Activated: 12/13/19.

**CTSU/A031901**, "Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: A randomized Phase 3 non-Inferiority Trial." Dr. D. Vaena. Activated: 12/10/20.

## Closed Studies

**S1500**, "A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)." Drs. S. Pal and P. Lara. Activated 4/5/16; Permanently closed: 12/15/19.

**S0931**, "EVEREST: Everolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study." Drs. C. Ryan, E. Heath, P. Lara, et al. Activated: 4/1/11; Permanently Closed: 9/15/16.

**CTSU/E2810**, "Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients with Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy." Dr. S. Pal. Activated: 8/8/12; Permanently closed: 7/25/17.

**CTSU/A031501**, "Phase III Randomized Adjuvant study of Pembrolizumab in Muscle Invasive and Locally Advanced Urothelial Carcinoma (AMBASSADOR) Versus Observation." Dr. G. Sonpavde. Activated: 9/21/17; Permanently Closed: 8/24/21.

**CTSU/EA8143**, "A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)." Drs. P. Lara and B. Shuch. Activated: 2/2/17; Permanently Closed: 6/9/21.

## Diverse Studies of Interest

**S1609**, "DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors." Drs. S. Patel, Y. Chae, R. Kurzrock, et al. Activated: 1/13/17; Permanently Closed: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 13, 14, 15, 16, 17, 18, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 39, 41, 42, 43, 44, 45, 48, 51, 52, and 53; Temporarily Closed: 38, 40, 46, and 51.

**CTSU/A031702**, "A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)" Dr. S. Liu. Activated: 4/12/19; Temporarily Closed: Cohort A, B, C, E, F, G, I.

**CTSU/EAY 131**, "Molecular Analysis for Therapy Choice (MATCH)." Dr. V. Villalobos. Activated: 8/12/15; EAY131 (MATCH) Subprotocol Z1C, EAY131-Z1C, is permanently Closed to Accrual: 5/25/21; EAY131 (MATCH) Subprotocol M, or EAY131-M, is suspended, effective immediately: 8/3/21; AY131 Subprotocols A, C1, C2, E, L, V, Z1E, and Z1G are closed to accrual: 1/31/22; Subprotocol ZIG reactivated: 2/23/22

**CTSU/EA8134**, "InPACT- International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)." Dr. C. Pettaway. Activated: 9/8/17.

# Genitourinary Committee

Accrual from trial opening through 6/30/2022 by Institution and Study

	S1802	S1806	S1931	S1937	A031102	A031501	A031701	A031702	A031704	A031801	A031803	A031902
Ascension Prov Hosp - Southfield	-	-	-	-	-	-	-	-	1	-	-	-
Banner MD Anderson CC	2	-	-	-	-	-	-	-	-	-	-	-
Banner U Med Ctr - Tucson	6	-	1	-	-	-	-	-	-	-	-	-
Baylor College of Med/Dan L Duncan CCC	2	3	-	-	-	1	-	-	-	-	-	-
CWRU Case CCC LAPS	-	-	-	-	-	-	5	-	-	-	-	3
Ca Res Consort of West Mich NCORP	2	3	-	-	-	-	-	-	-	-	-	-
Ca Res for the Ozarks NCORP	1	1	-	-	-	-	-	-	-	-	-	-
Ca Res of Wisconsin & N Mich Consort	1	4	-	-	-	-	-	-	-	-	-	-
Cedars-Sinai Med Ctr	-	5	1	-	-	-	-	-	-	-	-	-
City of Hope CCC	1	-	-	-	-	-	-	-	-	-	-	-
Columbia U MU NCORP	1	1	-	-	-	3	-	-	-	-	-	-
CommonSpirit Hlth Res Inst	1	4	-	2	-	-	-	-	-	-	-	-
Cotton O'Neil CC / Stormont Vail Hlth	-	-	-	-	-	1	-	-	-	-	-	-
Dayton NCORP	4	1	-	-	-	-	-	-	1	-	-	-
Fred Hutchinson Ca Res Ctr LAPS	11	-	-	-	-	-	-	-	-	-	-	-
Georgia Cares MU NCORP	1	-	-	-	-	-	-	-	-	-	-	-
Gulf South MU NCORP	66	45	1	-	-	2	-	-	-	1	12	-
Hawaii MU NCORP	-	2	-	-	-	-	-	-	-	-	-	-
Heartland Ca Res NCORP	8	6	-	-	-	-	-	-	-	-	-	-
Henry Ford Hosp	19	4	-	-	-	1	-	2	5	-	-	-
Kaiser Permanente NCORP	15	-	-	-	-	14	-	-	45	-	-	-
Lahey Hosp and Med Ctr	-	-	-	-	-	4	-	6	-	-	-	-
Loma Linda U Med Ctr	-	-	-	-	-	2	-	-	-	-	-	-
Loyola U Med Ctr	9	5	1	2	-	-	-	1	1	-	-	-
Massachusetts Vet Epi Res & Info Ctr	-	-	-	-	-	-	-	-	-	-	-	1
Medical U South Carolina MU NCORP	5	-	-	1	-	-	-	-	-	-	-	-
Michigan Ca Res Consort NCORP	7	13	-	1	-	-	-	-	-	-	-	-
Moffitt CC	-	-	-	-	-	-	-	-	-	-	-	-
Montana Cancer Consort NCORP	3	-	-	-	-	-	-	-	-	-	-	-
NCORP Carolinas (Prisma Hlth NCORP)	9	-	-	-	-	-	-	-	1	-	-	-
Nevada Ca Res Foundation NCORP	1	-	-	-	-	-	-	1	-	-	-	-
New Mexico MU NCORP	-	-	-	-	-	-	-	-	-	-	-	-
Northwell Hlth NCORP	-	1	-	-	-	-	-	-	1	-	-	-
Northwestern U LAPS	-	6	-	-	-	-	-	-	1	-	-	-

## Genitourinary Committee

Accrual from trial opening through 6/30/2022 by Institution and Study

	S1802	S1806	S1931	S1937	A031102	A031501	A031701	A031702	A031704	A031801	A031803	A031902
Ohio State U CCC LAPS	2	1	-	-	-	-	-	-	-	-	-	-
Oregon Hlth and Science U	-	1	-	-	-	-	-	3	3	-	-	-
SCL Hlth Saint Joseph Hosp	2	-	-	-	-	-	-	-	-	-	-	-
Southeast Clin Onc Res Consort NCORP	3	-	-	-	-	-	-	-	-	-	-	-
Sutter Ca Res Consort	-	2	-	-	-	-	-	-	-	-	-	-
Tulane U Hlth Sciences Ctr	-	-	7	-	-	-	-	-	1	-	-	-
UC Davis CCC LAPS	11	8	-	-	-	4	5	-	2	4	4	-
UC Irvine Hlth/Chao Family CCC	2	4	-	-	-	-	-	-	-	-	-	-
UC San Diego Moores CC	1	1	-	-	-	-	-	-	-	-	-	-
UCLA / Jonsson CCC	-	-	-	-	-	-	-	-	-	-	-	-
USC Norris CCC LAPS	5	-	-	3	12	13	-	4	-	-	-	-
U Alabama Birm/Deep South RC LAPS	-	-	-	-	-	-	-	1	-	1	4	-
U Arkansas for Medical Sciences	1	-	-	-	-	-	-	-	-	-	-	-
U Cincinnati CC-UC Med Ctr	5	4	1	-	-	-	-	-	6	-	-	-
U Colorado CC LAPS	4	5	-	-	-	13	-	-	10	-	-	-
U Kansas CC - MCA Rural MU NCORP	7	4	-	-	-	5	-	1	6	-	-	-
U Kentucky/Markey CC	-	3	-	-	-	-	-	-	-	-	-	-
U Michigan CCC LAPS	2	-	9	-	-	18	-	-	-	-	-	-
U Mississippi Med Ctr	1	-	-	-	-	-	-	1	-	-	-	-
U Oklahoma Hlth Sciences Ctr LAPS	26	14	4	-	-	-	-	-	-	-	-	-
U Rochester LAPS	17	-	1	-	-	-	-	3	5	-	-	-
U Texas Hlth Science Ctr at San Antonio	2	-	2	-	-	-	-	-	-	-	4	-
U Texas MD Anderson CC LAPS	69	-	-	-	-	-	-	-	-	-	-	-
U Utah - Huntsman Ca Inst LAPS	15	-	1	-	-	3	-	-	-	-	-	-
Upstate Carolina Consort NCORP	1	1	-	-	-	-	-	-	-	-	-	-
Vanderbilt U - Ingram CC LAPS	1	2	-	-	-	-	-	-	-	-	-	-
Virginia Mason Med Ctr	-	-	-	-	-	1	-	-	-	-	-	-
Wayne State U - Karmanos Ca Inst LAPS	1	-	-	-	-	-	-	-	-	-	-	-
Western States Ca Res NCORP	-	1	-	-	-	-	-	-	-	-	-	-
Wisconsin NCORP	8	5	-	-	-	-	-	-	-	-	-	-
Yale U - Yale CC LAPS	1	2	-	-	-	8	-	-	-	-	-	-
ALLIANCE	81	18	2	-	-	-	-	-	-	-	-	-
ECOG-ACRIN	56	27	1	-	-	-	-	-	-	-	-	-
NRG	66	86	1	1	-	-	-	-	-	-	-	-
<b>Total</b>	<b>565</b>	<b>293</b>	<b>33</b>	<b>10</b>	<b>12</b>	<b>93</b>	<b>10</b>	<b>23</b>	<b>89</b>	<b>6</b>	<b>24</b>	<b>4</b>



# Genitourinary Committee

Accrual from trial opening through 6/30/2022 by Institution and Study

	EA8134	EA8143	EA8153	EA8171	EA8183	EA8191	EA8192	NRGGU002	NRGGU005	NRGGU008	NRGGU009	NRGGU010
Ascension Prov Hosp - Southfield	-	-	-	-	-	-	-	-	-	-	-	-
Banner MD Anderson CC	-	-	-	-	-	-	-	-	-	-	-	-
Banner U Med Ctr - Tucson	-	7	-	-	-	-	-	-	-	-	-	-
Baylor College of Med/Dan L Duncan CCC	-	1	-	-	-	-	-	-	-	-	-	-
CWRU Case CCC LAPS	-	-	-	-	-	-	-	-	-	-	-	-
Ca Res Consort of West Mich NCORP	-	-	-	-	-	-	-	-	-	-	-	-
Ca Res for the Ozarks NCORP	-	-	-	-	-	-	-	-	-	-	-	-
Ca Res of Wisconsin & N Mich Consort	-	-	-	-	-	-	-	-	-	-	-	-
Cedars-Sinai Med Ctr	-	8	-	-	-	-	-	-	-	-	-	-
City of Hope CCC	-	-	-	-	-	-	-	-	-	-	-	-
Columbia U MU NCORP	-	1	-	-	-	-	-	-	-	-	-	-
CommonSpirit Hlth Res Inst	-	4	-	-	-	-	-	-	-	-	-	-
Cotton O'Neil CC / Stormont Vail Hlth	-	-	-	-	-	-	-	-	-	-	-	-
Dayton NCORP	-	1	-	-	-	-	-	-	-	-	-	-
Fred Hutchinson Ca Res Ctr LAPS	-	4	-	-	-	-	-	-	-	-	-	-
Georgia Cares MU NCORP	-	-	-	-	-	-	-	-	-	-	-	-
Gulf South MU NCORP	-	10	-	11	-	-	-	1	1	3	2	-
Hawaii MU NCORP	-	2	-	2	-	-	-	-	-	-	-	-
Heartland Ca Res NCORP	-	-	-	-	-	-	-	-	-	-	-	-
Henry Ford Hosp	-	3	-	-	-	-	-	-	-	-	-	-
Kaiser Permanente NCORP	-	41	10	-	-	-	-	-	-	-	-	-
Lahey Hosp and Med Ctr	-	4	-	-	3	-	-	-	-	-	-	-
Loma Linda U Med Ctr	-	-	-	-	-	-	-	-	-	-	-	-
Loyola U Med Ctr	-	4	-	-	-	-	-	-	-	-	-	-
Massachusetts Vet Epi Res & Info Ctr	-	-	-	-	-	-	-	-	-	-	-	-
Medical U South Carolina MU NCORP	-	-	-	-	-	-	-	-	-	-	-	-
Michigan Ca Res Consort NCORP	-	-	-	-	-	-	-	-	-	-	-	-
Moffitt CC	-	1	-	-	-	-	-	-	-	-	-	-
Montana Cancer Consort NCORP	-	-	-	-	-	-	-	-	-	-	-	-
NCORP Carolinas (Prisma Hlth NCORP)	-	1	-	-	-	-	-	-	-	-	-	-
Nevada Ca Res Foundation NCORP	-	2	-	-	-	-	-	-	-	-	-	-
New Mexico MU NCORP	-	-	-	-	-	-	-	-	1	-	-	-
Northwell Hlth NCORP	-	-	-	-	-	-	-	-	-	-	-	-
Northwestern U LAPS	-	-	-	-	-	-	-	-	-	-	-	-

## Genitourinary Committee

Accrual from trial opening through 6/30/2022 by Institution and Study

	EA8134	EA8143	EA8153	EA8171	EA8183	EA8191	EA8192	NRGGU002	NRGGU005	NRGGU008	NRGGU009	NRGGU010
Ohio State U CCC LAPS	-	-	-	-	-	-	-	-	-	-	-	-
Oregon Hlth and Science U	-	14	-	7	-	-	-	-	-	-	-	-
SCL Hlth Saint Joseph Hosp	-	-	-	-	-	-	-	-	-	-	-	3
Southeast Clin Onc Res Consort NCORP	-	-	-	-	-	-	-	-	-	-	-	-
Sutter Ca Res Consort	-	-	-	-	-	-	-	-	2	-	-	-
Tulane U Hlth Sciences Ctr	-	10	-	-	-	-	-	-	1	-	-	-
UC Davis CCC LAPS	-	1	-	-	-	-	-	-	-	-	-	-
UC Irvine Hlth/Chao Family CCC	-	1	-	-	-	-	-	-	-	1	-	-
UC San Diego Moores CC	-	2	-	-	-	-	-	-	-	-	-	-
UCLA / Jonsson CCC	-	8	-	-	-	-	-	-	-	-	-	-
USC Norris CCC LAPS	8	-	-	-	-	-	-	-	-	-	-	-
U Alabama Birm/Deep South RC LAPS	-	6	-	-	-	-	-	-	-	-	-	-
U Arkansas for Medical Sciences	-	-	-	-	-	-	-	-	-	-	-	-
U Cincinnati CC-UC Med Ctr	-	-	-	-	-	-	-	-	-	-	-	-
U Colorado CC LAPS	-	1	-	-	-	-	1	1	1	-	-	-
U Kansas CC - MCA Rural MU NCORP	-	2	1	-	-	-	-	-	-	1	-	-
U Kentucky/Markey CC	-	12	-	-	-	-	-	-	-	-	-	-
U Michigan CCC LAPS	-	-	-	-	-	-	-	-	-	-	-	-
U Mississippi Med Ctr	-	3	2	-	-	-	-	1	-	-	-	-
U Oklahoma Hlth Sciences Ctr LAPS	-	-	-	-	-	1	-	-	-	-	-	-
U Rochester LAPS	-	1	-	-	-	-	-	-	-	-	-	-
U Texas Hlth Science Ctr at San Antonio	-	14	-	50	-	-	-	-	-	-	-	-
U Texas MD Anderson CC LAPS	-	-	8	-	-	-	-	-	-	-	-	-
U Utah - Huntsman Ca Inst LAPS	-	2	8	-	-	-	-	-	-	-	-	-
Upstate Carolina Consort NCORP	-	-	-	-	-	-	-	-	-	-	-	-
Vanderbilt U - Ingram CC LAPS	-	-	-	-	-	-	-	-	-	-	-	-
Virginia Mason Med Ctr	-	-	-	-	-	-	-	-	3	-	-	-
Wayne State U - Karmanos Ca Inst LAPS	-	2	-	-	-	-	-	1	-	-	-	-
Western States Ca Res NCORP	-	-	-	-	-	-	-	-	-	-	1	-
Wisconsin NCORP	-	-	-	-	-	-	-	-	-	-	-	-
Yale U - Yale CC LAPS	-	1	2	-	-	-	-	-	-	-	-	-
ALLIANCE	-	-	-	-	-	-	-	-	-	-	-	-
ECOG-ACRIN	-	-	-	-	-	-	-	-	-	-	-	-
NRG	-	-	-	-	-	-	-	-	-	-	-	-
<b>Total</b>	<b>8</b>	<b>174</b>	<b>31</b>	<b>70</b>	<b>3</b>	<b>1</b>	<b>1</b>	<b>4</b>	<b>9</b>	<b>5</b>	<b>3</b>	<b>3</b>

# Immunotherapeutics Committee

## Leadership

Co-Chairs: ..... Siwen Hu-Lieskovan, MD, PhD  
 ..... Katerina Politi, PhD  
 Executive Officer: ..... Gary H. Lyman, MD  
 Protocol Project Manager: ..... Christopher Kippola  
 Clinical Trial Program Manager: ..... TBD

## Time/Location

Wednesday, October 19, 2022 4:30 pm - 6:30 pm  
 Room: Regency B (Ballroom Level, West Tower)

## Agenda

- |                       |   |
|-----------------------|---|
| <b>4:30 - 5:00 pm</b> | <b>S2101 – iMATCH Pilot (BICAZO) kick-off</b><br>Katerina Politi, Siwen Hu-Lieskovan, Paul Swiecicki,<br>Michael LeBlanc, Katherine Minichiello, Dana Sparks,<br>Chris Kippola, James Moon, Gary Lyman, and the SWOG<br>iMATCH team   |
| <b>5:00-5:10 pm</b>   | <b>Q &amp; A</b>  |
| <b>5:10-5:40 pm</b>   | <b>Computational modeling of response to immune<br/>Checkpoint inhibitors</b><br>Shirley Liu, PhD<br>Founder and CEO, GV20 Therapeutics<br>Previously Professor of Biostatistics and Computational<br>Biology at Dana-Farber Cancer Institute, Harvard T.H.<br>Chan School of Public Health |
| <b>5:40-5:50 pm</b>   | <b>Q &amp; A</b>  |
| <b>5:50-6:20 pm</b>   | <b>Single-cell based immune-monitoring for IO clinical<br/>trials</b><br>Sean Bendall, PhD<br>Associate Professor of Pathology at Stanford University   |
| <b>6:20-6:30 pm</b>   | <b>Q &amp; A</b>  |

## Developing Studies

[S2101](#), Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Participants with Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study. Dr. Hu-Lieskovan.

# Leukemia Committee

## Leadership

Chair: ..... Harry P. Erba, MD, PhD  
 Vice-Chair: ..... Anjali S. Advani, MD  
 Executive Officer: ..... Susan M. O'Brien, MD  
 Statisticians: ..... Megan Othus, PhD  
 ..... Anna Moseley, MS

## Scientific Leadership

Translational Medicine: ..... Jerald P. Radich, MD  
 Pathology: ..... David R. Head, MD  
 Cytogenetics Liaison: ..... Min Fang, MD, PhD

## Designates

Cancer Control: ..... Stephanie B. Tsai, MD  
 Data Coordinators: ..... Louise Highleyman  
 ..... Laura Kingsbury  
 Oncology Research Professionals:  
 CRA: ..... TBD  
 Nurse: ..... TBD  
 Patient Advocate: ..... Gail Sperling, MPH  
 Pharmaceutical Science: ..... Holly O. Chan, PharmD  
 ..... Ila M. Saunders, PharmD  
 Protocol Project Manager: ..... Sharon Palmer  
 Protocol Project Manager - MyeloMATCH: ..... Sarah Cantu  
 Clinical Trials Program Manager: ..... TBD

## Time/Location

Saturday, October 22, 2022 9:30 am - 12:30 pm  
 Room: Regency C (Ballroom Level, West Tower)

## Agenda

**9:30 - 9:50 am** Update in CLL clinical trials - Mazyar Shadman  
**9:50 - 10:20 am** Screening Trial for Myelomatch: Nuts and Bolts - Jerry Radich  
**10:20 - 10:50 am** Myelomatch: Science - Cecilia Yeung  
**10:50 - 11:10 am** Cytogenetics and Myelomatch - Min Fang  
**11:10 - 11:40 am** Myelomatch: Clinical Trials - Laura Michaelis  
**11:40 - 12:00 pm** How do sites open studies in Myelomatch, Beacon Builds, NCORP Sites - Harry Erba and group  
**12:00 - 12:20 pm** CML - Current and Upcoming Trials - Jerry Radich

## AML/MDS Studies

### Active Studies

**CTSUA041701**, "A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy." Dr. L. Liesveld. Activated: 1/16/19.

### Closed Studies

**S1612**, "A Randomized Phase II/III Trial of "Novel Therapeutics" Versus Azacitidine in Newly Diagnosed Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS), Age 60 or Older." Drs. L. Michaelis, R. Walter, S. Assouline, et al. Activated: 12/22/17; Closed: 9/1/20.

**S0919**, "A Phase II Study of Idarubicin and Ara-C in Combination with Pravastatin for Poor-Risk Acute Myelogenous Leukemia (AML)." Dr. A. Advani. Re-Activated: 4/1/13; Closed: 9/15/17.

**S1203**, "A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy or Idarubicin with High Dose Cytarabine (IA) versus IA with Vorinostat (NSC-701852) (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)." Drs. Garcia-Manero and Pagel. Activated: 12/15/12; Closed: 11/4/15.

**S1612**, "A Randomized Phase II/III Trial of "Novel Therapeutic(s)" versus Azacitidine in Newly Diagnosed Patients with Acute Myeloid Leukemia Age 60 or Older." Drs. Michaelis and Walter. Activated: 12/22/17; Closed: 10/22/18.

## ALL Studies

### Active Studies

**S1905**, "A Phase I/II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) / T-Cell Lymphoblastic Lymphoma (T-LBL)." Drs. A. Advani, N. Papadantonakis, and C. Yeung. Activated: 8/17/20.

**CTSUA041501**, "A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL." Dr. A. Advani. Activated: 6/1/17.

### Proposed Studies

**S2113**, "A Randomized Phase II Trial to Evaluate the Efficacy of Combination Bcl-2 Inhibitor Therapy with Chemotherapy Compared to Chemotherapy

# Leukemia Committee

Alone in Adult Patients with Newly Diagnosed T-Cell ALL and T-Cell Lymphoblastic Lymphoma." Dr. K. O'Dwyer.

## Closed Studies

S0333, "A Phase II Study of Double Induction Chemotherapy for Newly Diagnosed Non-L3 Adult Acute Lymphoblastic Leukemia with Investigation of Minimal Residual Disease and Risk of Relapse Following Maintenance Chemotherapy." Drs. Forman and O'Donnell. Activated: 4/15/05; Closed: 11/01/09.

S1312, "A Phase I Study of Inotuzumab Ozogamicin in Combination with CVP (Cyclophosphamide, Vincristine, Prednisone) for Patients with Relapsed/Refractory CD22-Positive Acute Leukemia (Including B-ALL, Mixed Phenotypic Leukemia, and Burkitt's Leukemia)." Drs. A. Advani and Liedtke. Activated: 4/1/14; Closed: 8/2/19.

S1318, "A Phase II Study of Blinatumomab and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients  $\geq$  65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphocytic Leukemia (ALL) and of Dasatinib, Prednisone and Blinatumomab for Patients  $\geq$  65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL and Philadelphia-Chromosome-Like Signature (Ph-like) ALL (Newly Diagnosed or Relapsed/Refractory) with Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (DSMKF)." Drs. A. Advani and K. O'Dwyer. Activated: 1/12/15; Closed: 4/15/21.

## CLL Studies

### Active Studies

S1925, "Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL): EVOLVE CLL/SLL Study." Drs. D. Stephens, B. Hill, J. Pagel, et al. Activated: 12/14/20.

CTSU/A041702, "A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients ( $\geq$  70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)." Dr. B. Hill. Activation: 1/4/19.

### Closed Studies

CTSU/EA9161, "A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)." Dr. M. Shadman. Activated: 1/3/19. Closed: 4/30/21.

## CML Studies

### Active Studies

S1712, "A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients with Molecular Evidence of Disease." Drs. K. Sweet and J. Radich. Activated: 7/20/18.

## MyeloMATCH

### Proposed Studies

MYELOMATCH, "Master Screening and Reassessment Protocol (MSRP) for the NCI MyeloMATCH Trials." Dr. J. Radich.

MM1YA-S01, "A Randomized Phase II Study of Novel Therapeutics in Younger Patients with High-Risk Acute Myeloid Leukemia." Drs. P. Shami and T. Lin.

MM10A-S02, "A Phase 2 Study of Targeted Agents with the Oral DNMT1 Inhibitor C-DEC (ASTX727) for the Treatment of TP53-Mutated Acute Myeloid Leukemia: A myeloMATCH treatment trial." Drs. R. Shallis, D. Sallman, and A. Zeidan.

### Proposed Studies (Pre-Triage)

MM1XX-S##, "A Randomized Phase 2 trial of C-DEC, venetoclax, and enasidenib compared with azacitidine and venetoclax for newly diagnosed older adults with IDH2 mutant AML: A myeloMATCH treatment trial." Drs. U. Borate and E. Huselton.

## Leukemia Committee

Accrual from trial opening through 6/30/2022 by Institution and Study

	S1318	S1712	S1905	S1925	A041501	A041701	A041702	A041703	EA9161	EA9171	EA9181
Ascension Via Christi Hospitals Wichita	1	-	-	-	-	-	-	-	-	-	-
Banner U Med Ctr - Tucson	-	-	-	-	-	-	5	-	4	-	-
Baptist Mem HC/Mid South MU NCORP	-	1	-	-	-	-	-	-	-	-	-
CWRU Case CCC LAPS	6	-	1	2	4	-	5	-	-	-	-
Ca Res for the Ozarks NCORP	-	1	-	-	-	-	-	-	-	-	-
City of Hope CCC	4	-	2	1	-	-	-	-	-	-	-
CommonSpirit Health Research Inst	-	-	-	-	-	-	-	-	1	-	-
Dayton NCORP	-	-	-	-	-	-	1	-	2	-	-
Duke U - Duke Ca Inst LAPS	-	3	-	-	-	-	-	-	9	-	-
Fred Hutchinson Ca Res Ctr LAPS	-	1	2	-	-	-	-	-	9	-	-
Hawaii MU NCORP	-	6	-	-	-	-	-	-	-	-	1
Heartland Ca Res NCORP	1	4	-	-	-	-	-	-	-	-	-
Henry Ford Hospital	-	-	-	2	-	4	3	-	1	-	-
Intermountain Med Ctr	-	-	-	-	2	-	-	-	-	-	-
Kaiser Permanente NCORP	-	-	-	-	-	-	7	-	32	-	-
Lahey Hospital & Med Ctr	-	-	-	-	-	-	1	-	-	-	-
Loma Linda U Med Ctr	1	-	-	-	-	-	-	-	-	-	-
Loyola U Med Ctr	-	1	-	-	-	-	1	-	2	-	1
Medical U of South Carolina MU NCORP	-	-	-	1	-	-	1	-	7	-	-
Michigan Ca Res Consortium NCORP	-	1	-	4	-	-	1	-	-	-	-
Moffitt CC	-	16	-	-	-	-	-	-	-	-	-
Montana Cancer Consortium NCORP	-	1	-	-	-	-	-	-	-	-	-
NCORP Carolinas (Prisma Hth NCORP)	1	1	-	-	-	-	-	-	1	-	-
Nevada Ca Res Foundation NCORP	-	2	-	-	-	-	3	-	5	-	-
New Mexico MU NCORP	1	3	-	-	-	-	-	-	1	-	-

## Leukemia Committee

Accrual from trial opening through 6/30/2022 by Institution and Study

	S1318	S1712	S1905	S1925	A041501	A041701	A041702	A041703	EA9161	EA9171	EA9181
Northwell Health NCORP	-	-	-	-	-	2	-	-	-	-	-
Northwestern U LAPS	-	-	-	-	3	1	2	-	-	-	3
Oregon Health & Science U	-	3	1	-	8	-	5	-	9	-	-
Orlando Health Ca Inst	1	-	-	-	-	-	-	-	-	-	-
Salem Hospital	-	-	-	-	-	-	-	-	4	-	-
Southeast Clin Onc Res Consort NCORP	-	-	-	-	-	-	-	-	2	-	-
Stanford Ca Inst Palo Alto	-	-	-	-	8	-	11	-	29	-	-
UC Davis CCC LAPS	-	-	-	1	2	-	-	-	-	-	-
UC Irvine Health/Chao Family CCC	4	-	-	-	3	-	-	-	-	-	3
UC San Diego Moores CC	1	-	-	-	-	-	-	-	-	-	-
USC Norris CCC LAPS	3	-	-	-	-	-	-	-	-	-	-
U Alabama Birm/Deep South RC LAPS	1	-	-	-	1	-	-	-	7	-	-
U Arkansas for Medical Sciences	-	-	-	-	-	4	-	-	-	-	-
U Cincinnati CC-UC Med Ctr	-	-	1	-	-	-	-	1	-	-	1
U Colorado CC LAPS	-	-	-	-	-	-	1	-	1	-	-
U Kansas CC - MCA Rural MU NCORP	-	-	-	-	-	-	6	-	8	-	-
U Michigan CCC LAPS	2	-	-	-	-	-	-	-	-	-	-
U Rochester LAPS	4	6	1	3	7	27	1	3	1	-	5
U Utah - Huntsman Ca Inst LAPS	-	7	-	5	1	-	5	-	22	-	-
Wayne State U - Karmanos Ca Inst LAPS	-	-	-	-	-	-	-	-	4	-	2
Western States Ca Res NCORP	-	-	-	-	-	-	2	-	1	-	-
Yale U - Yale CC LAPS	1	-	-	-	5	-	3	-	10	2	-
ALLIANCE	17	11	2	4	-	-	-	-	-	-	-
ECOG-ACRIN	6	6	-	4	-	-	-	-	-	-	-
NRG	2	2	-	-	-	-	-	-	-	-	-
<b>Total</b>	<b>57</b>	<b>76</b>	<b>10</b>	<b>27</b>	<b>44</b>	<b>38</b>	<b>64</b>	<b>4</b>	<b>172</b>	<b>2</b>	<b>16</b>

# Lung Committee

## Leadership

Chair: ..... Jhanelle E. Gray, MD  
 Vice-Chair: ..... Roy S. Herbst, MD, PhD  
 Executive Officer: ..... Anne Chiang, MD, PhD  
 Statisticians: ..... Mary Redman, PhD  
 ..... Yingqi Zhao, PhD  
 ..... Katherine Minichiello, MS  
 ..... Jieling Miao, MS  
 ..... James Moon, MS  
 ..... Lu Qian, MS

## Scientific Leadership

Translational Medicine:  
 Biology/Pathology: ..... Philip C. Mack, PhD  
 ..... Fred R. Hirsch, MD, PhD  
 ..... Ignacio I. Wistuba MD  
 Imaging: ..... Chadwick L. Wright MD, PhD  
 ..... Myrna C. Godoy, MD, PhD  
 Radiation Oncology: ..... Roy H. Decker, MD, PhD  
 Surgery: ..... Wayne L. Hofstetter, MD  
 Subcommittee Chairs:  
 Early Stage Disease: ..... Wayne L. Hofstetter, MD  
 ..... Raymond Osarogiagbon, MD  
 Locally Advanced Disease: ..... Roy H. Decker, MD, PhD  
 ..... Shirish Gadageel, MD (Early Therapeutics)  
 Metastatic Disease: ..... Ross Camidge, MD  
 ..... Karen Reckamp, MD  
 Community Engagement: ..... Paul J. Hesketh, MD  
 ..... Suzanne Cole, MD

## Designates

Cancer Control Liaison: ..... Gary E. Goodman, MD  
 DEI Champion: ..... Lucy Gansauer, MSN, RN, OCN, CCRP  
 Veterans Affairs: ..... Chao H. Huang, MD  
 ..... Cheryl M. Czerlanis, MD  
 Data Coordinators: ..... Leah Everhart  
 ..... Louise Highleyman  
 ..... Larry Kaye  
 ..... Amy Johnson  
 Clinical Research Project Manager: ..... TBD  
 Oncology Research Professionals:  
 CRAs: ..... Courtney L. Williamson  
 ..... Ginny M. Keeling, MS  
 Nurses: ..... Kimberly M. Belzer, MS, PAC  
 ..... Rosalie Zablocki, RN  
 Patient Advocate: ..... Judy Johnson, MBA

Pharmaceutical Science: ..... Joyce Lee, PharmD  
 ..... Kimberly McConnell, PharmD  
 Protocol Project Managers: ..... Mariah Norman  
 ..... Laura Gildner, MS (Lung-MAP)  
 ..... Jennifer Beeler (Lung-MAP)  
 Clinical Trials Program Manager: ..... Crystal Miwa

## Time/Location

Friday, October 21, 2022 4:15 pm - 7:15 pm  
 Room: Regency C (Ballroom Level, West Tower)

## Agenda

- 4:15 - 4:25 pm** General Update: Jhanelle E. Gray, MD
- 4:25 - 4:35 pm** Patient Advocate Update: Judy Johnson, MBA
- 4:35 - 4:45 pm** Thoracic Surgery Session: Wayne Hofstetter, MD
- 4:45 - 4:55 pm** Thoracic Radiation Session: Megan Daly, MD
- 4:55 - 5:05 pm** Translational Medicine Session: Phillip C. Mack, PhD
- 5:05 - 5:15 pm** Community Engagement Core: Paul J. Hesketh, MD
- 5:15 - 5:25 pm** DEI Session: Lucy Gansauer, MSN, RN
- 5:25 - 5:45 pm** Scientific Presentation #1  
 Patricia A. Robinson, MD  
 Assistant Dean - Diversity, Equity and Inclusion, SSOM, Associate  
 Professor of Medicine, Hematology Oncology, Loyola Medicine
- 5:45 - 6:45 pm** Thoracic Medical Oncology Session: Jhanelle Gray, MD
- 6:45 - 7:15 pm** Scientific Presentation #2  
 A Randomized Study of Pembrolizumab plus Ramucirumab Versus  
 Standard of Care for Patients Previously Treated with Immunotherapy for  
 Stage IV or Recurrent Non-Small Cell Lung Cancer  
 Karen L. Reckamp, MD  
 Directory of the Division of Medical Oncology, Medical Director of the  
 Women’s Guild Lung Institute, Associate Director for Clinical Research,  
 Department of Medicine, Cedars-Sinai Center

## Active Studies

**LUNGMAP**, “A Master Protocol to Evaluate Biomarker-Driven Therapies and  
 Immunotherapies in Previously-Treated Non-Small Cell Lung



# Lung Committee

Cancer (Lung-MAP Screening Study).” Drs. Herbst, Patel, Gandara, et al. Activation: 1/28/19.

**S1800D**, “A Phase II/III Study of N-803 (ALT-803) plus Pembrolizumab versus Standard of Care in Participants with Stage IV or Recurrent Non-Small Cell Lung Cancer Previously Treated with Anti-PD-1 or Anti-PD-L1 Therapy (Lung-MAP Non-Match Sub-Study).” Drs. Wrangle and Husain. Activation: 2/15/22.

**S1900E**, “A Phase II Study of Sotorasib (AMG 510) in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN Lung-MAP Sub-Study).” Drs. Padda and Gerber. Activation: 4/2/21.

**S1900F**, “A Randomized Phase II Study of Carboplatin and Pemetrexed with or Without Selpercatinib (LY3527723) in Participants with Non-Squamous RET Fusion-Positive Stage IV Non-Small Cell Lung Cancer and Progression of Disease on Prior RET Directed Therapy (Lung-MAP Sub-Study).” Drs. Gray and Elamin. Activation: 7/25/22.

**S1701**, “A Randomized Phase II Trial of Carboplatin-Paclitaxel with or without Ramucirumab in Patients with Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma.” Drs. Tsao and Koczywas. Activation: 8/9/18.

**S1827**, “MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK).” Drs. Rusthoven, Brown, Wefel, et al. Activation: 1/10/20.

**S1914**, “A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT versus SBRT Alone in High Risk, Early Stage NSCLC.” Drs. Daly, Simone, Kelly, et al. Activation: 3/25/20.

**S1929**, “Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination with Talazoparib in Patients with SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC).” Drs. Karim, Reckamp, Gay, et al. Activation: 6/15/20; Step 1 Registration Permanently Closed 8/15/22.

**S1933**, “A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients with Borderline Performance Status.” Drs. Aljumaily, Mitin, and Wozniak. Activation: 6/15/20.

**S1934**, “NASSIST (Neoadjuvant Chemoradiation +/- Immunotherapy Before Surgery for Superior Sulcus Tumors): A Randomized Phase II Trial of Trimodality +/- Atezolizumab in Resectable Superior Sulcus Non-Small

Cell Lung Cancer.” Drs. Osarogiagbon, Huang, Decker, et al. Activation: 9/9/21; Temporary closure: 11/5/21; Reactivation: 2/15/22.

**CTSU/EA5163/S1709**, “INSIGNA: A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-driven Analysis.” Dr. Chiang. Activation: 2/28/19.

**CTSU/A081801**, “Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO).” Dr. Gray. Activation: 6/3/20.

**CTSU/A151216**, “Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST).” Dr. Gandara. Activation: 8/18/14.

**CTSU/E4512**, “A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein.” Dr. Li. Activation: 8/18/14.

**CTSU/EA5181**, “Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC.” Dr. Harkenrider. Activation: 4/9/20.

**CTSU/EA5182**, “Randomized Phase III Study of Combination AZD9291 (Osimertinib) and Bevacizumab Versus AZD9291 (Osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC).” Dr. Goldberg. Activated:10/22/20.

**CTSU/EA5191**, “A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients with Previously Treated Non-Squamous NSCLC.” Dr. Massarelli. Activated: 5/22/20.

**CTSU/NRG-LU002**, “Maintenance Systemic Therapy versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial.” Dr. Gomez. Activation: 4/7/17; Temporary closure: 11/12/21.

**CTSU/NRG-LU005**, “Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab.” Dr. Hsu. Activation: 5/28/19; Closed to US and Canadian sites 6/23/22.

**CTSU/NRG-LU007**, “Randomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial.” Dr. Park. Activated: 8/17/20.

# Lung Committee

## Closed Studies

**CTSU/NRG-CC003**, "Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer." Dr. Gaspar. Activation: 12/7/15; Temporary closure: 5/28/20; Reactivation: 7/27/20; Permanent closure: 6/21/22.

**S1900A**, "A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)." Drs. Riess and Wheatley-Price. Activation: 1/28/19. Permanently closed: 2/2/21.

**S1900B**, "A Phase II Study of Selpercatinib (LOXO-292) in Patients with RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)." Drs. Elamin and Gray. Activation: 2/10/20. Permanently closed: 5/1/21.

**S1900C**, "A Phase II Study of Talazoparib Plus Avelumab in Patients with Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations (LUNG-MAP Sub-Study)." Drs. Skoulidis and Suga. Activation: 1/16/20. Permanently closed: 12/18/20.

**S1800A**, "A Phase II Randomized Study of Ramucirumab Plus Pembrolizumab (MK-3475) Versus Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)." Drs. Reckamp and Dragnev. Activation: 5/17/19. Permanently closed: 10/20/20.

## NCI-Approved Concepts

**S1900G**, "A Randomized Phase II Study of Capmatinib plus Osimertinib with or without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)." Drs. Goldberg and Camidge.

**S2302**, "PROJECT PRAGMATICA: A Prospective Randomized Study of Ramucirumab (NSC 749128) Plus Pembrolizumab (MK-3475; NSC 776864) Versus Standard of Care for Participants Previously Treated With Immunotherapy for Stage IV or Recurrent Non-small Cell Lung Cancer in Standard Practice." Drs. Reckamp and Dragnev.

## Concepts in Development

**S1900I**, "A Randomized Phase II study of Mobocertinib (TAK-788) with or without Ramucirumab in Participants with Previously Treated EGFR Exon 20 Insertion Non-Small-Cell Lung Cancer (Lung-MAP Sub-Study)." Drs. Doroshow and Patel.

**S1800E**, "A Randomized Phase II/III Study of Docetaxel and Ramucirumab with or without Cemiplimab for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)." Drs. Reckamp, Dragnev, and Waqar.

**S1800F**, "A Phase II Study Of MK7684A (coformulation of Vibostolimab plus Pembrolizumab) in combination with Lenvatinib versus Standard of Care in Patients with Anti-PD-1 or Anti-PD-L1 Relapsed and Refractory Stage IV Non-Small Cell Lung Cancer (Lung-MAP Non-Match Sub-Study)." Drs. Massarelli and Li.

# Lung Committee

## Accrual from trial opening through 6/30/2022 by Institution and Study

	LUNGMAP	S1701	S1800D	S1827	S1900B	S1900E	S1914	S1929	S1933	A081105	A081801
Ascension Prov Hosp - Southfield	13	-	-	-	-	-	-	1	-	-	-
Ascension Via Christi Hosp Wichita	1	-	-	-	-	-	-	-	-	-	-
Banner MD Anderson CC	-	-	-	1	-	-	-	-	-	-	1
Banner U Med Ctr - Tucson	-	-	-	-	-	-	-	-	-	-	-
Baptist Mem HC/Mid South MU NCORP	34	-	-	-	-	1	4	2	-	-	1
Baylor College of Med/Dan L Duncan CCC	-	-	-	1	-	-	-	-	-	-	-
Boston Med Ctr	-	-	-	4	-	-	-	-	-	-	-
CWRU Case CCC LAPS	10	-	-	-	-	2	-	-	-	6	4
Ca Res Consort of W Mich NCORP	3	-	-	-	-	-	2	-	-	-	-
Ca Res for the Ozarks NCORP	29	-	1	-	-	-	-	2	3	1	-
Ca Res of Wisconsin & N Mich Consort	23	-	1	-	-	3	-	-	-	-	-
Carle CC NCORP	2	-	-	-	-	-	2	-	-	-	-
Cedars-Sinai Med Ctr	7	-	-	-	-	1	-	-	-	-	-
City of Hope CCC	5	1	-	1	-	-	-	-	-	1	-
Columbia U MU NCORP	8	-	-	-	-	-	-	-	-	-	-
Columbus NCORP	26	-	-	3	-	-	-	-	-	-	-
CommonSpirit Hlth Res Inst	43	-	-	-	-	-	1	2	-	-	-
Cotton O'Neil CC / Stormont Vail Hlth	-	-	-	-	-	-	-	-	-	-	-
Dayton NCORP	2	-	-	-	-	-	-	1	-	-	1
Essentia Hlth NCORP	15	-	2	-	-	-	1	-	-	-	-
Fred Hutchinson Ca Res Ctr LAPS	4	-	-	-	-	-	-	-	-	1	-
Georgia Cares MU NCORP	6	-	-	1	-	-	2	3	1	-	-
Georgia NCORP	50	-	-	2	-	1	2	-	-	-	-
Gulf South MU NCORP	8	-	-	1	-	-	1	1	-	-	-
Hawaii MU NCORP	21	-	-	-	-	-	-	-	-	-	-
Heartland Ca Res NCORP	108	-	-	2	1	4	18	16	2	-	-
Henry Ford Hospital	7	-	-	-	-	-	-	1	-	2	2
Houston Methodist Hosp	-	-	-	-	-	-	-	-	-	2	-
Kaiser Permanente NCORP	60	-	1	-	-	6	1	-	-	19	2
Lahey Hospital & Med Ctr	29	-	-	-	-	-	1	1	2	-	-
Loma Linda U Med Ctr	5	-	-	-	-	-	-	-	-	3	-
Loyola U Med Ctr	22	-	-	-	-	-	-	1	-	-	-
Massachusetts Vet Epi Res & Info Ctr	39	-	1	1	-	-	-	-	-	1	6
Medical U South Carolina MU NCORP	10	-	-	-	-	1	-	-	-	-	-
Michigan Ca Res Consort NCORP	99	-	4	-	-	4	1	1	-	-	-
Moffitt CC	9	2	-	1	-	1	-	-	-	3	6
Montana Cancer Consort NCORP	24	-	-	-	-	-	-	3	1	-	-
Mount Sinai Hospital	-	-	-	-	-	-	7	-	-	-	-
NCORP Carolinas (Prisma Hlth NCORP)	15	-	-	-	-	1	-	-	-	-	-

## Lung Committee

## Accrual from trial opening through 6/30/2022 by Institution and Study

	LUNGMAP	S1701	S1800D	S1827	S1900B	S1900E	S1914	S1929	S1933	A081105	A081801
Nevada Ca Res Foundation NCORP	12	-	-	-	-	-	-	1	-	-	-
New Mexico MU NCORP	66	-	-	1	-	-	5	5	1	-	-
Northwell Hlth NCORP	-	-	-	-	-	-	-	-	-	-	1
Northwestern U LAPS	23	1	-	1	-	-	-	3	-	-	-
Oregon Hlth & Science U	1	-	-	-	-	-	1	-	-	1	5
Pacific Ca Res Consort NCORP	14	-	-	-	-	-	-	3	-	-	-
SCL Hlth Saint Joseph Hospital	1	-	-	-	-	-	1	-	-	-	1
Salem Hospital	3	-	-	-	-	-	-	-	-	-	-
Southeast Clin Onc Res Consort NCORP	45	-	-	4	-	-	3	5	-	-	-
Sutter Ca Res Consort	22	-	-	-	-	1	-	-	-	1	-
The Don and Sybil Harrington CC	7	-	1	-	-	-	-	-	-	-	-
The James Graham Brown CC at U Louisville	-	-	-	-	-	-	-	-	-	-	-
UC Davis CCC LAPS	26	3	5	1	-	-	6	2	-	4	-
UC Irvine Hlth/Chao Family CCC	18	-	-	1	-	-	1	-	-	2	-
UC San Diego Moores CC	11	-	-	-	-	1	-	-	-	1	-
UPMC Hillman CC LAPS	27	-	-	2	-	5	-	1	2	-	-
USC Norris CCC LAPS	-	-	-	1	-	-	3	-	-	1	-
U Arkansas for Medical Sciences	11	-	-	-	-	-	5	-	-	-	-
U Cincinnati CC-UC Med Ctr	-	-	-	-	-	-	-	-	-	1	-
U Colorado CC LAPS	10	-	-	1	-	-	3	2	-	9	3
U Kansas CC - MCA Rural MU NCORP	79	-	1	-	-	1	-	-	-	1	-
U Kentucky/Markey CC	42	-	-	1	-	-	-	-	-	1	-
U Michigan CCC LAPS	1	-	-	-	-	-	-	-	-	1	-
U Mississippi Med Ctr	1	-	-	-	-	-	-	-	-	2	-
U Oklahoma Hlth Sciences Ctr LAPS	28	-	-	1	-	-	-	1	8	-	-
U Rochester LAPS	53	-	1	-	-	5	2	-	-	-	-
U Texas Hlth Science Ctr at San Antonio	-	-	-	-	-	-	-	1	-	-	-
U Texas MD Anderson CC LAPS	3	6	-	-	-	-	-	4	-	-	-
U Utah - Huntsman Ca Inst LAPS	-	-	-	1	-	-	2	1	-	-	-
Upstate Carolina Consort NCORP	32	-	-	-	-	-	1	-	-	-	-
Wayne State U - Karmanos Ca Inst LAPS	1	-	-	-	-	-	-	-	-	-	-
Western States Ca Res NCORP	2	-	-	-	-	-	-	-	-	-	-
William Beaumont Hosp-Royal Oak	-	-	-	-	-	-	-	-	-	-	-
Wisconsin NCORP	37	-	-	1	-	-	5	-	-	-	-
Yale U - Yale CC LAPS	17	-	-	2	-	-	-	-	-	3	3
ALLIANCE	620	3	3	11	1	13	5	7	2	-	-
CCTG	-	-	-	11	-	-	-	-	-	-	-
ECOG-ACRIN	298	2	3	2	2	11	9	7	-	-	-
NRG	316	-	1	42	2	4	13	5	1	-	-
<b>Total</b>	<b>2,564</b>	<b>18</b>	<b>25</b>	<b>102</b>	<b>6</b>	<b>66</b>	<b>108</b>	<b>83</b>	<b>23</b>	<b>67</b>	<b>36</b>

# Lung Committee

Accrual from trial opening through 6/30/2022 by Institution and Study

	A151216	E4512	E45163	E45181	E45182	E45191	NRGCC003	NRGLU002	NRG0005	R1308
Ascension Prov Hosp - Southfield	14	1	2	3	-	1	-	-	-	-
Ascension Via Christi Hosp Wichita	-	-	-	-	-	-	-	-	-	-
Banner MD Anderson CC	1	-	-	-	-	-	-	-	2	-
Banner U Med Ctr - Tucson	7	2	-	4	-	-	-	-	1	-
Baptist Mem HC/Mid South MU NCORP	21	-	1	-	-	-	-	1	4	-
Baylor College of Med/Dan L Duncan CCC	-	-	-	-	-	-	-	-	-	-
Boston Med Ctr	3	-	-	1	-	-	-	-	-	-
CWRU Case CCC LAPS	48	-	8	14	-	-	-	-	-	-
Ca Res Consort of W Mich NCORP	1	-	-	-	-	-	-	-	-	-
Ca Res for the Ozarks NCORP	1	-	-	-	-	-	-	-	-	-
Ca Res of Wisconsin & N Mich Consort	-	-	-	-	-	-	-	-	-	-
Carle CC NCORP	-	-	-	-	-	-	-	-	-	-
Cedars-Sinai Med Ctr	-	-	-	-	-	-	-	-	-	-
City of Hope CCC	4	-	-	-	-	-	-	-	-	-
Columbia U MU NCORP	-	-	-	-	-	-	-	-	-	-
Columbus NCORP	-	-	-	-	-	-	-	-	-	-
CommonSpirit Hlth Res Inst	2	-	-	-	-	-	-	-	-	-
Cotton O'Neil CC / Stormont Vail Hlth	3	-	-	-	-	-	-	-	-	-
Dayton NCORP	8	-	-	-	-	-	-	-	-	-
Essentia Hlth NCORP	-	-	-	-	-	-	-	-	-	-
Fred Hutchinson Ca Res Ctr LAPS	15	-	-	-	-	-	-	-	-	-
Georgia Cares MU NCORP	-	-	-	-	-	-	-	-	-	-
Georgia NCORP	9	-	1	-	-	-	-	-	-	-
Gulf South MU NCORP	-	-	3	-	-	-	-	-	-	-
Hawaii MU NCORP	-	-	-	-	-	-	-	-	-	-
Heartland Ca Res NCORP	-	-	-	-	-	-	1	-	-	-
Henry Ford Hospital	29	-	-	-	-	-	-	-	-	-
Houston Methodist Hosp	8	-	-	-	-	-	-	-	-	-
Kaiser Permanente NCORP	199	4	5	-	1	-	-	-	-	-
Lahey Hospital & Med Ctr	30	-	2	-	-	-	-	-	-	-
Loma Linda U Med Ctr	9	-	-	-	-	-	-	-	-	1
Loyola U Med Ctr	21	-	-	2	-	-	-	-	-	-
Massachusetts Vet Epi Res & Info Ctr	25	-	3	-	-	2	-	-	-	-
Medical U South Carolina MU NCORP	-	-	-	-	-	-	-	-	-	-
Michigan Ca Res Consort NCORP	-	-	-	-	-	-	-	-	-	-
Moffitt CC	83	1	-	-	-	-	-	-	-	-
Montana Cancer Consort NCORP	-	-	-	-	-	-	-	-	-	-
Mount Sinai Hospital	-	-	-	1	-	-	-	-	1	-
NCORP Carolinas (Prisma Hlth NCORP)	1	-	-	-	-	-	-	-	-	-

## Lung Committee

Accrual from trial opening through 6/30/2022 by Institution and Study

	A151216	EA512	EA5163	EA5181	EA5182	EA5191	NRGCC003	NRGLU002	NRGLU005	R1308
Nevada Ca Res Foundation NCORP	-	-	-	-	-	-	-	-	-	-
New Mexico MU NCORP	-	-	-	-	-	-	-	-	-	-
Northwell Hlth NCORP	1	-	-	-	-	-	-	-	-	-
Northwestern U LAPS	-	-	-	-	-	-	-	-	-	-
Oregon Hlth & Science U	20	-	-	-	-	-	-	-	-	-
Pacific Ca Res Consort NCORP	4	-	-	-	-	-	-	-	-	-
SCL Hlth Saint Joseph Hospital	2	-	-	-	-	-	-	-	-	-
Salem Hospital	-	-	-	-	-	-	-	-	-	-
Southeast Clin Onc Res Consort NCORP	-	-	-	-	-	-	-	-	-	-
Sutter Ca Res Consort	10	-	-	2	-	-	-	-	-	-
The Don and Sybil Harrington CC	-	-	-	-	-	-	-	-	-	-
The James Graham Brown CC at U Louisville	5	-	-	-	-	-	-	-	-	-
UC Davis CCC LAPS	41	1	6	-	1	-	-	-	-	-
UC Irvine Hlth/Chao Family CCC	13	-	-	-	-	-	-	-	-	-
UC San Diego Moores CC	5	-	-	-	-	-	-	-	-	-
UPMC Hillman CC LAPS	-	-	-	-	-	-	-	-	1	-
USC Norris CCC LAPS	12	-	-	-	-	-	-	-	-	-
U Arkansas for Medical Sciences	2	-	1	-	-	-	-	-	1	-
U Cincinnati CC-UC Med Ctr	22	1	-	-	1	-	-	-	-	-
U Colorado CC LAPS	58	2	-	-	-	1	-	-	1	-
U Kansas CC - MCA Rural MU NCORP	28	-	5	-	-	1	-	-	2	-
U Kentucky/Markey CC	5	-	-	-	-	-	-	-	-	-
U Michigan CCC LAPS	62	-	-	-	-	-	-	-	-	-
U Mississippi Med Ctr	26	-	-	-	-	-	-	-	-	-
U Oklahoma Hlth Sciences Ctr LAPS	-	-	-	-	-	-	-	-	-	-
U Rochester LAPS	-	-	2	13	-	-	4	-	1	-
U Texas Hlth Science Ctr at San Antonio	-	-	2	-	-	-	-	-	-	-
U Texas MD Anderson CC LAPS	2	1	-	-	-	-	-	-	-	-
U Utah - Huntsman Ca Inst LAPS	-	-	1	-	-	-	-	-	-	-
Upstate Carolina Consort NCORP	-	-	-	-	-	-	-	-	-	-
Wayne State U - Karmanos Ca Inst LAPS	1	-	-	-	-	-	-	1	-	-
Western States Ca Res NCORP	1	-	-	-	-	-	-	-	-	-
William Beaumont Hosp-Royal Oak	2	-	-	-	-	-	-	-	-	-
Wisconsin NCORP	-	-	-	-	-	-	-	-	-	-
Yale U - Yale CC LAPS	52	4	10	-	-	-	-	-	-	-
ALLIANCE	-	-	-	-	-	-	-	-	-	-
CCTG	-	-	-	-	-	-	-	-	-	-
ECOG-ACRIN	-	-	-	-	-	-	-	-	-	-
NRG	-	-	-	-	-	-	-	-	-	-
<b>Total</b>	<b>916</b>	<b>17</b>	<b>52</b>	<b>40</b>	<b>3</b>	<b>5</b>	<b>5</b>	<b>2</b>	<b>14</b>	<b>1</b>

# Lymphoma Committee

## Leadership

Chair: .....Jonathan W. Friedberg, MD  
 Vice-Chair: ..... Sonali M. Smith, MD  
 Executive Officer: .....Susan M. O'Brien, MD  
 Statisticians: .....Michael LeBlanc, PhD  
 ..... Hongli Li, MS

## Scientific Leadership

Translational Medicine: ..... Alexey Danilov, MD, PhD  
 Radiation Oncology: ..... Louis S. Constine, MD  
 Imaging: ..... Lawrence H. Schwartz, MD  
 Pathology: ..... Joo Y. Song, MD  
 Early Therapeutics: ..... Nasheed Mohammad Hossain, MD

## Designates

Cancer Control: .....Hayder Saeed, MD  
 Digital Engagement: ..... Mazyar Shadman, MD  
 Veterans Affairs: ..... Helen Ma, MD  
 Data Coordinators: ..... Iris Syquia  
 ..... Gabi Herbert  
 Oncology Research Professionals:  
 CRA: ..... Erin M. Cebula, MPH  
 Nurse: ..... Molly Beth Adamek, BSN, RN  
 Patient Advocate: ..... Hildy Dillon, MPH  
 Pharmaceutical Science: ..... Holly O. Chan, PharmD  
 ..... Martina Fraga, PharmD  
 Protocol Project Manager: ..... Katarina Gasic  
 Clinical Trials Program Manager: ..... TBD

## Time/Location

Friday, October 21, 2022 9:00 am - 11:00 am  
 Room: Crystal A (Lobby Level, West Tower)

## Agenda

**9:00 - 9:05 am**     **Welcome** - Jonathan Friedberg and Sonali Smith

**9:05 - 9:45 am**     **Mini-symposium: The pursuit of equity and inclusion in lymphoma careers** - Sonali Smith, Elwood V. Jensen Professor, Chief, Hematology/Oncology Section, University of Chicago

**9:45 - 10:45 am**     **Spotlight on studies pending activation**  
 S2114 DLBCL post CAR-T cell therapy     Dr. Hess  
 COG Early stage Hodgkin lymphoma     Dr. Hu

**10:50 - 11:55 am**     **Ongoing Studies**  
 S1826: Dr. Herrera  
 S1918: Dr. Brem

S1608: Dr. Barr  
 A051902: Dr. Amengual  
 ANHL1931: Dr. Kamdar  
 EA4151: Dr. Till  
 EA4181: Dr. Spurgeon  
 S1925 (CLL): Dr. Stephens  
 A051301: Dr. Stiff

**11:55 - 12:00 pm**     **Other Business/Concluding Remarks**

## Proposed Studies

**S2114**, "A Randomized Phase II Trial of Consolidation Therapy Following CD19 CAR T-Cell Treatment for Relapsed/Refractory Diffuse Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma." Drs. Hess and Hossain.

**S2207**, "Randomized phase II study of the addition of Targeted therapeutic agents to tafasitamab-based therapy in non-transplant-eligible patients with Relapsed/refractory Large B-cell Lymphoma." Drs. Amengual and Reagan.

## Active Studies

**S1826**, "A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age  $\geq$  12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma." Drs. Herrera and Friedberg. Activated: 7/19/19.

**S1608**, "Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma." Drs. Barr and Burack. Activated: 8/10/17. Temporarily closed: 02/09/2022.

**S1918**, "A Phase II/III Randomized Study of R-miniCHOP With or Without CC-486 (Oral Azacytidine) in Participants Age 75 Years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIB Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements." Drs. Brem and Smith. Activated: 3/19/21.

**CTSU/A051301**, "A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype." Drs. Andreadis. SWOG Champion: Dr. Stiff. Activated: 7/6/16.

**CTSU/A051701**, "Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas." Dr. Abramson. SWOG Champion: Dr. Vallurupalli. Activated: 8/7/19. Temporarily closed: 8/2/21.

# Lymphoma Committee

**CTSU/EA4151**, "A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission. Dr. Fenske. SWOG Champion: Dr. Till. Activated: 8/29/17.

**CTSU/EA4181**, "A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CA-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients  $\leq$  70 years Old with Untreated Mantle Cell Lymphoma. Dr. Wagner-Johnson. SWOG Champion: Dr. Spurgeon. Activated: 10/3/19.

**CTSU/ANHL1931**, "A Randomized Phase 3 trial of Nivolumab (NSC# 748726 IND# 125462) in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma." SWOG Champion: Dr. Kamdar. SWOG Champion: Dr. Manali. Activated 6/7/2021.

**CTSU/A051902**, "A Randomized Phase II Study of CHO(E)P vs Oral Azacitidine-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-cell Lymphomas." Dr. Neha Mehta-Shah. SWOG Champion: Dr. Amengual. Activated 7/30/2021.

## Open Leukemia Studies

**S1925**, A Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study. Dr. Stephens. Activated: 12/14/20.

**S1905**, "A Phase I/II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients with Re-lapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)/T-Cell Lymphoblastic Lymphoma (T-LBL)." Drs. Advani and Papadantonakis. Activated: 8/17/20.

**A041702**, "A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients ( $\geq$  65 Years of Age) with Chronic Lymphocytic Leukemia (CLL)." Dr. Woyach. SWOG Champion: Dr. Hill. Activated: 1/4/19.

## Open Rare Cancers Study

**CTSU/EAY131**, "Molecular Analysis for Therapy Choice (MATCH)." Drs. Chen, Flaherty, Conley, et al. Activated: 8/12/15.

## Open Cancer Care Delivery Study

**S1912CD**, "A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)." Dr. Shankaran. Activated 7/26/2021.



## Lymphoma Committee

Accrual from trial opening through 6/30/2022 by Institution and Study

	S1608	S1826	S1918	A051301	ANHL1931	E4412	EA4151	EA4181
Ascension Providence Hospitals - Southfield	-	5	-	-	-	-	-	-
Banner University Medical Center - Tucson	2	-	-	1	-	-	1	2
Baptist Memorial Health Care/Mid South Minority Underserved NCORP	-	3	-	-	-	-	-	-
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	-	-	-	1	-	-	-	-
Boston Medical Center	-	2	-	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-	-	-	11	11
Cancer Research Consortium of West Michigan NCORP	3	13	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	1	4	-	-	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	-	2	-	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	1	3	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	8	20	2	1	-	-	17	-
Columbia University Minority Underserved NCORP	-	1	2	-	-	1	-	-
Columbus NCI Community Oncology Research Program	1	2	-	-	-	-	-	-
CommonSpirit Health Research Institute	-	3	-	-	-	-	-	-
Essentia Health NCI Community Oncology Research Program	-	3	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	-	-	-	-	13	-
Georgia Cares Minority Underserved NCORP	-	5	1	-	-	-	-	-
Gulf South Minority Underserved NCORP	-	-	1	-	-	-	-	-
Heartland Cancer Research NCORP	1	17	-	-	-	-	-	-
Henry Ford Hospital	-	7	-	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	2	10	-	-	-	11	-	9
King Faisal Specialist Hospital and Research Centre	-	-	-	4	-	-	-	-
Loyola University Medical Center	-	8	-	-	-	-	3	-
Medical University of South Carolina Minority Underserved NCORP	2	17	1	-	-	-	2	-
Michigan Cancer Research Consortium NCORP	1	5	2	-	-	-	-	-
Moffitt Cancer Center	-	15	-	-	-	-	-	-
Montana Cancer Consortium NCORP	-	8	-	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	11	-	-	-	-	2	-

## Lymphoma Committee

Accrual from trial opening through 6/30/2022 by Institution and Study

	S1608	S1826	S1918	A051301	ANHL1931	E4412	EA4151	EA4181
Nevada Cancer Research Foundation NCORP	-	2	-	-	-	1	-	-
Northwestern University LAPS	1	-	-	-	-	-	-	-
Oregon Health and Science University	-	4	-	-	-	-	5	5
Pacific Cancer Research Consortium NCORP	-	5	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	5	-	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	-	15	-	-	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	4	-	-	1	-	-	-
UC San Diego Moores Cancer Center	-	8	-	-	-	-	1	-
University of Alabama at Birmingham / Deep South Research Consortium LAPS	-	11	-	-	-	7	5	-
University of Arkansas for Medical Sciences	-	1	-	-	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	6	-	-	-	-	2	2
University of Colorado Cancer Center LAPS	-	3	-	1	-	-	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	-	-	-	-	-	-	-	1
University of Kentucky/Markey Cancer Center	-	2	-	-	-	-	-	-
University of Michigan Comprehensive Cancer Center LAPS	-	-	-	-	-	-	1	-
University of Mississippi Medical Center	-	1	-	-	-	-	-	-
University of Rochester LAPS	13	30	-	3	-	-	10	17
University of Texas Health Science Center at San Antonio	-	16	-	-	-	-	11	-
University of Texas MD Anderson Cancer Center LAPS	3	29	-	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	1	14	1	-	-	-	14	11
Upstate Carolina Consortium Community Oncology Research Program	1	7	-	-	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	3	-	1	-	-	1	6
Wisconsin NCI Community Oncology Research Program	-	9	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	6	-	-	-	-	4	-
ALLIANCE	15	119	18	-	-	-	-	-
CCTG	-	20	-	-	-	-	-	-
COG	-	288	-	-	-	-	-	-
ECOG-ACRIN	5	77	5	-	-	-	-	-
NRG	11	44	2	-	-	-	-	-
<b>Total</b>	<b>72</b>	<b>893</b>	<b>35</b>	<b>12</b>	<b>1</b>	<b>20</b>	<b>103</b>	<b>64</b>

# Melanoma Committee

## Leadership

Chair: ..... Sapna P. Patel, MD  
 Vice-Chair: ..... Roger S. Lo, MD, PhD  
 Executive Officer: ..... Christopher W. Ryan, MD  
 Statisticians: ..... Michael Wu, PhD  
 ..... Megan Othus, PhD  
 ..... James Moon, MS  
 ..... Hongli Li, MS

## Scientific Leadership

Translational Medicine: ..... William E. Carson, III, MD  
 Radiation Oncology: ..... Evan J. Wuthrick, MD  
 Surgery: ..... John Robert Hyngstrom, MD  
 Dermatology: ..... Clara Curiel-Lewandrowski, MD  
 Imaging: ..... Ari M. VanderWalde, MD  
 Medical Oncology: ..... Sapna Pradyuman Patel, MD  
 Pathology: ..... TBD  
 Non-Melanoma Skin Cancer: ..... Nikhil I. Khushalani, MD  
 Early Therapeutics: ..... Jeffrey A. Sosman, MD  
 SWOG's ECOG Liaisons: ..... Thach-Giao Truong, MD  
 ECOG's SWOG Liaisons: ..... David H. Lawson, MD  
 ..... Andrew Poklepovic, MD  
 Digital Engagement: ..... Zeynep Eroglu, MD

## Designates

Cancer Control Liaison: ..... Sancy Leachman, MD, PhD  
 ..... Thach-Giao Truong, MD (Survivorship)  
 Data Coordinator: ..... Tonya Johnson  
 ..... Laura Kingsbury, MRT  
 ..... Leah Everhart  
 ..... Hannah Hale  
 Oncology Research Professionals:  
 CRA: ..... Kathryn Allen, BA, CCRP  
 Nurse: ..... Lisa S. Morgan, RN, OCN  
 Patient Advocate: ..... Samantha Guild, J.D.  
 Pharmaceutical Science: ..... Sun "Coco" Yang, PharmD, PhD  
 ..... Kimberly McConnell, PharmD  
 Protocol Project Manager: ..... Catrina De Los Santos-Mireles  
 Clinical Trials Program Manager: ..... TBD

## Time/Location

Friday, October 21, 2022 2:30 pm - 4:30 pm  
 Room: Crystal C (Lobby Level, West Tower)

## Agenda

- 2:30 - 2:40 pm Welcome and Introduction:** Sapna Patel, MD
- 2:40 - 3:20 pm Keynote Speaker: Treating Mucosal Melanoma: Progress and Challenges in the PD-1 Era** - Alexander Shoushtari, M.D., Memorial Sloan Ketterin Cancer Center
- 3:20 - 3:35 pm Active Studies update - Study design, eligibility criteria, endpoints, accrual to date**
- S2015**, A Phase III, Multi-centre Randomised Controlled Trial Investigating 1cm vs. 2cm Wide Excision Margins for Primary Cutaneous Melanoma, MASC  
 PI: Joshua Mammen, M.D., Ph.D. (University of Nebraska)
- S2000**, A Randomized Phase II Trial Of Encorafenib + Binimetinib + Nivolumab Vs Ipilimumab + Nivolumab In Braf-V600 Mutant Melanoma With Brain Metastases.  
 PI: Zeynep Eroglu, M.D. (Moffit)  
 Biostatisticians: Michael Wu, Ph.D. & James Moon, M.S.
- 3:35 - 4:10 pm Closed to Patient Accrual, Manuscript & Translational Medicine Updates**
- S1801**, A Phase II Randomized Study of Adjuvant Versus Neo-Adjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-risk Melanoma. Sapna Patel (MDACC). Activated PI: Sapna Patel, M.D. (MD Anderson)  
 Biostatisticians: Megan Othus, Ph.D. & James Moon, M.S.
- S1616**, A Phase II Study of Ipilimumab and Nivolumab in Advanced Melanoma Following Progression on a PD-1 Inhibitor Alone  
 PI: Ari VanderWalde, M.D., M.P.H. (West Cancer Clinic)  
 Biostatisticians: Michael Wu, Ph.D. & James Moon, M.S.
- S1512**, A Study of PD-1 Blockade with Pembrolizumab In Patients with Primary Desmoplastic Melanoma (DM), Locally Advanced, Locally Recurrent, or Metastatic Desmoplastic Melanoma (DM)  
 PI: Kari Kendra, M.D. (Ohio State) and Siwen Hu-Lieskovan, M.D., Ph.D. (Huntsman Cancer Institute)  
 Biostatisticians: Michael Wu, Ph.D. & James Moon, M.S.
- S1607**, A Phase II Study of Combining T-VEC and PD-1 Blockade With Pembrolizumab In Patients With Advanced Melanoma Who Have Progressed On Anti-PD1 Therapy.  
 PI: Siwen Hu-Lieskovan, M.D., Ph.D. (Huntsman Cancer Institute)  
 Biostatisticians: Michael Wu, Ph.D. & James Moon, M.S.

# Melanoma Committee

**S1404**, A Phase III Randomized Study of MK3475 versus High-Dose Interferon alfa-2b for Resected High-Risk Melanoma  
 PI: Sapna Patel, M.D. (MD Anderson)  
 Biostatisticians: Megan Othus, Ph.D., James Moon, M.S., & Hongli Li, M.S.

**S1320**, A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib and Trametinib in BRAFV600E/K Mutant Melanoma  
 PI: Alain Algazi, M.D. (University of California San Francisco)  
 Biostatisticians: Megan Othus, Ph.D., James Moon, M.S.

**S1221**, Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination with the BRAF Inhibitor Dabrafenib and Trametinib in Patients with BRAF Mutant Cancer  
 PI: Alain Algazi, M.D. (University of California San Francisco) and Antoni Ribas (UCLA)  
 Biostatisticians: Megan Othus, Ph.D. & James Moon, M.S.

**4:10 - 4:20 pm**      **ECOG / ALLIANCE Updates:** David Lawson, MD

**4:20 - 4:25 pm**      **Advocate Update:** Remarks (Samantha Guild, JD, AIM at Melanoma)

**4:25 - 4:30 pm**      **Closing**

## Other Active Studies

**CTSU/EA6174**, "STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma with Pembrolizumab, a Phase III Trial." SWOG Champion: Dr. Hsu. Activated: 10/1/18.

**CTSU/EA6141**, "Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma." SWOG Champion: Dr. K. Kim. Activated: 9/10/15.

**CTSU/EA6192**, "The BAMB2 (BRAF, Autophagy, MEK Inhibition in Melanoma) Study: A Randomized Double Blind Phase II Study of Dabrafenib and Trametinib with or Without Hydroxychloroquine in Advanced BRAF V600E/K Melanoma with Elevated LDH". SWOG Champion: Dr. Truong. Activated:10/23/20.

## Other Closed Studies

**CTSU/EA6134**, "DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial." SWOG Champion: Dr. Chmielowski. Activated: 7/13/15. Closed: 9/30/2021.

## Studies in Development

**S2300**, "A Phase 3 Randomized Trial of Complete Circumferential Peripheral and Deep Margin Assessment for Excision of Localized Cutaneous Melanoma: The CAEC ("Cake") Trial" Dr. Yu.

## Melanoma Committee

### Accrual from trial opening through 6/30/2022 by Institution and Study

	S1512	S1801	S2000	S2015	EA6134	EA6141	EA6174	EA6192
Banner MD Anderson CC	-	3	-	-	-	-	-	-
Banner U Med Ctr - Tucson	-	7	-	-	-	-	3	-
Baptist Mem Hlth Care/Mid South MU NCORP	-	1	-	-	-	-	-	-
Boston Med Ctr	-	1	-	-	-	-	-	-
CWRU Case CCC LAPS	-	-	-	-	6	-	14	-
Ca Res Consort of W Mich NCORP	-	26	-	8	-	-	-	-
Ca Res for the Ozarks NCORP	-	-	1	-	-	1	-	-
Ca Res of Wisconsin & N Mich Consort	-	2	-	-	-	-	-	-
Carle CC NCORP	-	1	1	-	-	-	-	-
City of Hope CCC	-	6	-	-	2	3	-	-
Columbus NCORP	-	1	-	-	-	-	-	-
Dayton NCORP	-	-	-	-	-	2	-	-
Georgia NCORP	1	-	-	-	-	-	-	-
Gulf South MU NCORP	-	1	-	-	-	-	-	-
Hawaii MU NCORP	-	2	-	-	2	-	-	-
Heartland Ca Res NCORP	-	6	-	-	-	-	-	-
Intermountain Med Ctr	1	-	-	-	-	-	-	-
Kaiser Permanente NCORP	-	14	-	-	19	23	-	-
Loma Linda U Med Ctr	-	2	-	-	-	-	-	-
Massachusetts Vet Epi Res & Info Ctr	-	5	-	-	-	-	-	-
Medical U South Carolina MU NCORP	-	1	-	-	-	-	-	-
Michigan Ca Res Consort NCORP	-	5	-	-	-	-	-	-
Moffitt CC	19	-	4	-	-	-	-	-
Montana Cancer Consort NCORP	-	4	-	-	-	-	-	-
NCORP Carolinas (Prisma Hlth NCORP)	-	-	-	-	2	-	-	-
Nevada Ca Res Foundation NCORP	-	-	-	-	-	-	1	-
New Mexico MU NCORP	-	1	-	-	-	-	-	-
Northwell Hlth NCORP	-	7	-	-	-	-	-	-

## Melanoma Committee

Accrual from trial opening through 6/30/2022 by Institution and Study

	S1512	S1801	S2000	S2015	EA6134	EA6141	EA6174	EA6192
Northwestern U LAPS	1	13	-	-	-	-	-	2
Ohio State U CCC LAPS	6	13	-	-	4	-	3	1
Pacific Ca Res Consort NCORP	-	3	-	-	-	-	-	-
SCL Hlth Saint Joseph Hospital	-	-	-	-	-	-	1	-
Southeast Clin Onc Res Consort NCORP	1	-	-	-	-	-	-	-
Sutter Ca Res Consort	-	-	-	-	2	5	1	-
The Don and Sybil Harrington CC	-	3	-	-	-	-	-	-
UC Irvine Hlth/Chao Family CCC	-	3	-	-	-	2	7	-
UCLA / Jonsson CCC	4	6	-	-	7	-	-	-
USC Norris CCC LAPS	5	8	-	-	-	-	2	-
U Alabama Birm/Deep South RC LAPS	-	1	-	-	-	-	-	-
U Arkansas for Medical Sciences	-	-	-	-	3	-	-	-
U Cincinnati CC-UC Med Ctr	-	-	-	-	-	2	3	-
U Colorado CC LAPS	-	-	-	-	1	-	-	-
U Kansas CC - MCA Rural MU NCORP	2	8	-	-	2	-	-	-
U Kentucky/Markey CC	-	4	-	-	-	-	-	-
U Michigan CCC LAPS	-	15	1	-	-	-	-	-
U Rochester LAPS	-	4	-	-	2	-	1	-
U Texas Hlth Science Ctr at San Antonio	-	-	-	-	-	1	-	-
U Texas MD Anderson CC LAPS	-	10	-	-	-	-	-	-
U Utah - Huntsman Ca Inst LAPS	10	20	-	-	-	-	6	-
Wayne State U - Karmanos Ca Inst LAPS	-	-	-	-	2	-	-	-
Western States Ca Res NCORP	-	-	-	-	-	1	-	-
Wisconsin NCORP	-	9	-	-	-	-	-	-
Yale U - Yale CC LAPS	-	-	-	-	-	6	-	-
ALLIANCE	1	32	1	-	-	-	-	-
ECOG-ACRIN	2	50	3	-	-	-	-	-
NRG	4	47	1	-	-	-	-	-
<b>Total</b>	<b>57</b>	<b>345</b>	<b>12</b>	<b>8</b>	<b>54</b>	<b>46</b>	<b>42</b>	<b>3</b>

# Publication List by Committee

The publications listed below were received by the Group Chair's Office as published (including online), accepted, or submitted since the SWOG Spring 2022 Hybrid Group Meeting.

Conference abstracts are not included.

## ADOLESCENT AND YOUNG ADULT (AYA) COMMITTEE

### Published/Accepted Manuscripts

(none this cycle)

### Submitted Manuscripts

(none this cycle)

## BARLOGIE-SALMON MYELOMA COMMITTEE

### Published/Accepted Manuscripts

S0777 Restricted survival benefit with right-censored data. Zhang S, LeBlanc M, Zhao Y. *Biometrical Journal* Apr;64(4):696-713,2022. <https://pubmed.ncbi.nlm.nih.gov/34970772/>

S0777/S1211 Current approaches to management of newly diagnosed multiple myeloma [Review]. Goel U, Usmani S, Kumar S. *American Journal of Hematology* May;97 Suppl 1:S3-S25, 2022. <https://pubmed.ncbi.nlm.nih.gov/35234302/>

### Submitted Manuscripts

(none this cycle)

## BREAST COMMITTEE

### Published/Accepted Manuscripts

MA.32 Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical Trial. Goodwin PJ, Chen BE, Gelmon KA, Whelan TJ, Ennis M, Lemieux J, Ligibel JA, Hershman DL, Mayer IA, Hobday TJ, Bliss JM, Rastogi P, Rabaglio-Poretti M, Mukherjee SD, Mackey JR, Abramson VG, Oja C, Wesolowski R, Thompson AM, Rea DW, Stos PM, Shepherd LE, Stambolic V, Parulekar WR. *JAMA*. May 24;327(20):1963-1973, 2022. <https://pubmed.ncbi.nlm.nih.gov/35608580/>

S1202/S1207 Recent Advances in Adjuvant Endocrine Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer [Editorial]. Cobain EF, Hayes DF. *Journal of Clinical Oncology* Jun 29;JCO2200702. doi: 10.1200/JCO.22.00702. Online ahead of print, 2022. <https://pubmed.ncbi.nlm.nih.gov/35767772/>

S1418/Other Use of Immune Checkpoint Inhibitors in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline

Rapid Recommendation Update Q and A. Vikas P, Korde LA, Somerfield MR, Hershman DL. *JCO Oncol Pract*. May 20;40(15):1696-1698, 2022. <https://pubmed.ncbi.nlm.nih.gov/35417251/>

Multiple Studies\* Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update. Andre F, Ismaila N, Allison KH, Barlow WE, Collyar DE, Damodaran S, Henry NL, Jhaveri K, Kalinsky K, Kuderer NM, Litvak A, Mayer EL, Puzstai L, Raab R, Wolff AC, Stearns V. *Journal of Clinical Oncology* Jun 1;40(16):1816-1837, 2022. [\*including S1007] <https://pubmed.ncbi.nlm.nih.gov/35439025/>

### Submitted Manuscripts

S0500 Tumor-derived Extracellular Vesicles as Complementary Prognostic Factors to Circulating Tumor Cells in Metastatic Breast Cancer (SWOG S0500). Nanou A, Miao J, Coumans F, Dolce E, Darga E, Barlow W, Smerage J, Hortobagyi G, Terstappen L, Hayes D. *JCO Precision Oncology*, submitted 2022.

S0800 Image analysis-based tumor infiltrating lymphocyte measurement predicts pathologic complete response to neoadjuvant chemotherapy in breast cancer (SWOG S0800). Fanucci K, Blenman K, Bai Y, Pelekanou V, Nahleh Z, Shafi S, Burela S, Barlow W, Sharma P, Thompson A, Godwin A, Rimm D, Hortobagyi G, Puzstai L. *npj Breast Cancer*, submitted 2022.

S1416 Results of a Phase II Randomized Trial of Cisplatin With ABT-888 (Veliparib) or Placebo in Metastatic Triple-Negative Breast Cancer and/or BRCA1/2 Mutation-Associated Breast Cancer (S1416). Rodler E, Sharma P, Barlow W, Galow J, Puhalla S, Anders C, Goldstein L, Tripathy D, Brown-Glaberman U, Huynh T, Szyarto C, Godwin A, Pathak H, Swisher E, Radke M, Timms K, Lew D, Miao J, Puzstai L, Hayes D, Hortobagyi G. *Lancet Oncology*, submitted 2022

S8814 Evaluation of the predicted sensitivity to endocrine therapy (SET<sub>2,3</sub> index) and the 21-gene Breast Recurrence Score assay in the SWOG S8814 trial. Speers C, Symmans WF, Barlow W, Trevarton A, The S, Du L, Rae J, Shak S, Baehner R, Sharma P, Puzstai L, Hortobagyi G, Hayes D, Albain K, Godwin A, Thompson A. *Journal of Clinical Oncology*, submitted 2022.

# Publication List by Committee

## CANCER CONTROL AND PREVENTION COMMITTEES

### CANCER CARE DELIVERY COMMITTEE

#### Published/Accepted Manuscripts

**S1404** Adjuvant pembrolizumab improves quality-of-life outcomes compared to high dose interferon or ipilimumab in patients with resected melanoma; SWOG S1404, A Randomized Clinical Trial Unger J, Darke A, Othus M, Tarhini A, Kirkwood J, Sharon E, Sondak V, Guild S, Truong T, Eroglu Z, Kendra K, Lewis K, Faller B, Funchain P, Buchbinder E, Grossmann K, Ribas A, Patel S. *JAMA Oncology*, accepted 2022.[see also Melanoma Committee]

**S1415CD** Successes and challenges of implementing a cancer care delivery intervention in community oncology practices: lessons learned from SWOG S1415CD. Watabayashi K, Bell-Brown A, Kreizenbeck K, Egan K, Lyman G, Hershman D, Arnold K, Bansal A, Barlow WE, Sullivan S, Ramsey S. *BMC Health Services Research* Apr 1;22(1):432, 2022. <https://pubmed.ncbi.nlm.nih.gov/35365139/>

**S1415CD** Effects of a guideline-informed clinical decision support system intervention to improve colony stimulating factor prescribing: A Pragmatic Cluster-Randomized Trial. Ramsey S, Bansal S, Sullivan S, Lyman G, Barlow W, Arnold K, Watabayashi K, Bell-Brown A, Kreizenbeck K, Le-Lindqwister N, Dul C, Brown-Glaberman U, Behrens R, Vogel V, Alluri N, Hershman D. *JAMA Network Open*, accepted 2022.

**S1415CD** A Pragmatic Cluster-Randomized Trial of a Standing Order Entry Intervention for Colony Stimulating Factor Use Among Patients at Intermediate Risk for Febrile Neutropenia. Hershman DL, Bansal A, Sullivan S, Lyman G, Barlow W, Arnold K, Watabayashi K, Bell-Brown A, Le-Lindquister N, Dul C, Brown-Glaberman U, Behrens R, Vogel V, Alluri N, Ramsey S. *Journal of Clinical Oncology*, accepted 2022.

**Multiple Studies** Patterns of Scientific and Clinical Impact in Cancer Randomized Clinical Trials. Nghiem VT, Vaidya R, Unger JM. *JAMA Network Open* Jun 1;5(6):e2219657, 2022. <https://pubmed.ncbi.nlm.nih.gov/35771578/>

**Multiple Studies** Trends in Obesity Prevalence Among Patients Registered to Cancer Clinical Treatment Trials. Vaidya R, Till C, Greenlee H, Hershman D, Unger J. *JAMA Open Network*, accepted 2022.

#### Submitted Manuscripts

**S1204** Antiviral Therapy Use and Related Outcomes in Patients with Cancer and Viral Infections: Results from SWOG S1204. Hwang J, Arnold K, Unger J, Chugh R, Tincopa M, Loomba R, Hershman D, Ramsey S. *Supportive Care in Cancer*, revised and resubmitted 2022.

**S1204** Prediction Model for Identifying Patients at Highest Risk of Hepatitis B Virus, Hepatitis C Virus, and HIV Infection Among Patients with Newly Diagnosed Cancer Enrolled in SWOG S1204. Unger JM, Till C, Hwang JP, Arnold KB, Hershman DL, Ramsey SD. *Journal of the National Cancer Institute*, submitted 2022.

**S1400I** Novel Approaches for Dynamic Visualization of Adverse Event Data in Oncology Clinical Trials: A Case Study Using Immunotherapy Trial S1400-I (SWOG). Lee S, Fan W, Wang A, Vaidya R, Redman M, Gettinger S, Bazhenova L, Herbst R, Hershman D, Unger J. Pending submission to alternative journal, 2022. [see also Lung Committee]

**S1415CD** An Evaluation of Stakeholder Engagement in Comparative Effectiveness Research: Lessons Learned from SWOG S1415CD. Bell-Brown A, Watabayashi K, Kreizenbeck K, Ramsey S, Bansal A, Barlow W, Lyman G, Hershman D, Mercurio AM, Segarra-Vazquez B, Kurttila F, Myers J, Golenski J, Johnson J, Erwin R, Walia G, Crawford J, Sullivan S. *Journal of Comparative Effectiveness Research*, submitted 2022.

**S1912CD** A Randomized Trial Addressing Cancer-Related Financial Hardship through Delivery of a Proactive Financial Navigation Intervention (CREDIT) (SWOG S1912CD). Shankaran V, Unger J, Carlos R, Langer S, Darke A, Hershman D, Ramsey S. *Trials*, submitted 2022.

**Multiple Studies** Population, Clinical, and Scientific Impact of National Cancer Institute's National Clinical Trials Network Treatment Studies. Unger J, LeBlanc M, Bertagnolli M, Wolmark N, Curran W, O'Dwyer P, Schnall M, Mannel R, Mandrekars S, Gray R, Zhao F, Bah M, Hong F, Vaidya R, Blanke C. *Journal of Clinical Oncology*, under revision for resubmission 2022.

**Multiple Studies** The Medicaid Expansion of the Affordable Care Act and the Participation of Patients with Medicaid in Cancer Clinical Trials. Unger J, Xiao H, Vaidya R, LeBlanc M, Hershman DL. *Journal of Clinical Oncology*, submitted 2022.

## CANCER SURVIVORSHIP COMMITTEE

#### Published/Accepted Manuscripts

**C70807** Diet and Health-related Quality of Life Among Men on Active Surveillance for Early-Stage Prostate Cancer: The Men's Eating and Living (MEAL) Study (CALGB 70807 [Alliance]). Parsons JK, Zahrieh D, Patel D, Mohler J, Chen R, Paskett E, Liu H, Peil E, Rock C, Hahn O, Taylor J, Van Veldhuizen P, Small E, Morris M, Naughton M, Pierce J, Marshall J. *European Urology Focus* Apr 30;:S2405-4569(22)00061-X, 2022. <https://pubmed.ncbi.nlm.nih.gov/35504836/> [See also GU and Prevention & Epidemiology Committees]



# Publication List by Committee

**C89803** Diet- and Lifestyle-Based Prediction Models to Estimate Cancer Recurrence and Death in Stage III Colon Cancer Patients (Alliance). Cheng E, Ma C, Spiegelman D, Zhou X, Ou F, Niedzwiecki D, Mayer R, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Giovannucci E, Van Blarigan E, Ng K, Gross C, Meyerhardt J, Fuchs C. *Journal of Clinical Oncology* Mar 1;40(7):740-751, 2022. <https://pubmed.ncbi.nlm.nih.gov/34995084/> [see also GI Committee]

**C89803** Associations Between Unprocessed Red Meat and Processed Meat With Risk of Recurrence and Mortality in Patients With Stage III Colon Cancer. Van Blarigan E, Ou F, Bainter T, Fuchs C, Niedzwiecki D, Zhang S, Saltz L, Mayer R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Ogino S, Sanoff H, Giovannucci E, Ng K, Meyerhardt J. *JAMA Network Open* Feb 1;5(2):e220145, 2022. <https://pubmed.ncbi.nlm.nih.gov/35191970/> [see also GI Committee]

**C89803** Marital Status, Living Arrangement, and Cancer Recurrence and Survival in Patients with Stage III Colon Cancer: Findings from CALGB 89803 (Alliance). Lee S, Ma C, Zhang S, Ou F-S, Bainter T, Niedzwiecki D, Saltz L, Mayer R, Whittom R, Hantel A, Benson AB, Atienza D, Kindler H, Gross C, Irwin M, Meyerhardt J, Fuchs C. *Oncologist* Jun 8;27(6):e494-e505, 2022. <https://pubmed.ncbi.nlm.nih.gov/35641198/> [see also GI Committee]

## Submitted Manuscripts

(none this cycle)

## PALLIATIVE AND END OF LIFE CARE COMMITTEE

### Published/Accepted Manuscripts

**S1820** Altering Intake and Managing Symptoms (AIMS): Feasibility of a Diet Modification Intervention for Post-Treatment Bowel Dysfunction in Rectal Cancer [S1820 Pilot]. Sun V, Crane T, Freylersthe S, Slack S, Yung A, Krouse R, Thomson C. *Clinical Journal of Oncology Nursing* Jun 1;26(3):283-292, 2022. <https://pubmed.ncbi.nlm.nih.gov/35604741/>

**None** Development of a measure of clinicians' self-efficacy for medical communication (SEMC). Feldman DB, O'Rourke MA, Corn BW, Hudson MF, Patel N, Agarwal R, Fraser VL, Deiningner H, Fowler LA, Bakitas MA, Krouse RA, Subbiah IM. *BMJ Support Palliat Care*. 2022 May 9; doi: 10.1136/bmjspcare-2022-003593. [Epub ahead of print]. <https://pubmed.ncbi.nlm.nih.gov/35534186/>

## Submitted Manuscripts

**S1316** A Novel Trial for Patients with Advanced Cancer: S1316 Prospective Comparative Effectiveness Trial for Malignant Bowel Obstruction (SWOG S1316). Krouse R, Anderson G, Arnold K, Thomson C, Nfonsam V, Al-kasspoles M, Walker J Sun V, Alvarez Secord A, Han E, Leon-Takahashi A, Isla-Ortiz D, Rodgers P, Hendren S, Sanchez Salcedo M, Laryea J, Graybill W., Flaherty D, Mogal H, Miner T, Pimiento J, Kitano M, Badgwell B, Whalen G., Lamont J, Guevara O, Senthil M, Dewdney S, Silberfein E, Wright J, Friday B, Fahy B, Anantha S, O'Rourke M, Bakitas M, Sloan J, Grant M., Deutsch G, Deneve J. *Journal of Clinical Oncology*, submitted 2022.

**None** Healthcare Professionals' Lay Definitions of Hope. Feldman D, Jazaieri H, O'Rourke M., Bakitas M, Krouse R, Deiningner H, Hudson M, Corn B. Submitted to *Journal of Happiness Studies*, submitted 2022.

**None** Feasibility and Acceptability of an Online Intervention to Enhance Hopefulness Among Oncology Professionals. Feldman D, Jazaieri H, O'Rourke M, Bakitas M, Krouse R, Deiningner H, Hudson M, Corn B. Submitted to *BMJ Supportive and Palliative Care*, submitted 2022.

## PREVENTION AND EPIDEMIOLOGY COMMITTEE

### Published/Accepted Manuscripts

**S0000** Differential Biopsy Patterns Influence Associations Between Multivitamin Use and Prostate Cancer Risk in the Selenium and Vitamin E Cancer Prevention Trial. Schenk J, Till C, Neuhaus M, Goodman P, Lucia MS, Thompson IM, Tangen CM. *Cancer Epidemiology, Biomarkers & Prevention*, accepted 2022.

**S0000/S9217** Large-scale integrated analysis of genetics and metabolomic data reveals potential links between lipids and colorectal cancer risk. Shu X, Chen Z, Long J, Guo X, Yang Y, Qu C, Ahn Y, Tangen C, Wu A, Peters U, Zheng W. *Cancer Epidemiology, Biomarkers & Prevention* Jun 1;31(6):1216-1226, 2022. <https://pubmed.ncbi.nlm.nih.gov/35266989/>

**S0000/Other** Prediction of future risk of any and higher-grade prostate cancer based on the PLCO and SELECT trials. Gelfond J, Hernandez B, Goros M, Ibrahim J, Chen M, Sun W, Liss M, Leach R, Thompson I, Ankerst D. *BMC Urology* Mar 26;22(1):45. doi: 10.1186/s12894-022-00986-w, 2022. <https://pubmed.ncbi.nlm.nih.gov/35351104/>

**S0000/Other** Beyond GWAS of Colorectal Cancer: Evidence of Interaction with Alcohol Consumption and Putative Causal Variant for the 10q24.2 Region. Jordahl K, Shcherbina A, Kim A, Su Y, Lin Y, Wang J, Albanes D, Platz E, Tangen C, Hsu L, Kundaje A, Peters U. *Cancer Epidemiology*,

# Publication List by Committee

**Biomarkers & Prevention** May 4;31(5):1077-1089, 2022.  
<https://pubmed.ncbi.nlm.nih.gov/35438744/>

**S0000/Other** A causal inference approach to the external validation of risk prediction models. Chen Y, Pfeiffer R, Shepherd B, Ankerst D. *Biometrical Journal*, accepted 2021.

**S9217** Association of Serum Carotenoids and Retinoids with Intraprostatic Inflammation in Men without Prostate Cancer or Clinical Indication for Biopsy in the Placebo Arm of the Prostate Cancer Prevention Trial. Chadid S, Song X, Schenk J, Gurel B, Lucia MS, Thompson I, Jr., Neuhouser M, Goodman P, Parnes H, Lippman S, Nelson W, DeMarzo A, Platz E. *Nutrition and Cancer* 74(1):141-148, 2022.  
<https://pubmed.ncbi.nlm.nih.gov/33511883/>

**S9217/Other** Circulating free testosterone and risk of aggressive prostate cancer: prospective and Mendelian randomisation analyses in international consortia. Watts E, Perez-Cornago A, Fensom G, Smith-Byrne K, Noor A, Andrews C, Gunter M, Holmes M, Martin R, Tsilidis K, Albanes D, Goodman G, Platz E, Schenk J, Consortium Practical, Allen N, Key T, Travis R. *International Journal of Cancer*, Oct 1;151(7):1033-1046, 2022. <https://pubmed.ncbi.nlm.nih.gov/35579976/>

**S9217/Other** Circulating insulin-like growth factors and risks of overall, aggressive and early-onset prostate cancer: a collaborative analysis of 20 prospective studies and Mendelian randomization analysis. Watts EL, Perez-Cornago A, Fensom GK, Smith-Byrne K, Noor U, Andrews CD, Gunter MJ, Holmes MV, Martin RM, Tsilidis KK, Albanes D, Barricarte A, Bueno-de-Mesquita HB, Cohn BA, Deschasaux-Tanguy M, Dimou NL, Ferrucci L, Flicker L, Freedman ND, Giles GG, Giovannucci EL, Haiman CA, Hankey GJ, Holly JMP, Huang J, Huang WY, Hurwitz LM, Kaaks R, Kubo T, Le Marchand L, MaInnis RJ, Männistö S, Metter EJ, Mikami K, Mucci LA, Olsen AW, Ozasa K, Palli D, Penney KL, Platz EA, Pollak MN, Roobol MJ, Schaefer CA, Schenk JM, Stattin P, Tamakoshi A, Thysell E, Tsai CJ, Touvier M, Van Den Eeden SK, Weiderpass E, Weinstein SJ, Wilkens LR, Yeap BB; PRACTICAL Consortium, CRUK, BPC3, CAPS, PEGASUS, Allen NE, Key TJ, Travis RC. *International Journal of Epidemiology* Jun 21;dyac124. doi: 10.1093/ije/dyac124. Online ahead of print.  
<https://pubmed.ncbi.nlm.nih.gov/35726641/>

**S9217/Other** Assessing the causal role of epigenetic clocks in the development of multiple cancers: a Mendelian randomization study. Morales Bernstein F, McCartney DL, Lu AT, Tsilidis KK, Bouras E, Haycock P, Burrows K, Phipps AI, Buchanan DD, Cheng I; PRACTICAL consortium, Martin RM, Davey Smith G, Relton CL, Horvath S, Marioni RE, Richardson TG, Richmond RC. *eLife* Mar 29;11:e75374.  
<https://pubmed.ncbi.nlm.nih.gov/35346416/>

**S9217/Other** Intake Patterns of Specific Alcoholic Beverages by Prostate Cancer Status. Lin HY, Tseng TS, Wang X, Fang Z, Zea AH, Wang L, Pow-Sang J, Tangen CM, Goodman PJ, Wolk A, Håkansson N, Kogevinas M, Llorca J, Brenner H, Schöttker B, Castela JE, Gago-Dominguez M, Gamulin M, Lessel D, Claessens F, Joniau S, The Practical Consortium, Park JY. *Cancers (Basel)*. 2022 Apr 14;14(8):1981. doi: 10.3390/cancers14081981. <https://pubmed.ncbi.nlm.nih.gov/35454886/>

**C70807** Diet and Health-related Quality of Life Among Men on Active Surveillance for Early-Stage Prostate Cancer: The Men's Eating and Living (MEAL) Study (CALGB 70807 [Alliance]). Parsons JK, Zahrieh D, Patel D, Mohler J, Chen R, Paskett E, Liu H, Peil E, Rock C, Hahn O, Taylor J, Van Veldhuizen P, Small E, Morris M, Naughton M, Pierce J, Marshall J. *European Urology Focus* Apr 30;:S2405-4569(22)00061-X, 2022. [See also GU and Cancer Survivorship Committees]  
<https://pubmed.ncbi.nlm.nih.gov/35504836/>

## Submitted Manuscripts

**S0000/Other** Shedding light on the association between genetically-defined BMI and early-onset colorectal cancer in a pooled analysis [Brief Communication]. Archambault A, Gruber S, Le Marchand L, Hsu L, Peters U, Hayes R, on behalf of the Colorectal Transdisciplinary (CORECT) Study, the Colon Cancer Family Registry (CCFR), Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO) [P Goodman, C Tangen, GECCO collaborators]. *Gastroenterology*, under review .

**Multiple Studies\*** A prostate cancer susceptibility PSA variant that confers lower risk is also associated with more aggressive disease and poor survival. Srinivasan S, Kryza T, Bock N, Stephens C, Dong Y, Panchadsaram J, Moya L, Rohl J, Perry-Keene J, Buzacott K, Gago M, Schleutker J, Maier C, Muir K, Tangen C, Gronberg H, Pashayan N, Albanes D, Wolk A, Eles R, Clements J, Batra J. *Cancer Discovery*, under review.[\*S0000, S9217, OTHER]

## Symptom Control and Quality of Life Committee

### Published/Accepted Manuscripts

(none this cycle)

### Submitted Manuscripts

**E3805** Effect of Metformin and Body Mass Index on Quality of Life and Survival in the E3805 CHARTED Trial. Jerrard D, Chen Y, Morgans A, Carducci M, Liu G, Eisenberger M, Wong Y-N, Hahn N, Bryce A, Cooney M, Dreicer R, Vogelzang N, Picus J, Shevrin D, Hussain M, Garcia J, DiPaola R, Sweeney C. *Prostate Cancer and Prostatic Diseases*, under review. [see also GU cmte]

# Publication List by Committee

**N0147** Cetuximab reduces patient quality of life when administered with mFOLFOX6 as adjuvant treatment following complete resection of KRAS wild-type tumors for stage III colorectal cancer (N0147 Alliance). Mahoney MR, Sloan JA, Hubbard JM, Tan AD, Liu H, Goldberg RM, Nair SG, Shields AF, Gill S, Jahagirdar B, Benson A, Sargent DJ, Alberts SR. *Journal of Patient Reported Outcomes*, under review. [see also GI Committee]

## DIGITAL ENGAGEMENT COMMITTEE

### Published/Accepted Manuscripts

(none this cycle)

### Submitted Manuscripts

(none this cycle)

## EARLY THERAPEUTICS AND RARE CANCERS COMMITTEE

### Published/Accepted Manuscripts

(none this cycle)

### Submitted Manuscripts

(none this cycle)

## EXECUTIVE COMMITTEE

### Published/Accepted Manuscripts

(none this cycle)

### Submitted Manuscripts

(none this cycle)

## GASTROINTESTINAL COMMITTEE

### Published/Accepted Manuscripts

**S0809** Adjuvant Chemoradiation in Patients with Lymph Node Positive Biliary Tract Cancers: A Secondary Analysis of SWOG S0809. Gholami S, Colby S, Horowitz D, Guthrie K, Ben-Josef E, El-Khoueiry A, Blanke CD, Philip P, Kachnic L, Ahmad S, Rocha F. Trial. *Annals of Surgical Oncology*, accepted 2022.

**C89803** Associations Between Unprocessed Red Meat and Processed Meat With Risk of Recurrence and Mortality in Patients With Stage III Colon Cancer. Van Blarigan E, Ou F, Bainter T, Fuchs C, Niedzwiecki D, Zhang S, Saltz L, Mayer R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Ogino S, Sanoff H, Giovannucci E, Ng K, Meyerhardt J. *JAMA Network Open* Feb 1;5(2):e220145, 2022. <https://pubmed.ncbi.nlm.nih.gov/35191970/> [see also Cancer Survivorship Committee]

**C89803** Marital Status, Living Arrangement, and Cancer Recurrence and Survival in Patients with Stage III Colon Cancer: Findings from CALGB 89803 (Alliance). Lee S, Ma C, Zhang S, Ou F-S, Bainter T, Niedzwiecki D, Saltz L, Mayer R, Whittom R, Hantel A, Benson AB, Atienza D, Kindler H, Gross C, Irwin M, Meyerhardt J, Fuchs C. *Oncologist* Jun 8;27(6):e494-e505, 2022. <https://pubmed.ncbi.nlm.nih.gov/35641198/> [see also Cancer Survivorship Committee]

**C89803** Diet- and Lifestyle-Based Prediction Models to Estimate Cancer Recurrence and Death in Stage III Colon Cancer Patients (Alliance). Cheng E, Ma C, Spiegelman D, Zhou X, Ou F, Niedzwiecki D, Mayer R, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Giovannucci E, Van Blarigan E, Ng K, Gross C, Meyerhardt J, Fuchs C. *Journal of Clinical Oncology* Mar 1;40(7):740-751, 2022. <https://pubmed.ncbi.nlm.nih.gov/34995084/> [see also Cancer Survivorship Committee]

**C80405** Dietary fat in relation to all-cause mortality and cancer progression and death among people with metastatic colorectal cancer: data from CALGB 80405 (Alliance)/SWOG 80405, Van Blarigan EL, Ma C, Ou FS, Bainter TM, Venook AP, Ng K, Niedzwiecki D, Giovannucci E, Lenz HJ, Polite BN, Hochster HS, Goldberg RM, Mayer RJ, Blanke CD, O'Reilly EM, Ciombor KK, Meyerhardt JA. *International Journal of Cancer* Jul 29. doi: 10.1002/ijc.34230. Online ahead of print, 2022. <https://pubmed.ncbi.nlm.nih.gov/35904874/>

**C80405** Tumor immunogenomic features determine outcomes in patients with metastatic colorectal cancer of CALGB/SWOG 80405 (Alliance) treated with standard-of-care combinations of bevacizumab and cetuximab. Innocenti F, Yazdani A, Rashid N, Qu X, Ou F-S, Van Buren S, Bertagnolli M, Kabbarah O, Blanke C, Venook A, Lenz H-J, Vincent B. *Clinical Cancer Research* Apr 14;28(8):1690-1700, 2022. <https://pubmed.ncbi.nlm.nih.gov/35176136/>

**C80701** Everolimus with or without bevacizumab in advanced pNET: CALGB 80701 (Alliance). Kulke M, Ou F-S, Niedzwiecki D, Heubner L, Kunz P, Kennecke H, Wolin E, Chan J, O'Reilly E, Meyerhardt J, Venook A. *Endocrine Related Cancer* May 9;29(6):335-344, 2022. <https://pubmed.ncbi.nlm.nih.gov/35324465/>

### Submitted Manuscripts

**N0147** Cetuximab reduces patient quality of life when administered with mFOLFOX6 as adjuvant treatment following complete resection of KRAS wild-type tumors for stage III colorectal cancer (N0147 Alliance). Mahoney MR, Sloan JA, Hubbard JM, Tan AD, Liu H, Goldberg RM, Nair

# Publication List by Committee

SG, Shields AF, Gill S, Jahagirdar B, Benson A, Sargent DJ, Alberts SR. Journal of Patient Reported Outcomes, under review. [see also SCQOL Cmte]

## GENITOURINARY COMMITTEE

Note: All PCPT and SELECT publications are listed under Cancer Control & Prevention Committees

### Published/Accepted Manuscripts

**S0337** Risk-Based Assessment Of the Impact Of Intravesical Therapy on Recurrence-Free Survival Rate Following Resection of Suspected Low-grade, Non-muscle-invasive Bladder Cancer (NMIBC): A Southwest Oncology Groups (SWOG) S0337 Posthoc Analysis. Corsi N, Messing E, Sood A, Keeley J, Bronchema C, Rakic N, Jamil M, Dalela D, Arora S, Piontkowski A, Majdalany S, Butaney M, Rakic I, Li P, Menon M, Rogers C, Abdollah F. Clinical Genitourinary Cancer Jun 25;:S1558-7673(22)00140-9, 2022. <https://pubmed.ncbi.nlm.nih.gov/35871040/>

**S0337** Paper Alert: Implementing a New Standard of Care [Commentary]. Messing E. Bladder Cancer, accepted 2022.

**S1216** Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216). Agarwal N, Tangen C, Hussain M, Gupta S, Plets M, Lara P, Harzstark A, Twardowski P, Paller C, Zylla D, Zibelman M, Levine E, Roth B, Goldkorn A, Vaena D, Kohli M, Crispino A, Vogelzang N, Thompson IM, Quinn DI. Journal of Clinical Oncology Apr 21;:JCO2102517. doi: 10.1200/JCO.21.02517. Online ahead of print, 2022. <https://pubmed.ncbi.nlm.nih.gov/35446628/>

**S1314** Using Cell Lines To Guide Neoadjuvant Therapy in Bladder Cancer COXEN and SWOG S1314. Dancik G, Theodorescu D. European Urology Focus Mar 23;:S2405-4569(22)00067-0, 2022. <https://pubmed.ncbi.nlm.nih.gov/35339415/>

**S1931** "PROBE"ing the Role of Cytoreductive Nephrectomy in Advanced Renal Cancer. Bell H, Cotta BH, Salami SS, Kim H, Vaishampayan U. Kidney Cancer Journal Mar 15;6(1):3-9. doi: 10.3233/kca-210010, 2022. <https://pubmed.ncbi.nlm.nih.gov/35310961/>

**C70807** Diet and Health-related Quality of Life Among Men on Active Surveillance for Early-Stage Prostate Cancer: The Men's Eating and Living (MEAL) Study (CALGB 70807 [Alliance]). Parsons JK, Zahrieh D, Patel D, Mohler J, Chen R, Paskett E, Liu H, Peil E, Rock C, Hahn O, Taylor J, Van Veldhuizen P, Small E, Morris M, Naughton M, Pierce J, Marshall J. European Urology Focus Apr 30;:S2405-4569(22)00061-X, 2022. [See also Cancer Survivorship and Prevention & Epidemiology Committees] <https://pubmed.ncbi.nlm.nih.gov/35504836/>

**E3805** Association between baseline body mass index and survival in men with metastatic hormone-sensitive prostate cancer: ECOG-ACRIN CHARTED E3805. Morgans A, Chen Y, Jarrard D, Carducci M, Liu G, Eisenberger M, Plimack E, Bryce A, Garcia J, Dreicer R, Vogelzang N, Picus J, Shevin D, Hussain M, DiPaola R, Cella D, Sweeney C. Prostate Sep;82(12):1176-1185, 2022. <https://pubmed.ncbi.nlm.nih.gov/35538398/>

**None** Bangs R, Lynn J, Obot E, Osborne S, Norris K. Improving Patient Advocacy in NCI Scientific Steering Committees and Task Forces. Journal of the National Cancer Institute, Aug 8;114(8):1059-1064.2022. <https://pubmed.ncbi.nlm.nih.gov/35552713/>

**None** Checklist for Improving Patient Communication on Bladder Preservation Options: The Patient Advocate Perspective. Bangs R, Quale DZ, Reed T. Clinical Oncology. <https://pubmed.ncbi.nlm.nih.gov/36057507/>

### Submitted Manuscripts

**S1216** Bone biomarkers and subsequent survival in men with hormone sensitive prostate cancer. Lara P, Mayerson E, Gertz E, Tangen C, Goldkorn A, Van Loan M, Hussain M, Gupta S, Zhang J, Parikh M, Twardowski P, Quinn D, Vogelzang N, Thompson I, Agarwal N. Clinical Cancer Research, revised/resubmitted, 2022.

**S1314** A randomized phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for localized, muscle-invasive bladder cancer with overall survival follow up (SWOG S1314; NCT02177695). Flaig TW, Tangen CM, Daneshmand S, Alva AS, Lucia MS, McConkey, Dan Theodorescu,6 Amir Goldkorn,7 Matthew I. Milowsky,8 Rick Bangs,9 Gary R. MacVicar,10 DJ, Bastos BR, Fowles JS, Gustafson DL, Plets M, Thompson IM, Jr, Lerner. SP Journal of Clinical Oncology, submitted 2022.

**E3805** Effect of Metformin and Body Mass Index on Quality of Life and Survival in the E3805 CHARTED Trial. Jerrard D, Chen Y, Morgans A, Carducci M, Liu G, Eisenberger M, Wong Y-N, Hahn N, Bryce A, Cooney M, Dreicer R, Vogelzang N, Picus J, Shevrin D, Hussain M, Garcia J, DiPaola R, Sweeney C. Prostate Cancer and Prostatic Diseases, under review. [see also SCQOL cmte]

## LEUKEMIA COMMITTEE

### Published/Accepted Manuscripts

**C10403** Disparities in trial enrollment and outcomes of Hispanic adolescent and young adult acute lymphoblastic leukemia. Muffly L, Yin J, Jacobson S, Wall A, Quiroz E, Advani A, Luger S, Tallman M, Litzow M, Foster M, Appelbaum F, Erba H, Larson R, Keegan T, Stock W. Blood

# Publication List by Committee

Advances Jul 26;6(14):4085-4092, 2022.

<https://pubmed.ncbi.nlm.nih.gov/35838753/>

**E1912** Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial. Shanafelt TD, Wang XV, Hanson CA, Paietta EM, O'Brien S, Barrientos J, Jelinek DF, Braggio E, Leis JF, Zhang CC, Coutre SE, Barr PM, Cashen AF, Mato AR, Singh AK, Mullane MP, Little RF, Erba H, Stone RM, Litzow M, Tallman M, Kay NE. Blood. 2022 Jul 14;140(2):112-120. <https://pubmed.ncbi.nlm.nih.gov/35427411/>

**Multiple Studies\*** Improved outcomes with 7+3 induction chemotherapy for acute myeloid leukemia over the past four decades: Analysis of SWOG trial data. Othus M, Garcia-Manero G, Godwin J, Weick J, Appelbaum F, Erba H, Estey E. Haematologica Jun 14;14(12):2934, 2022. [\*S0106,S1203,S8600,S9031] <https://pubmed.ncbi.nlm.nih.gov/35833298/>

## Submitted Manuscripts

**S1318** Dasatinib and Blinatumomab for Ph+ or Ph-Like Acute Lymphoblastic Leukemia [Letter]. Advani A, Moseley A, O'Dwyer K, Wood B, Park J, Wieduwilt M, Jeyakumar D, Yaghmour G, Attalah E, Gerds A, O'Brien S, Liesveld J, Othus M, Litzow M, Stone R, Sharon E, Erba H. Blood Advances, revised/resubmitted 2022.

**S1612** A Randomized Phase II/III Study Of Novel Therapeutics versus Azacitidine in Newly Diagnosed Patients with Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML), Age 60 or Older: A Report of the Comparison of Azacitidine and Nivolumab to Azacitidine: SWOG S1612. Assouline S, Michaelis L, Othus M, Hay A, Walter R, Jacoby M, Schroeder M, Uy G, Law L, Cheema F, Sweet K, Asch A, Liu J, Moseley A, Maher T, Kingsbury L, Fang M, Radich J, Little R, Erba H. Leukemia and Lymphoma, under revision for resubmission 2022.

**Multiple Studies\*** Identification and Validation of Novel Prognostic Transcript Biomarkers in CD34-Positive Blasts from Patients with AML: A SWOG Report. Pogossova-Agadjanyan E, Hua X, Othus M, Appelbaum F, Chauncey T, Erba H, Fitzgibbon M, Godwin J, Jenkins I, Fang M, Moseley A, Naru J, Radich J, Willborg B, Willman C, Wu F, Meshichi S, Stirewalt D. Leukemia, submitted 2022. [\*S0106,S0112,S9031,S9333]

**Multiple Studies\*** Long Non-coding RNA Expression Independently Predicts Outcome in Pediatric Acute Myeloid Leukemia. Ferrar J, Smith J, Othus M, Huang B, Wang Y, Ries R, Hylkema T, Pogossova-Agadjanyan E, Leonti A, Shaw T, Triche T, Gamis A, Aplenc R, Kolb E, Ma X, Stirewalt D, Alonzo T, Meshinchi S. Journal of Clinical Oncology, submitted 2022. [\*S0106,S0112,S9031,S9333,OTHER]

## LUNG COMMITTEE

### Published/Accepted Manuscripts

**S1400I** Nivolumab Plus Ipilimumab for Previously Treated Stage IV Squamous Cell Lung Cancer-Reply. Gettinger S, Redman M, Herbst R. JAMA Oncology Apr 1;8(4):1, 2022. <https://pubmed.ncbi.nlm.nih.gov/35142793/>

**S1403** Circulating tumor DNA (ctDNA) kinetics predict progression-free and overall survival in EGFR TKI-treated patients with EGFR-mutant NSCLC (SWOG S1403). Mack P, Miao J, Redman M, Moon J, Goldberg S, Herbst R, Melnick M, Walther Z, Hirsch F, Politi K, Kelly K, Gandara D. Clinical Cancer Research Jun 17;clincanres.CCR-22-0741-A.2022-3-8 14:09:41.447. doi:10.1158/1078-0432.CCR-22-0741. Online ahead of print., 2022. <https://pubmed.ncbi.nlm.nih.gov/35713632/>

**S1800A** Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small Cell Lung Cancer Previously Treated with Immunotherapy: Lung-MAP S1800A. Rekcamp K, Redman M, Dragnev K, Villaruz L, Faller B, Al Baghdadi T, Hines S, Everhart L, Highleyman L, Minichiello K, Papadimitrakopoulou V, Neal J, Waqar S, Patel J, Gray J, Gandara D, Kelly K, Herbst R. Journal of Clinical Oncology Jul 20;40(21):2295-2306, 2022. <https://pubmed.ncbi.nlm.nih.gov/35658002/>

**A082002** Alliance A082002 -a randomized phase II/III trial of modern immunotherapy-based systemic therapy with or without SBRT for PD-L1-negative, advanced non-small cell lung cancer. Schild S, Wang X, Bestvina C, Williams T, Masters G, Singh A, Stinchcombe T, Salama J, Wolf S, Zemla T, Duma N, Chun S, Amini A, Kozono D, Watt C. Clinical Lung Cancer Apr 30;S1525-7304(22)00065-1. doi: 10.1016/j.clc.2022.04.004. Online ahead of print., 2022. <https://pubmed.ncbi.nlm.nih.gov/35613998/>

**A151216** Rates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients With Early-Stage Lung Cancer in the US ALCHEMIST Study (Alliance A151216). Kehl KL, Zahrieh D, Yang P, Hillman SL, Tan AD, Sands JM, Oxnard GR, Gillaspie EA, Wigle D, Malik S, Stinchcombe TE, Ramalingam SS, Kelly K, Govindan R, Mandrekar SJ, Osarogiagbon RU, Kozono D. JAMA Oncology May 1;8(5):717-728, 2022. <https://pubmed.ncbi.nlm.nih.gov/35297944/>

**Multiple Studies\*** Lung-MAP: A Collaborative Roadmap to Improve Cancer Outcomes [Editorial]. Leal T, Dahlberg S, Ramalingam S. Journal of Clinical Oncology Jun 3;JCO2201035. doi: 10.1200/JCO.22.01035, 2022. [\*S1400, S1800A] <https://pubmed.ncbi.nlm.nih.gov/35658027/>

# Publication List by Committee

## Submitted Manuscripts

**S1400I** Lee S, Fan W, Wang A, Vaidya R, Redman M, Gettinger S, Bazhenova L, Herbst R, Hershman D, Unger J. Novel Approaches for Dynamic Visualization of Adverse Event Data in Oncology Clinical Trials: A Case Study Using Immunotherapy Trial S1400-I (SWOG). Pending submission to alternative journal, 2022. [see also CCD Committee]

## LYMPHOMA COMMITTEE

### Published/Accepted Manuscripts

**Multiple Studies\*** Relevance of bone marrow biopsies for response assessment in U.S. National Cancer Institute National Clinical Trials Network follicular lymphoma clinical trials. Rutherford S, Yin J, Pederson L, Perez Burbano G, LaPlant P, Shadman M, Li H, LeBlanc M, Kenkre V, Hong F, Blum K, Dockter T, Martin P, Jung S, Grant B, Rosenbaum C, Ujjani C, Barr P, Unger J, Cheson B, Bartlett N, Kahl B, Friedberg JW, Mandrekar S, Leonard J. *Journal of Clinical Oncology*, Jul 5;JCO2102301. doi: 10.1200/JCO.21.02301. Online ahead of print.2022. [\*CALGB,S0016,S0801] <https://pubmed.ncbi.nlm.nih.gov/35787017/>

**Multiple Studies\*** Extranodal presentation in limited stage DLBCL as a prognostic marker in three SWOG trials S0014, S0313 and S1001 [Letter to Editor]. Stephens D, Li H, Constine L, Fitzgerald T, Leonard J, Kahl B, LeBlanc M, Smith S, Friedberg JW, Persky D. *Haematologica* Jul 14. doi: 10.3324/haematol.2022.281004. Online ahead of print., 2022. [\*S0014,S0313,S1001] <https://pubmed.ncbi.nlm.nih.gov/35833300/>

### Submitted Manuscripts

(none this cycle)

## MELANOMA COMMITTEE

### Published/Accepted Manuscripts

**S1404** Adjuvant pembrolizumab improves quality-of-life outcomes compared to high dose interferon or ipilimumab in patients with resected melanoma; SWOG S1404, A Randomized Clinical Trial Unger J, Darke A, Othus M, Tarhini A, Kirkwood J, Sharon E, Sondak V, Guild S, Truong T, Eroglu Z, Kendra K, Lewis K, Faller B, Funchain P, Buchbinder E, Grossmann K, Ribas A, Patel S. *JAMA Oncology*, accepted 2022.[see also CCD Committee]

### Submitted Manuscripts

**S0826** SWOG S0826: A phase II trial of SCH 727965 (NSC727135, dinaciclib) in patients with stage IV melanoma.Lao CD, Moon J, Fruehauf JP, Flaherty LE, Bury MJ, Ribas A, Sondak V. *BMC Cancer*, pending resubmission, Melanoma management, 2022.

**S1404** Adjuvant pembrolizumab improves quality-of-life outcomes compared to high dose interferon or ipilimumab in patients with resected melanoma; SWOG S1404, A Randomized Clinical Trial Unger J, Darke A, Othus M, Tarhini A, Kirkwood J, Sharon E, Sondak V, Guild S, Truong T, Eroglu Z, Kendra K, Lewis K, Faller B, Funchain P, Buchbinder E, Grossmann K, Ribas A, Patel S. *JAMA Oncology*, accepted 2022.[see also CCD Committee]

## PHARMACEUTICAL SCIENCES COMMITTEE

### Published/Accepted Manuscripts

**None** Survey of US Medical Oncologists: Practices and Beliefs regarding DPYD Testing Prior to Fluoropyrimidine Chemotherapy. Koo K, Pasternak A, Henry NL, Sahai V, Hertz D. *Journal of Oncology Practice* Jun;18(6):e958-e965, 2022. <https://pubmed.ncbi.nlm.nih.gov/35239419/>

### Submitted Manuscripts

(none this cycle)



